US7972611B2	NNP	O
-	:	O
Fungus-induced	JJ	O
inflammation	NN	O
and	CC	O
eosinophil	JJ	O
degranulation	NN	O
-	:	O
Google	NN	O
Patents	NNS	O
Info	NNP	O
Links	NNP	O
Images	NNP	O
Classifications	NNP	O
Abstract	NNP	O
Description	NNP	O
CROSS-REFERENCE	NNP	O
TO	NNP	O
RELATED	NNP	O
APPLICATIONS	NNP	O
This	DT	O
application	NN	O
is	VBZ	O
a	DT	O
divisional	JJ	O
of	IN	O
U.S.	NNP	O
application	NN	O
Ser	NNP	O
.	.	O
No	DT	O
.	.	O
12/835,592	CD	O
,	,	O
filed	VBN	O
Jul	NNP	O
.	.	O
13	CD	O
,	,	O
2010	CD	O
,	,	O
now	RB	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
7,887,820	CD	O
which	WDT	O
is	VBZ	O
a	DT	O
divisional	JJ	O
of	IN	O
U.S.	NNP	O
application	NN	O
Ser	NNP	O
.	.	O
No	DT	O
.	.	O
12/629,638	CD	O
,	,	O
filed	VBN	O
Dec.	NNP	O
2	CD	O
,	,	O
2009	CD	O
(	(	O
now	RB	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
7,815,919	CD	O
)	)	O
,	,	O
which	WDT	O
is	VBZ	O
a	DT	O
divisional	JJ	O
of	IN	O
U.S.	NNP	O
application	NN	O
Ser	NNP	O
.	.	O
No	DT	O
.	.	O
11/580,454	CD	O
,	,	O
filed	VBN	O
Oct.	NNP	O
13	CD	O
,	,	O
2006	CD	O
(	(	O
now	RB	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
7,662,400	CD	O
)	)	O
,	,	O
which	WDT	O
claims	VBZ	O
the	DT	O
benefit	NN	O
of	IN	O
U.S	NNP	O
.	.	O
Provisional	JJ	O
Application	NNP	O
Ser	NNP	O
.	.	O
No	DT	O
.	.	O
60/726,553	CD	O
,	,	O
filed	VBN	O
Oct.	NNP	O
14	CD	O
,	,	O
2005	CD	O
.	.	O
The	DT	O
disclosure	NN	O
of	IN	O
the	DT	O
prior	JJ	O
applications	NNS	O
are	VBP	O
considered	VBN	O
part	NN	O
of	IN	O
(	(	O
and	CC	O
are	VBP	O
incorporated	VBN	O
by	IN	O
reference	NN	O
in	IN	O
)	)	O
the	DT	O
disclosure	NN	O
of	IN	O
this	DT	O
application	NN	O
.	.	O
STATEMENT	NNP	O
AS	NNP	O
TO	NNP	O
FEDERALLY	NNP	O
SPONSORED	NNP	O
RESEARCH	NNP	O
This	DT	O
invention	NN	O
was	VBD	O
made	VBN	O
with	IN	O
government	NN	O
support	NN	O
under	IN	O
AI049235	NNP	O
awarded	VBN	O
by	IN	O
the	DT	O
National	NNP	O
Institute	NNP	O
of	IN	O
Allergy	NNP	O
and	CC	O
Infectious	NNP	O
Diseases	NNP	O
.	.	O
The	DT	O
government	NN	O
has	VBZ	O
certain	JJ	O
rights	NNS	O
in	IN	O
the	DT	O
invention	NN	O
.	.	O
BACKGROUND	NNP	O
1	CD	O
.	.	O
Technical	JJ	O
Field	NNP	O
This	DT	O
document	NN	O
relates	VBZ	O
to	TO	O
methods	NNS	O
and	CC	O
materials	NNS	O
involved	VBN	O
in	IN	O
fungus-induced	JJ	O
inflammation	NN	O
and	CC	O
eosinophil	JJ	O
degranulation	NN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
this	DT	O
document	NN	O
relates	VBZ	O
to	TO	O
isolated	VB	O
nucleic	JJ	O
acids	NNS	O
encoding	VBG	O
fungal	JJ	O
polypeptides	NNS	O
,	,	O
fungal	JJ	O
polypeptides	NNS	O
,	,	O
methods	NNS	O
for	IN	O
assessing	VBG	O
fungus-induced	JJ	O
inflammation	NN	O
,	,	O
methods	NNS	O
for	IN	O
assessing	VBG	O
eosinophil	JJ	O
degranulation	NN	O
,	,	O
and	CC	O
methods	NNS	O
for	IN	O
identifying	VBG	O
inhibitors	NNS	O
of	IN	O
fungus-induced	JJ	O
inflammation	NN	O
and/or	NN	O
eosinophil	JJ	O
degranulation	NN	O
.	.	O
2	CD	O
.	.	O
Background	NNP	O
Information	NNP	O
The	DT	O
National	NNP	O
Center	NNP	O
for	IN	O
Health	NNP	O
Statistics	NNPS	O
describes	VBZ	O
the	DT	O
increasingly	RB	O
expensive	JJ	O
health	NN	O
care	NN	O
burden	NN	O
that	WDT	O
chronic	JJ	O
rhinosinusitis	NN	O
(	(	O
CRS	NNP	O
)	)	O
inflicts	VBZ	O
in	IN	O
the	DT	O
United	NNP	O
States	NNPS	O
.	.	O
With	IN	O
an	DT	O
estimated	VBN	O
18	CD	O
to	TO	O
22	CD	O
million	CD	O
cases	NNS	O
and	CC	O
at	IN	O
least	JJS	O
30	CD	O
million	CD	O
courses	NNS	O
of	IN	O
antibiotics	NNS	O
per	IN	O
year	NN	O
,	,	O
CRS	NNP	O
is	VBZ	O
one	CD	O
of	IN	O
the	DT	O
predominant	JJ	O
chronic	NN	O
diseases	NNS	O
in	IN	O
the	DT	O
U.S	NNP	O
.	.	O
In	IN	O
1996	CD	O
,	,	O
there	EX	O
were	VBD	O
26.7	CD	O
million	CD	O
visits	NNS	O
to	TO	O
physicians	NNS	O
,	,	O
hospital	NN	O
offices	NNS	O
,	,	O
and	CC	O
emergency	NN	O
departments	NNS	O
for	IN	O
sinusitis—at	NN	O
a	DT	O
total	JJ	O
cost	NN	O
of	IN	O
$	$	O
5.8	CD	O
billion	CD	O
.	.	O
Sinusitis	NNP	O
significantly	RB	O
impacts	VBZ	O
quality	NN	O
of	IN	O
life	NN	O
,	,	O
even	RB	O
when	WRB	O
compared	VBN	O
to	TO	O
typical	JJ	O
chronic	JJ	O
debilitating	NN	O
diseases	NNS	O
,	,	O
such	JJ	O
as	IN	O
diabetes	NNS	O
and	CC	O
congestive	JJ	O
heart	NN	O
failure	NN	O
.	.	O
CRS	NNP	O
presents	VBZ	O
a	DT	O
challenge	NN	O
to	TO	O
various	JJ	O
medical	JJ	O
specialties	NNS	O
,	,	O
including	VBG	O
infectious	JJ	O
diseases	NNS	O
,	,	O
ear	NN	O
,	,	O
nose	RB	O
,	,	O
and	CC	O
throat	NN	O
(	(	O
ENT	NNP	O
)	)	O
,	,	O
allergy	RB	O
,	,	O
asthma	NN	O
,	,	O
and	CC	O
clinical	JJ	O
immunology	NN	O
.	.	O
The	DT	O
FDA	NNP	O
has	VBZ	O
not	RB	O
approved	VBN	O
any	DT	O
medication	NN	O
for	IN	O
effective	JJ	O
use	NN	O
in	IN	O
CRS	NNP	O
.	.	O
Many	JJ	O
antibiotic	JJ	O
treatments	NNS	O
are	VBP	O
prescribed	VBN	O
without	IN	O
objective	JJ	O
evidence	NN	O
of	IN	O
infection	NN	O
.	.	O
Roughly	RB	O
40,000	CD	O
patients	NNS	O
per	IN	O
year	NN	O
undergo	NN	O
sinus	NN	O
surgery	NN	O
,	,	O
but	CC	O
controlled	VBD	O
evidence	NN	O
about	IN	O
the	DT	O
surgical	JJ	O
outcomes	NNS	O
is	VBZ	O
lacking	VBG	O
.	.	O
Even	RB	O
with	IN	O
aggressive	JJ	O
medical	JJ	O
and	CC	O
surgical	JJ	O
therapies	NNS	O
,	,	O
many	JJ	O
patients	NNS	O
have	VBP	O
persistent	JJ	O
or	CC	O
recurrent	JJ	O
disease	NN	O
,	,	O
leading	VBG	O
to	TO	O
frequent	JJ	O
courses	NNS	O
of	IN	O
antibiotics	NNS	O
and	CC	O
multiple	JJ	O
surgical	JJ	O
interventions	NNS	O
.	.	O
SUMMARY	NN	O
This	DT	O
document	NN	O
relates	VBZ	O
to	TO	O
methods	NNS	O
and	CC	O
materials	NNS	O
involved	VBN	O
in	IN	O
fungus-induced	JJ	O
inflammation	NN	O
and	CC	O
eosinophil	JJ	O
degranulation	NN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
this	DT	O
document	NN	O
relates	VBZ	O
to	TO	O
isolated	VB	O
nucleic	JJ	O
acids	NNS	O
encoding	VBG	O
fungal	JJ	O
polypeptides	NNS	O
,	,	O
fungal	JJ	O
polypeptides	NNS	O
,	,	O
methods	NNS	O
for	IN	O
assessing	VBG	O
fungus-induced	JJ	O
inflammation	NN	O
,	,	O
methods	NNS	O
for	IN	O
assessing	VBG	O
eosinophil	JJ	O
degranulation	NN	O
,	,	O
and	CC	O
methods	NNS	O
for	IN	O
identifying	VBG	O
inhibitors	NNS	O
of	IN	O
fungus-induced	JJ	O
inflammation	NN	O
and/or	NN	O
eosinophil	JJ	O
degranulation	NN	O
.	.	O
In	IN	O
general	JJ	O
,	,	O
one	CD	O
aspect	NN	O
of	IN	O
this	DT	O
document	NN	O
features	VBZ	O
a	DT	O
substantially	RB	O
pure	JJ	O
polypeptide	NN	O
comprising	NN	O
,	,	O
or	CC	O
consisting	VBG	O
essentially	RB	O
of	IN	O
,	,	O
an	DT	O
amino	NN	O
acid	NN	O
sequence	NN	O
at	IN	O
least	JJS	O
95	CD	O
percent	JJ	O
identical	JJ	O
to	TO	O
the	DT	O
amino	NN	O
acid	JJ	O
sequence	NN	O
set	VBN	O
forth	NN	O
in	IN	O
SEQ	NNP	O
ID	NNP	O
NO:2	NNP	O
,	,	O
4	CD	O
,	,	O
6	CD	O
,	,	O
8	CD	O
,	,	O
10	CD	O
,	,	O
12	CD	O
,	,	O
14	CD	O
,	,	O
16	CD	O
,	,	O
18	CD	O
,	,	O
20	CD	O
,	,	O
22	CD	O
,	,	O
24	CD	O
,	,	O
26	CD	O
,	,	O
28	CD	O
,	,	O
30	CD	O
,	,	O
32	CD	O
,	,	O
or	CC	O
34	CD	O
.	.	O
The	DT	O
polypeptide	NN	O
can	MD	O
comprise	VB	O
the	DT	O
amino	NN	O
acid	JJ	O
sequence	NN	O
set	VBN	O
forth	NN	O
in	IN	O
SEQ	NNP	O
ID	NNP	O
NO:10	NNP	O
.	.	O
The	DT	O
polypeptide	NN	O
can	MD	O
comprise	VB	O
an	DT	O
amino	NN	O
acid	NN	O
sequence	NN	O
having	VBG	O
99	CD	O
%	NN	O
identity	NN	O
to	TO	O
the	DT	O
sequence	NN	O
set	VBN	O
forth	NN	O
in	IN	O
SEQ	NNP	O
ID	NNP	O
NO:10	NNP	O
.	.	O
The	DT	O
polypeptide	NN	O
can	MD	O
comprise	VB	O
the	DT	O
amino	NN	O
acid	JJ	O
sequence	NN	O
set	VBN	O
forth	NN	O
in	IN	O
SEQ	NNP	O
ID	NNP	O
NO:12	NNP	O
or	CC	O
22	CD	O
.	.	O
The	DT	O
polypeptide	NN	O
can	MD	O
comprise	VB	O
an	DT	O
amino	NN	O
acid	NN	O
sequence	NN	O
having	VBG	O
99	CD	O
%	NN	O
identity	NN	O
to	TO	O
the	DT	O
sequence	NN	O
set	VBN	O
forth	NN	O
in	IN	O
SEQ	NNP	O
ID	NNP	O
NO	NNP	O
:	:	O
12	CD	O
or	CC	O
22	CD	O
.	.	O
In	IN	O
another	DT	O
aspect	NN	O
,	,	O
this	DT	O
document	NN	O
features	VBZ	O
an	DT	O
isolated	JJ	O
nucleic	NN	O
acid	NN	O
comprising	NN	O
,	,	O
or	CC	O
consisting	VBG	O
essentially	RB	O
of	IN	O
,	,	O
a	DT	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
that	WDT	O
encodes	VBZ	O
a	DT	O
polypeptide	NN	O
comprising	VBG	O
an	DT	O
amino	NN	O
acid	NN	O
sequence	NN	O
at	IN	O
least	JJS	O
95	CD	O
percent	JJ	O
identical	JJ	O
to	TO	O
the	DT	O
amino	NN	O
acid	JJ	O
sequence	NN	O
set	VBN	O
forth	NN	O
in	IN	O
SEQ	NNP	O
ID	NNP	O
NO:2	NNP	O
,	,	O
4	CD	O
,	,	O
6	CD	O
,	,	O
8	CD	O
,	,	O
10	CD	O
,	,	O
12	CD	O
,	,	O
14	CD	O
,	,	O
16	CD	O
,	,	O
18	CD	O
,	,	O
20	CD	O
,	,	O
22	CD	O
,	,	O
24	CD	O
,	,	O
26	CD	O
,	,	O
28	CD	O
,	,	O
30	CD	O
,	,	O
32	CD	O
,	,	O
or	CC	O
34	CD	O
.	.	O
The	DT	O
polypeptide	NN	O
can	MD	O
comprise	VB	O
the	DT	O
amino	NN	O
acid	JJ	O
sequence	NN	O
set	VBN	O
forth	NN	O
in	IN	O
SEQ	NNP	O
ID	NNP	O
NO:10	NNP	O
.	.	O
The	DT	O
polypeptide	NN	O
can	MD	O
comprise	VB	O
an	DT	O
amino	NN	O
acid	NN	O
sequence	NN	O
having	VBG	O
99	CD	O
%	NN	O
identity	NN	O
to	TO	O
the	DT	O
sequence	NN	O
set	VBN	O
forth	NN	O
in	IN	O
SEQ	NNP	O
ID	NNP	O
NO:10	NNP	O
.	.	O
The	DT	O
polypeptide	NN	O
can	MD	O
comprise	VB	O
the	DT	O
amino	NN	O
acid	JJ	O
sequence	NN	O
set	VBN	O
forth	NN	O
in	IN	O
SEQ	NNP	O
ID	NNP	O
NO:12	NNP	O
or	CC	O
22	CD	O
.	.	O
The	DT	O
polypeptide	NN	O
can	MD	O
comprise	VB	O
an	DT	O
amino	NN	O
acid	NN	O
sequence	NN	O
having	VBG	O
fewer	JJR	O
than	IN	O
5	CD	O
mismatches	NNS	O
as	IN	O
compared	VBN	O
to	TO	O
the	DT	O
sequence	NN	O
set	VBN	O
forth	NN	O
in	IN	O
SEQ	NNP	O
ID	NNP	O
NO:10	NNP	O
,	,	O
12	CD	O
,	,	O
or	CC	O
22	CD	O
.	.	O
The	DT	O
nucleic	JJ	O
acid	NN	O
can	MD	O
hybridize	VB	O
under	IN	O
highly	RB	O
stringent	JJ	O
hybridization	NN	O
conditions	NNS	O
to	TO	O
the	DT	O
nucleic	JJ	O
acid	JJ	O
sequence	NN	O
set	VBN	O
forth	NN	O
in	IN	O
SEQ	NNP	O
ID	NNP	O
NO:1	NNP	O
,	,	O
3	CD	O
,	,	O
5	CD	O
,	,	O
7	CD	O
,	,	O
9	CD	O
,	,	O
11	CD	O
,	,	O
13	CD	O
,	,	O
15	CD	O
,	,	O
17	CD	O
,	,	O
19	CD	O
,	,	O
21	CD	O
,	,	O
23	CD	O
,	,	O
25	CD	O
,	,	O
27	CD	O
,	,	O
29	CD	O
,	,	O
31	CD	O
,	,	O
or	CC	O
33	CD	O
.	.	O
The	DT	O
nucleic	JJ	O
acid	NN	O
can	MD	O
hybridize	VB	O
under	IN	O
highly	RB	O
stringent	JJ	O
hybridization	NN	O
conditions	NNS	O
to	TO	O
the	DT	O
nucleic	JJ	O
acid	JJ	O
sequence	NN	O
set	VBN	O
forth	NN	O
in	IN	O
SEQ	NNP	O
ID	NNP	O
NO:9	NNP	O
,	,	O
11	CD	O
,	,	O
or	CC	O
21	CD	O
.	.	O
In	IN	O
another	DT	O
aspect	NN	O
,	,	O
this	DT	O
document	NN	O
features	VBZ	O
a	DT	O
purified	JJ	O
antibody	NN	O
having	VBG	O
the	DT	O
ability	NN	O
to	TO	O
bind	VB	O
to	TO	O
a	DT	O
polypeptide	NN	O
comprising	NN	O
,	,	O
or	CC	O
consisting	VBG	O
essentially	RB	O
of	IN	O
,	,	O
an	DT	O
amino	NN	O
acid	NN	O
sequence	NN	O
at	IN	O
least	JJS	O
95	CD	O
percent	JJ	O
identical	JJ	O
to	TO	O
the	DT	O
amino	NN	O
acid	JJ	O
sequence	NN	O
set	VBN	O
forth	NN	O
in	IN	O
SEQ	NNP	O
ID	NNP	O
NO:2	NNP	O
,	,	O
4	CD	O
,	,	O
6	CD	O
,	,	O
8	CD	O
,	,	O
10	CD	O
,	,	O
12	CD	O
,	,	O
14	CD	O
,	,	O
16	CD	O
,	,	O
18	CD	O
,	,	O
20	CD	O
,	,	O
22	CD	O
,	,	O
24	CD	O
,	,	O
26	CD	O
,	,	O
28	CD	O
,	,	O
30	CD	O
,	,	O
32	CD	O
,	,	O
or	CC	O
34	CD	O
.	.	O
The	DT	O
antibody	NN	O
can	MD	O
have	VB	O
a	DT	O
dissociation	NN	O
constant	NN	O
that	WDT	O
is	VBZ	O
less	JJR	O
than	IN	O
10−7	CD	O
for	IN	O
the	DT	O
polypeptide	NN	O
.	.	O
The	DT	O
polypeptide	NN	O
can	MD	O
be	VB	O
a	DT	O
polypeptide	JJ	O
having	VBG	O
the	DT	O
sequence	NN	O
set	VBN	O
forth	NN	O
in	IN	O
SEQ	NNP	O
ID	NNP	O
NO:10	NNP	O
,	,	O
12	CD	O
,	,	O
or	CC	O
22	CD	O
.	.	O
In	IN	O
another	DT	O
aspect	NN	O
,	,	O
this	DT	O
document	NN	O
features	VBZ	O
a	DT	O
method	NN	O
of	IN	O
identifying	VBG	O
an	DT	O
inhibitor	NN	O
of	IN	O
fungus-induced	JJ	O
eosinophil	JJ	O
degranulation	NN	O
.	.	O
The	DT	O
method	NN	O
comprises	VBZ	O
,	,	O
or	CC	O
consists	VBZ	O
essentially	RB	O
of	IN	O
,	,	O
determining	VBG	O
whether	IN	O
or	CC	O
not	RB	O
a	DT	O
test	NN	O
agent	NN	O
reduces	VBZ	O
the	DT	O
amount	NN	O
of	IN	O
eosinophil	JJ	O
degranulation	NN	O
induced	VBN	O
by	IN	O
a	DT	O
preparation	NN	O
comprising	VBG	O
a	DT	O
polypeptide	NN	O
having	VBG	O
an	DT	O
amino	NN	O
acid	NN	O
sequence	NN	O
at	IN	O
least	JJS	O
95	CD	O
percent	JJ	O
identical	JJ	O
to	TO	O
the	DT	O
amino	NN	O
acid	JJ	O
sequence	NN	O
set	VBN	O
forth	NN	O
in	IN	O
SEQ	NNP	O
ID	NNP	O
NO:2	NNP	O
,	,	O
4	CD	O
,	,	O
6	CD	O
,	,	O
8	CD	O
,	,	O
10	CD	O
,	,	O
12	CD	O
,	,	O
14	CD	O
,	,	O
16	CD	O
,	,	O
18	CD	O
,	,	O
20	CD	O
,	,	O
22	CD	O
,	,	O
24	CD	O
,	,	O
26	CD	O
,	,	O
28	CD	O
,	,	O
30	CD	O
,	,	O
32	CD	O
,	,	O
or	CC	O
34	CD	O
,	,	O
wherein	VBD	O
the	DT	O
reduction	NN	O
indicates	VBZ	O
that	IN	O
the	DT	O
test	NN	O
agent	NN	O
is	VBZ	O
the	DT	O
inhibitor	NN	O
.	.	O
The	DT	O
polypeptide	NN	O
can	MD	O
be	VB	O
a	DT	O
recombinantly	RB	O
produced	VBN	O
polypeptide	NN	O
.	.	O
The	DT	O
amount	NN	O
of	IN	O
eosinophil	JJ	O
degranulation	NN	O
can	MD	O
be	VB	O
determined	VBN	O
by	IN	O
measuring	VBG	O
major	JJ	O
basic	JJ	O
protein	NN	O
or	CC	O
eosinophil-derived	JJ	O
neurotoxin	NN	O
.	.	O
In	IN	O
another	DT	O
aspect	NN	O
,	,	O
this	DT	O
document	NN	O
features	VBZ	O
a	DT	O
method	NN	O
of	IN	O
identifying	VBG	O
an	DT	O
inhibitor	NN	O
of	IN	O
fungus-induced	JJ	O
inflammation	NN	O
.	.	O
The	DT	O
method	NN	O
comprises	VBZ	O
,	,	O
or	CC	O
consists	VBZ	O
essentially	RB	O
of	IN	O
,	,	O
determining	VBG	O
whether	IN	O
or	CC	O
not	RB	O
a	DT	O
test	NN	O
agent	NN	O
reduces	VBZ	O
the	DT	O
amount	NN	O
of	IN	O
inflammation	NN	O
induced	VBN	O
in	IN	O
a	DT	O
mammal	NN	O
by	IN	O
a	DT	O
preparation	NN	O
comprising	VBG	O
a	DT	O
polypeptide	NN	O
having	VBG	O
an	DT	O
amino	NN	O
acid	NN	O
sequence	NN	O
at	IN	O
least	JJS	O
95	CD	O
percent	JJ	O
identical	JJ	O
to	TO	O
the	DT	O
amino	NN	O
acid	JJ	O
sequence	NN	O
set	VBN	O
forth	NN	O
in	IN	O
SEQ	NNP	O
ID	NNP	O
NO:2	NNP	O
,	,	O
4	CD	O
,	,	O
6	CD	O
,	,	O
8	CD	O
,	,	O
10	CD	O
,	,	O
12	CD	O
,	,	O
14	CD	O
,	,	O
16	CD	O
,	,	O
18	CD	O
,	,	O
20	CD	O
,	,	O
22	CD	O
,	,	O
24	CD	O
,	,	O
26	CD	O
,	,	O
28	CD	O
,	,	O
30	CD	O
,	,	O
32	CD	O
,	,	O
or	CC	O
34	CD	O
,	,	O
wherein	VBD	O
the	DT	O
reduction	NN	O
indicates	VBZ	O
that	IN	O
the	DT	O
test	NN	O
agent	NN	O
is	VBZ	O
the	DT	O
inhibitor	NN	O
.	.	O
The	DT	O
polypeptide	NN	O
can	MD	O
be	VB	O
a	DT	O
recombinantly	RB	O
produced	VBN	O
polypeptide	NN	O
.	.	O
Unless	IN	O
otherwise	RB	O
defined	VBN	O
,	,	O
all	DT	O
technical	JJ	O
and	CC	O
scientific	JJ	O
terms	NNS	O
used	VBN	O
herein	NNS	O
have	VBP	O
the	DT	O
same	JJ	O
meaning	NN	O
as	IN	O
commonly	RB	O
understood	VBN	O
by	IN	O
one	CD	O
of	IN	O
ordinary	JJ	O
skill	NN	O
in	IN	O
the	DT	O
art	NN	O
to	TO	O
which	WDT	O
this	DT	O
invention	NN	O
pertains	VBZ	O
.	.	O
Although	IN	O
methods	NNS	O
and	CC	O
materials	NNS	O
similar	JJ	O
or	CC	O
equivalent	JJ	O
to	TO	O
those	DT	O
described	VBN	O
herein	NNS	O
can	MD	O
be	VB	O
used	VBN	O
to	TO	O
practice	NN	O
the	DT	O
invention	NN	O
,	,	O
suitable	JJ	O
methods	NNS	O
and	CC	O
materials	NNS	O
are	VBP	O
described	VBN	O
below	IN	O
.	.	O
All	DT	O
publications	NNS	O
,	,	O
patent	NN	O
applications	NNS	O
,	,	O
patents	NNS	O
,	,	O
and	CC	O
other	JJ	O
references	NNS	O
mentioned	VBN	O
herein	NNS	O
are	VBP	O
incorporated	VBN	O
by	IN	O
reference	NN	O
in	IN	O
their	PRP$	O
entirety	NN	O
.	.	O
In	IN	O
case	NN	O
of	IN	O
conflict	NN	O
,	,	O
the	DT	O
present	JJ	O
specification	NN	O
,	,	O
including	VBG	O
definitions	NNS	O
,	,	O
will	MD	O
control	VB	O
.	.	O
In	IN	O
addition	NN	O
,	,	O
the	DT	O
materials	NNS	O
,	,	O
methods	NNS	O
,	,	O
and	CC	O
examples	NNS	O
are	VBP	O
illustrative	JJ	O
only	RB	O
and	CC	O
not	RB	O
intended	VBN	O
to	TO	O
be	VB	O
limiting	VBG	O
.	.	O
The	DT	O
details	NNS	O
of	IN	O
one	CD	O
or	CC	O
more	JJR	O
embodiments	NNS	O
of	IN	O
the	DT	O
invention	NN	O
are	VBP	O
set	VBN	O
forth	NN	O
in	IN	O
the	DT	O
accompanying	JJ	O
drawings	NNS	O
and	CC	O
the	DT	O
description	NN	O
below	IN	O
.	.	O
Other	JJ	O
features	NNS	O
,	,	O
objects	NNS	O
,	,	O
and	CC	O
advantages	NNS	O
of	IN	O
the	DT	O
invention	NN	O
will	MD	O
be	VB	O
apparent	JJ	O
from	IN	O
the	DT	O
description	NN	O
and	CC	O
drawings	NNS	O
,	,	O
and	CC	O
from	IN	O
the	DT	O
claims	NNS	O
.	.	O
DESCRIPTION	NN	O
OF	IN	O
THE	NNP	O
DRAWINGS	NNP	O
FIG	NNP	O
.	.	O
1	CD	O
.	.	O
Production	NN	O
of	IN	O
IL-5	NNP	O
from	IN	O
PBMC	NNP	O
from	IN	O
normal	JJ	O
individuals	NNS	O
(	(	O
n=15	NN	O
)	)	O
and	CC	O
patients	NNS	O
with	IN	O
CRS	NNP	O
(	(	O
n=18	NN	O
)	)	O
cultured	VBD	O
with	IN	O
extracts	NNS	O
of	IN	O
common	JJ	O
environmental	JJ	O
fungi	NNS	O
.	.	O
FIG	NNP	O
.	.	O
2	CD	O
.	.	O
Correlation	NN	O
between	IN	O
Alternaria-specific	NNP	O
IgE	NNP	O
(	(	O
A	NNP	O
)	)	O
and	CC	O
IgG	NNP	O
(	(	O
B	NNP	O
)	)	O
in	IN	O
sera	NN	O
and	CC	O
Alternaria-induced	JJ	O
PBMC	NNP	O
production	NN	O
of	IN	O
IL-5	NNP	O
in	IN	O
patients	NNS	O
with	IN	O
CRS	NNP	O
.	.	O
FIG	NNP	O
.	.	O
3	CD	O
.	.	O
Serum	NNP	O
levels	NNS	O
of	IN	O
IgG4	NNP	O
antibodies	NNS	O
to	TO	O
Alternaria	NNP	O
(	(	O
left	VBN	O
)	)	O
and	CC	O
Aspergillus	NNP	O
(	(	O
right	JJ	O
)	)	O
in	IN	O
normal	JJ	O
individuals	NNS	O
and	CC	O
patients	NNS	O
with	IN	O
allergic	JJ	O
rhinitis	NN	O
(	(	O
AR	NNP	O
)	)	O
and	CC	O
CRS	NNP	O
.	.	O
Each	DT	O
dot	NN	O
represents	VBZ	O
one	CD	O
subject	NN	O
Assay	NNP	O
sensitivity	NN	O
,	,	O
100	CD	O
μg/L	NN	O
.	.	O
Statistical	JJ	O
analysis	NN	O
by	IN	O
Mann-Whitney	NNP	O
U	NNP	O
test	NN	O
.	.	O
FIG	NNP	O
.	.	O
4	CD	O
.	.	O
H	NNP	O
&	CC	O
E	NNP	O
(	(	O
A	DT	O
)	)	O
.	.	O
GMS	NNP	O
(	(	O
B	NNP	O
)	)	O
,	,	O
anti-Alternaria	JJ	O
(	(	O
C	NNP	O
)	)	O
,	,	O
and	CC	O
anti-MSP	NN	O
(	(	O
D	NNP	O
)	)	O
staining	NN	O
of	IN	O
sinus	JJ	O
tissue	NN	O
specimen	NNS	O
from	IN	O
a	DT	O
patients	NNS	O
with	IN	O
CRS	NNP	O
.	.	O
Arrowheads	NNS	O
point	NN	O
to	TO	O
GMS-positive	JJ	O
fungi	NN	O
,	,	O
which	WDT	O
are	VBP	O
barely	RB	O
detectable	JJ	O
by	IN	O
this	DT	O
staining	NN	O
.	.	O
Also	RB	O
note	VBP	O
presence	NN	O
of	IN	O
fungal	JJ	O
organisms	NNS	O
as	IN	O
detected	VBN	O
by	IN	O
anti-Alternaria	JJ	O
Ab	NNP	O
(	(	O
panel	NN	O
C	NNP	O
)	)	O
and	CC	O
diffuse	JJ	O
deposition	NN	O
of	IN	O
MBP	NNP	O
(	(	O
panel	NN	O
D	NNP	O
)	)	O
in	IN	O
sinus	NN	O
mucus	NN	O
,	,	O
but	CC	O
not	RB	O
in	IN	O
sinus	JJ	O
tissue	NN	O
.	.	O
FIG	NNP	O
.	.	O
5	CD	O
.	.	O
Effects	NNS	O
of	IN	O
fungi	NNS	O
on	IN	O
eosinophil	JJ	O
degranulation	NN	O
.	.	O
Eosinophils	NNS	O
were	VBD	O
incubated	VBN	O
with	IN	O
culture	NN	O
extracts	NNS	O
of	IN	O
various	JJ	O
fungi	NNS	O
for	IN	O
3	CD	O
hours	NNS	O
.	.	O
EDN	NNP	O
concentrations	NNS	O
in	IN	O
the	DT	O
supernatants	NNS	O
were	VBD	O
measured	VBN	O
by	IN	O
RIA	NNP	O
as	IN	O
an	DT	O
indicator	NN	O
of	IN	O
degranulation	NN	O
.	.	O
*	NN	O
,	,	O
p	NN	O
<	VBD	O
0.05	CD	O
compared	VBN	O
to	TO	O
medium	VB	O
alone	RB	O
,	,	O
n=5	NNS	O
.	.	O
FIG	NNP	O
.	.	O
6	CD	O
.	.	O
Characterization	NN	O
of	IN	O
activity	NN	O
in	IN	O
Alternaria	NNP	O
extract	NN	O
.	.	O
Panel	NNP	O
A	NNP	O
,	,	O
Alternaria	NNP	O
extracts	NNS	O
were	VBD	O
treated	VBN	O
at	IN	O
various	JJ	O
temperatures	NNS	O
before	IN	O
incubation	NN	O
with	IN	O
eosinophils	NNS	O
.	.	O
Panel	NNP	O
B	NNP	O
,	,	O
size	NN	O
exclusion	NN	O
chromatography	NN	O
with	IN	O
Superdex	NNP	O
200-10/30	JJ	O
column	NN	O
.	.	O
FIG	NNP	O
.	.	O
7	CD	O
.	.	O
Mechanism	NN	O
of	IN	O
PAR-2	NNP	O
activation	NN	O
.	.	O
FIG	NNP	O
.	.	O
8	CD	O
.	.	O
Desensitization	NN	O
of	IN	O
eosinophil	JJ	O
calcium	NN	O
response	NN	O
(	(	O
Panel	NNP	O
A	NNP	O
)	)	O
and	CC	O
EDN	NNP	O
release	NN	O
(	(	O
Panel	NNP	O
B	NNP	O
)	)	O
by	IN	O
PAR-2	NNP	O
peptides	NNS	O
.	.	O
Cells	NNS	O
were	VBD	O
preincubated	VBN	O
with	IN	O
PAR-2	NNP	O
agonist	NN	O
(	(	O
SLIGKV	NNP	O
;	:	O
SEQ	NNP	O
ID	NNP	O
NO:38	NNP	O
)	)	O
,	,	O
PAR-2	JJ	O
antagonist	NN	O
(	(	O
LSIGKV	NNP	O
;	:	O
SEQ	NNP	O
ID	NNP	O
NO:35	NNP	O
)	)	O
or	CC	O
control	VB	O
peptide	NN	O
(	(	O
GLIVKS	NNP	O
;	:	O
SEQ	NNP	O
ID	NNP	O
NO:36	NNP	O
)	)	O
(	(	O
all	DT	O
at	IN	O
100	CD	O
μM	NNS	O
)	)	O
before	IN	O
stimulation	NN	O
with	IN	O
Alternaria	NNP	O
extract	NN	O
(	(	O
Panel	NNP	O
A	NNP	O
)	)	O
or	CC	O
with	IN	O
Alternaria	NNP	O
extract	NN	O
,	,	O
PAF	NNP	O
or	CC	O
PMA	NNP	O
(	(	O
Panel	NNP	O
B	NNP	O
)	)	O
.	.	O
FIG	NNP	O
.	.	O
9	CD	O
.	.	O
Effects	NNS	O
of	IN	O
protease	NN	O
inhibitors	NNS	O
on	IN	O
PAR-2	NNP	O
cleavage	NN	O
activity	NN	O
(	(	O
Panel	NNP	O
A	NNP	O
)	)	O
and	CC	O
EDN	NNP	O
release	NN	O
activity	NN	O
(	(	O
Panel	NNP	O
B	NNP	O
)	)	O
of	IN	O
Alternaria	NNP	O
extract	NN	O
.	.	O
Alternaria	NNP	O
extract	NN	O
,	,	O
trypsin	NN	O
,	,	O
or	CC	O
PMA	NNP	O
was	VBD	O
pretreated	VBN	O
with	IN	O
pepstatin	NN	O
A	NNP	O
agarose	RB	O
,	,	O
control	NN	O
agarose	NN	O
,	,	O
or	CC	O
APMSF	NNP	O
,	,	O
and	CC	O
added	VBD	O
to	TO	O
the	DT	O
PAR-2	NNP	O
peptide	NN	O
substrate	NN	O
(	(	O
Panel	NNP	O
A	NNP	O
)	)	O
or	CC	O
eosinophils	NNS	O
(	(	O
Panel	NNP	O
B	NNP	O
)	)	O
.	.	O
In	IN	O
Panel	NNP	O
B	NNP	O
,	,	O
*	NNP	O
,	,	O
p	NN	O
<	VBD	O
0.05	CD	O
compared	VBN	O
to	TO	O
no	DT	O
inhibitors	NNS	O
,	,	O
n=4	NN	O
.	.	O
FIG	NNP	O
.	.	O
10	CD	O
.	.	O
Effects	NNS	O
of	IN	O
fungi	NNS	O
on	IN	O
IL-6	NNP	O
production	NN	O
by	IN	O
BEAS-2B	NNP	O
cells	NNS	O
.	.	O
BEAS-2B	JJ	O
cells	NNS	O
were	VBD	O
incubated	VBN	O
with	IN	O
culture	NN	O
extracts	NNS	O
of	IN	O
various	JJ	O
fungi	NNS	O
for	IN	O
24	CD	O
hours	NNS	O
.	.	O
IL-6	JJ	O
concentrations	NNS	O
in	IN	O
the	DT	O
supernatants	NNS	O
were	VBD	O
measured	VBN	O
by	IN	O
ELISA	NNP	O
.	.	O
*	NN	O
,	,	O
p	NN	O
<	VBD	O
0.05	CD	O
compared	VBN	O
to	TO	O
medium	VB	O
alone	RB	O
,	,	O
n=3	NNS	O
.	.	O
FIG	NNP	O
.	.	O
11	CD	O
.	.	O
Effects	NNS	O
of	IN	O
an	DT	O
aspartate	JJ	O
protease	NN	O
inhibitor	NN	O
,	,	O
ritonavir	NN	O
,	,	O
on	IN	O
IL-8	NNP	O
production	NN	O
by	IN	O
BEAS-2B	NNP	O
cells	NNS	O
.	.	O
Alternaria	NNP	O
extract	NN	O
or	CC	O
TNF-α	NN	O
was	VBD	O
pretreated	VBN	O
with	IN	O
ritonavir	NN	O
and	CC	O
added	VBD	O
to	TO	O
BEAS-2B	NNP	O
cells	NNS	O
.	.	O
IL-8	JJ	O
concentrations	NNS	O
in	IN	O
the	DT	O
supernatants	NNS	O
were	VBD	O
measured	VBN	O
after	IN	O
24	CD	O
hours	NNS	O
.	.	O
Data	NNS	O
are	VBP	O
normalized	VBN	O
to	TO	O
the	DT	O
values	NNS	O
without	IN	O
ritonavir	NN	O
as	IN	O
100	CD	O
%	NN	O
.	.	O
*	NN	O
,	,	O
p	NN	O
<	VBD	O
0.05	CD	O
compared	VBN	O
to	TO	O
no	DT	O
inhibitor	NN	O
,	,	O
n=4	NN	O
.	.	O
FIG	NNP	O
.	.	O
12	CD	O
.	.	O
Panel	NNP	O
A.	NN	O
DEAE	NNP	O
fractionation	NN	O
of	IN	O
Alternaria	NNP	O
extract	NN	O
.	.	O
Alternaria	NNP	O
extract	NN	O
was	VBD	O
separated	VBN	O
by	IN	O
DEAE	NNP	O
anion-exchange	NN	O
chromatography	NN	O
(	(	O
Buffer	NNP	O
A	NNP	O
,	,	O
20	CD	O
mM	NN	O
Tris	NNP	O
pH	VBZ	O
7.5	CD	O
;	:	O
Buffer	NNP	O
B	NNP	O
,	,	O
20	CD	O
mM	NN	O
Tris	NNP	O
1M	CD	O
NaCl	NNP	O
pH	RB	O
7.5	CD	O
)	)	O
and	CC	O
individual	JJ	O
fractions	NNS	O
were	VBD	O
analyzed	VBN	O
for	IN	O
their	PRP$	O
PAR-2	JJ	O
cleavage	NN	O
activity	NN	O
,	,	O
aspartate	JJ	O
protease	NN	O
activity	NN	O
,	,	O
and	CC	O
eosinophil	JJ	O
degranulation	NN	O
activity	NN	O
.	.	O
Panel	NNP	O
B	NNP	O
.	.	O
A	DT	O
silver-stained	JJ	O
SDS-PAGE	JJ	O
analysis	NN	O
.	.	O
Lane	NNP	O
1	CD	O
;	:	O
crude	NN	O
Alternaria	NNP	O
extract	NN	O
,	,	O
Lane	NNP	O
2	CD	O
;	:	O
DEAE	NNP	O
fraction	NN	O
#	#	O
18	CD	O
further	RB	O
purified	VBN	O
by	IN	O
hydroxyapatite	JJ	O
chromatography	NN	O
.	.	O
FIG	NNP	O
.	.	O
13	CD	O
.	.	O
Morphology	NNP	O
of	IN	O
eosinophils	NNS	O
incubated	VBN	O
with	IN	O
germinating	VBG	O
A.	NN	O
alternata	NNS	O
(	(	O
Panel	NNP	O
A	NNP	O
)	)	O
and	CC	O
release	NN	O
of	IN	O
EDN	NNP	O
by	IN	O
these	DT	O
eosinophils	NNS	O
(	(	O
Panel	NNP	O
B	NNP	O
)	)	O
.	.	O
Spores	NNS	O
of	IN	O
A.	NN	O
alternata	NNS	O
were	VBD	O
cultured	VBN	O
in	IN	O
RPMI	NNP	O
medium	NN	O
with	IN	O
10	CD	O
%	NN	O
FCS	NNP	O
for	IN	O
12	CD	O
hours	NNS	O
.	.	O
Freshly	RB	O
isolated	VBN	O
eosinophils	NNS	O
were	VBD	O
added	VBN	O
to	TO	O
the	DT	O
wells	NNS	O
at	IN	O
indicated	JJ	O
eosinophil	NN	O
:	:	O
spore	NN	O
ratios	NNS	O
and	CC	O
incubated	VBD	O
for	IN	O
an	DT	O
additional	JJ	O
4	CD	O
hours	NNS	O
.	.	O
Concentrations	NNS	O
of	IN	O
EDN	NNP	O
released	VBD	O
into	IN	O
the	DT	O
supernatants	NNS	O
were	VBD	O
measured	VBN	O
by	IN	O
ELISA	NNP	O
.	.	O
Data	NNS	O
are	VBP	O
presented	VBN	O
as	IN	O
mean±range	NN	O
from	IN	O
a	DT	O
duplicate	JJ	O
experiment	NN	O
.	.	O
Left	NNP	O
panel	NN	O
and	CC	O
right	JJ	O
panel	NN	O
in	IN	O
Panel	NNP	O
A	NNP	O
shows	VBZ	O
bright	JJ	O
field	NN	O
image	NN	O
and	CC	O
anti-MBP	JJ	O
immunofluorescence	NN	O
staining	NN	O
(	(	O
to	TO	O
visualize	VB	O
eosinophils	NNS	O
)	)	O
,	,	O
respectively	RB	O
.	.	O
FIG	NNP	O
.	.	O
14	CD	O
.	.	O
Morphology	NNP	O
of	IN	O
spores	NNS	O
from	IN	O
GFP-transformed	NNP	O
A.	NN	O
alternata	NN	O
.	.	O
FIG	NNP	O
.	.	O
15	CD	O
.	.	O
Growth	NNP	O
of	IN	O
A.	NNP	O
alternata	NN	O
and	CC	O
production	NN	O
of	IN	O
PAR-2	NNP	O
activating	VBG	O
enzyme	NN	O
(	(	O
s	NN	O
)	)	O
.	.	O
Spores	NNS	O
of	IN	O
GFP-transformed	NNP	O
A.	NN	O
alternata	NN	O
(	(	O
1,000	CD	O
spore/well	NN	O
of	IN	O
96-well	NNP	O
tissue	NN	O
culture	NN	O
plates	NNS	O
)	)	O
were	VBD	O
cultured	VBN	O
in	IN	O
HBSS	NNP	O
medium	NN	O
supplemented	VBD	O
with	IN	O
different	JJ	O
concentrations	NNS	O
of	IN	O
bovine	NN	O
mucin	NN	O
from	IN	O
submaxillary	JJ	O
glands	NNS	O
.	.	O
Fungal	NNP	O
growth	NN	O
was	VBD	O
quantitated	VBN	O
after	IN	O
48	CD	O
hours	NNS	O
by	IN	O
measuring	VBG	O
the	DT	O
intensity	NN	O
of	IN	O
GFP	NNP	O
fluorescence	NN	O
in	IN	O
each	DT	O
well	NN	O
(	(	O
Panel	NNP	O
A	NNP	O
)	)	O
.	.	O
Production	NN	O
of	IN	O
PAR-2	NNP	O
activating	VBG	O
proteases	NNS	O
by	IN	O
fungi	NN	O
into	IN	O
the	DT	O
supernatants	NNS	O
was	VBD	O
measured	VBN	O
at	IN	O
24	CD	O
hours	NNS	O
or	CC	O
48	CD	O
hours	NNS	O
by	IN	O
using	VBG	O
a	DT	O
fluorescence	NN	O
quenched	VBD	O
PAR-2	NNP	O
peptide	NN	O
substrate	NN	O
(	(	O
Abz-SKGRSLIGK	NNP	O
(	(	O
Dnp	NNP	O
)	)	O
D	NNP	O
)	)	O
(	(	O
Panel	NNP	O
B	NNP	O
)	)	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:37	NNP	O
)	)	O
.	.	O
Data	NNS	O
are	VBP	O
presented	VBN	O
as	IN	O
mean±SEM	NN	O
from	IN	O
a	DT	O
triplicate	JJ	O
experiment	NN	O
.	.	O
FIG	NNP	O
.	.	O
16	CD	O
.	.	O
Effects	NNS	O
of	IN	O
intranasal	NN	O
exposure	NN	O
to	TO	O
fungal	VB	O
antigens	NNS	O
or	CC	O
OVA	NNP	O
on	IN	O
airway	JJ	O
inflammation	NN	O
.	.	O
Naive	JJ	O
mice	NN	O
were	VBD	O
exposed	VBN	O
intranasally	RB	O
to	TO	O
antigens	NNS	O
(	(	O
250	CD	O
μg/exposure	NN	O
)	)	O
without	IN	O
prior	JJ	O
sensitization	NN	O
.	.	O
Alt	NNP	O
(	(	O
cult	NN	O
)	)	O
,	,	O
Alternaria	NNP	O
culture	NN	O
supernatant	NN	O
;	:	O
Alt	NNP	O
(	(	O
cell	NN	O
)	)	O
,	,	O
Alternaria	NNP	O
cellular	JJ	O
extract	NN	O
;	:	O
Can	NNP	O
,	,	O
Candida	NNP	O
extract	NN	O
;	:	O
Asp	NNP	O
,	,	O
Aspergillus	NNP	O
extract	NN	O
.	.	O
FIG	NNP	O
.	.	O
17	CD	O
.	.	O
Effects	NNS	O
of	IN	O
immune	NN	O
cell	NN	O
deficiency	NN	O
on	IN	O
Alternaria-induced	NNP	O
airway	NN	O
eosinophilia	NN	O
and	CC	O
early	JJ	O
cytokine	NN	O
response	NN	O
.	.	O
Naive	JJ	O
Rag-1	NNP	O
knockout	NN	O
(	(	O
Rag-1	NNP	O
)	)	O
or	CC	O
wild	JJ	O
type	NN	O
(	(	O
WT	NNP	O
)	)	O
mice	NN	O
were	VBD	O
exposed	VBN	O
to	TO	O
Alternaria	NNP	O
(	(	O
Alt	NNP	O
)	)	O
intranasally	RB	O
on	IN	O
days	NNS	O
0	CD	O
,	,	O
3	CD	O
,	,	O
and	CC	O
6	CD	O
.	.	O
Panel	VB	O
A	DT	O
shows	JJ	O
kinetics	NNS	O
of	IN	O
airway	NN	O
eosinophilia	NN	O
.	.	O
Panel	NNP	O
B	NNP	O
shows	VBZ	O
early	JJ	O
cytokine	NN	O
response	NN	O
12	CD	O
hours	NNS	O
after	IN	O
the	DT	O
first	JJ	O
exposure	NN	O
(	(	O
i.e	NN	O
.	.	O
day	NN	O
0.5	CD	O
)	)	O
,	,	O
n=4-9	JJ	O
.	.	O
FIG	NNP	O
.	.	O
18	CD	O
.	.	O
Early	JJ	O
airway	RB	O
IL-5	JJ	O
production	NN	O
in	IN	O
response	NN	O
to	TO	O
Alternaria	NNP	O
exposure	NN	O
.	.	O
Panel	VB	O
A	DT	O
:	:	O
BALB/c	JJ	O
mice	NNS	O
were	VBD	O
pretreated	VBN	O
by	IN	O
intranasal	JJ	O
administration	NN	O
of	IN	O
LPS	NNP	O
(	(	O
1	CD	O
μg	NN	O
)	)	O
or	CC	O
PBS	NNP	O
on	IN	O
day	NN	O
−3	NNP	O
,	,	O
and	CC	O
then	RB	O
exposed	VBD	O
to	TO	O
Alternaria	NNP	O
(	(	O
Alt	NNP	O
)	)	O
on	IN	O
day	NN	O
0	CD	O
.	.	O
BAL	NNP	O
fluids	NNS	O
were	VBD	O
collected	VBN	O
12	CD	O
hours	NNS	O
later	RB	O
.	.	O
Panel	NNP	O
B	NNP	O
:	:	O
C3H/HeOuJ	NN	O
or	CC	O
C3H/HeJ	NNP	O
mice	NNS	O
were	VBD	O
exposed	VBN	O
to	TO	O
Alternaria	NNP	O
or	CC	O
PBS	NNP	O
on	IN	O
day	NN	O
0	CD	O
without	IN	O
prior	JJ	O
treatment	NN	O
.	.	O
BAL	NNP	O
fluids	NNS	O
were	VBD	O
collected	VBN	O
12	CD	O
hours	NNS	O
later	RB	O
.	.	O
n=5-6	NN	O
.	.	O
FIG	NNP	O
.	.	O
19	CD	O
.	.	O
Alternaria	NNP	O
extract	NN	O
was	VBD	O
pretreated	VBN	O
with	IN	O
pepstain	JJ	O
A-agarose	NNP	O
(	(	O
Pep	NNP	O
A	NNP	O
)	)	O
or	CC	O
control	VB	O
agarose	JJ	O
(	(	O
Cont	NNP	O
)	)	O
.	.	O
Panel	VB	O
A	DT	O
:	:	O
Mice	NN	O
were	VBD	O
intranasally	RB	O
challenged	VBN	O
with	IN	O
treated	JJ	O
Alternaria	NNP	O
extract	NN	O
on	IN	O
day	NN	O
0	CD	O
,	,	O
and	CC	O
BAL	NNP	O
fluids	NNS	O
were	VBD	O
analyzed	VBN	O
for	IN	O
IL-5	NNP	O
after	IN	O
12	CD	O
hours	NNS	O
.	.	O
Panel	NNP	O
B	NNP	O
:	:	O
Mice	NNP	O
were	VBD	O
intranasally	RB	O
challenged	VBN	O
with	IN	O
treated	JJ	O
Alternaria	NNP	O
extract	NN	O
or	CC	O
PBS	NNP	O
on	IN	O
days	NNS	O
0	CD	O
,	,	O
3	CD	O
,	,	O
and	CC	O
6	CD	O
,	,	O
and	CC	O
BAL	NNP	O
fluids	NNS	O
were	VBD	O
analyzed	VBN	O
for	IN	O
eosinophil	JJ	O
numbers	NNS	O
on	IN	O
day	NN	O
8.	CD	O
n=4-7	NN	O
.	.	O
FIG	NNP	O
.	.	O
20	CD	O
.	.	O
Effects	NNS	O
of	IN	O
Alternaria	NNP	O
DEAE	NNP	O
fractions	NNS	O
on	IN	O
airway	DT	O
inflammation	NN	O
.	.	O
Naive	JJ	O
mice	NN	O
were	VBD	O
exposed	VBN	O
intranasally	RB	O
to	TO	O
PBS	NNP	O
or	CC	O
DEAE	NNP	O
fractions	NNS	O
of	IN	O
Alternaria	NNP	O
extract	NN	O
without	IN	O
prior	JJ	O
sensitization	NN	O
.	.	O
The	DT	O
fractions	NNS	O
used	VBN	O
are	VBP	O
those	DT	O
described	VBN	O
in	IN	O
FIG	NNP	O
.	.	O
12.	CD	O
n=3	NN	O
.	.	O
FIG	NNP	O
.	.	O
21	CD	O
.	.	O
Effects	NNS	O
of	IN	O
Trichoderma	NNP	O
xylanase	NNP	O
on	IN	O
eosinophil	JJ	O
degranulation	NN	O
(	(	O
Panel	NNP	O
A	NNP	O
)	)	O
.	.	O
Effects	NNS	O
of	IN	O
Trichoderma	NNP	O
xylanase	NNP	O
on	IN	O
IL-5	NNP	O
production	NN	O
in	IN	O
mouse	NN	O
airways	NNS	O
(	(	O
Panel	NNP	O
B	NNP	O
)	)	O
.	.	O
Panel	VB	O
A	DT	O
:	:	O
Eosinophils	NNS	O
were	VBD	O
incubated	VBN	O
with	IN	O
various	JJ	O
concentrations	NNS	O
of	IN	O
Trichoderma	NNP	O
xylanase	NNP	O
for	IN	O
3	CD	O
hours	NNS	O
.	.	O
EDN	NNP	O
concentrations	NNS	O
in	IN	O
the	DT	O
supernatants	NNS	O
were	VBD	O
measured	VBN	O
by	IN	O
RIA	NNP	O
as	IN	O
an	DT	O
indicator	NN	O
of	IN	O
degranulation	NN	O
.	.	O
Panel	NNP	O
B	NNP	O
:	:	O
Naive	JJ	O
BALB/c	NNP	O
mice	NN	O
were	VBD	O
exposed	VBN	O
intranasally	RB	O
to	TO	O
various	JJ	O
doses	NNS	O
of	IN	O
Trichoderma	NNP	O
xylanase	NNP	O
.	.	O
After	IN	O
12	CD	O
hours	NNS	O
,	,	O
BAL	NNP	O
fluids	NNS	O
were	VBD	O
collected	VBN	O
and	CC	O
the	DT	O
concentrations	NNS	O
of	IN	O
IL-5	NNP	O
were	VBD	O
measured	VBN	O
by	IN	O
ELISA	NNP	O
.	.	O
Mean±range	NNP	O
,	,	O
n=2	NN	O
.	.	O
FIG	NNP	O
.	.	O
22	CD	O
.	.	O
PBMC	NNP	O
proliferation	NN	O
monitored	VBD	O
using	VBG	O
CFSE	NNP	O
labeling	NN	O
.	.	O
PBMCs	NN	O
from	IN	O
a	DT	O
CRS	NNP	O
patient	NN	O
were	VBD	O
isolated	VBN	O
,	,	O
labeled	VBN	O
with	IN	O
CFSE	NNP	O
,	,	O
and	CC	O
cultured	VBD	O
in	IN	O
the	DT	O
presence	NN	O
of	IN	O
25	CD	O
μg/ml	JJ	O
Alternaria	NNP	O
extract	NN	O
(	(	O
Alt	NNP	O
)	)	O
or	CC	O
medium	VB	O
alone	RB	O
(	(	O
Med	NNP	O
)	)	O
.	.	O
On	IN	O
days	NNS	O
4	CD	O
and	CC	O
7	CD	O
,	,	O
cells	NNS	O
were	VBD	O
collected	VBN	O
,	,	O
stained	VBN	O
with	IN	O
CD4	NNP	O
PE	NNP	O
,	,	O
and	CC	O
analyzed	VBN	O
by	IN	O
FACS	NNP	O
.	.	O
Numbers	NNS	O
represent	VBP	O
the	DT	O
percentage	NN	O
of	IN	O
CFSElow	NNP	O
CD4+	NNP	O
cells	NNS	O
among	IN	O
total	JJ	O
CD4+	NNP	O
cells	NNS	O
.	.	O
FIG	NNP	O
.	.	O
23	CD	O
.	.	O
Comparison	NNP	O
of	IN	O
normal	JJ	O
and	CC	O
CRS	NNP	O
proliferation	NN	O
using	VBG	O
CFSE	NNP	O
labeling	NN	O
.	.	O
PBMCs	NN	O
from	IN	O
a	DT	O
normal	JJ	O
individual	NN	O
and	CC	O
a	DT	O
CRS	NNP	O
patient	NN	O
were	VBD	O
CFSE	NNP	O
labeled	VBD	O
and	CC	O
cultured	VBD	O
with	IN	O
25	CD	O
μg/ml	NNS	O
Alternaria	NNP	O
extract	NN	O
(	(	O
Alt	NNP	O
)	)	O
,	,	O
2	CD	O
μg/ml	JJ	O
tetanus	NN	O
toxoid	NN	O
(	(	O
TT	NNP	O
)	)	O
or	CC	O
medium	VB	O
alone	RB	O
(	(	O
Med	NNP	O
)	)	O
.	.	O
On	IN	O
day	NN	O
7	CD	O
,	,	O
cells	NNS	O
were	VBD	O
collected	VBN	O
,	,	O
stained	VBN	O
with	IN	O
CD4	NNP	O
PE	NNP	O
,	,	O
and	CC	O
analyzed	VBN	O
by	IN	O
FACS	NNP	O
.	.	O
FIG	NNP	O
.	.	O
24	CD	O
.	.	O
Temporary	JJ	O
deglycosylation	NN	O
and	CC	O
downregulation	NN	O
of	IN	O
PAR-2	NNP	O
by	IN	O
xylanase	NNP	O
.	.	O
Isolated	VBN	O
eosinophils	NNS	O
were	VBD	O
incubated	VBN	O
with	IN	O
medium	NN	O
alone	RB	O
(	(	O
Med	NNP	O
)	)	O
or	CC	O
Aspergillus	JJ	O
xylanase	NN	O
(	(	O
Xyl	NNP	O
)	)	O
for	IN	O
the	DT	O
indicated	JJ	O
time	NN	O
.	.	O
Cells	NNS	O
were	VBD	O
lysed	VBN	O
and	CC	O
analyzed	VBN	O
for	IN	O
PAR-2	NNP	O
molecules	NNS	O
by	IN	O
anti-PAR-2	JJ	O
antibody	NN	O
(	(	O
which	WDT	O
recognizes	VBZ	O
the	DT	O
N-terminus	NNP	O
of	IN	O
the	DT	O
molecule	NN	O
)	)	O
and	CC	O
Western	JJ	O
blot	NN	O
.	.	O
The	DT	O
41	CD	O
kDa	NN	O
and	CC	O
70	CD	O
kDa	NNS	O
PAR-2	JJ	O
molecules	NNS	O
were	VBD	O
deglycosylated	VBN	O
by	IN	O
xylanase	NNP	O
temporarily	RB	O
.	.	O
Arrow	NNP	O
;	:	O
PAR-2	NNP	O
core	NN	O
protein	NN	O
,	,	O
Arrow	NNP	O
heads	VBZ	O
;	:	O
glycosylated	VBN	O
PAR-2	NNP	O
molecules	NNS	O
.	.	O
FIG	NNP	O
.	.	O
25	CD	O
.	.	O
Partial	JJ	O
characterization	NN	O
of	IN	O
Alternaria	NNP	O
extract	NN	O
.	.	O
A	DT	O
,	,	O
Before	IN	O
incubation	NN	O
with	IN	O
eosinophils	NNS	O
,	,	O
aliquots	NNS	O
of	IN	O
100	CD	O
μg/mL	JJ	O
Alternaria	NNP	O
and	CC	O
10	CD	O
ng/mL	JJ	O
IL-5	NNP	O
were	VBD	O
heated	VBN	O
at	IN	O
37	CD	O
,	,	O
56	CD	O
,	,	O
or	CC	O
100°	CD	O
C.	NNP	O
for	IN	O
30	CD	O
min	NNS	O
or	CC	O
were	VBD	O
treated	VBN	O
at	IN	O
4°	CD	O
C.	NNP	O
for	IN	O
30	CD	O
min	NN	O
.	.	O
Eosinophils	NNS	O
were	VBD	O
incubated	VBN	O
in	IN	O
duplicate	NN	O
with	IN	O
these	DT	O
treated	VBN	O
stimuli	NN	O
for	IN	O
3	CD	O
hours	NNS	O
at	IN	O
37°	CD	O
C.	NNP	O
Results	NNP	O
show	VBP	O
the	DT	O
mean±SEM	NN	O
from	IN	O
five	CD	O
different	JJ	O
eosinophil	NN	O
preparations	NNS	O
.	.	O
B	NNP	O
,	,	O
Size	NNP	O
exclusion	NN	O
chromatography	NN	O
used	VBD	O
a	DT	O
Superdex	NNP	O
200-10/30	JJ	O
column	NN	O
and	CC	O
produced	VBD	O
a	DT	O
broad	JJ	O
absorbance	NN	O
peak	NN	O
(	(	O
smooth	JJ	O
line	NN	O
)	)	O
of	IN	O
the	DT	O
Alternaria	NNP	O
culture	NN	O
extract	NN	O
.	.	O
The	DT	O
dots	NNS	O
connected	VBN	O
by	IN	O
lines	NNS	O
show	VBP	O
the	DT	O
levels	NNS	O
of	IN	O
EDN	NNP	O
release	NN	O
when	WRB	O
portions	NNS	O
of	IN	O
fractions	NNS	O
21-39	JJ	O
were	VBD	O
incubated	VBN	O
with	IN	O
eosinophils	NNS	O
.	.	O
The	DT	O
molecular	JJ	O
weight	NN	O
calibration	NN	O
of	IN	O
the	DT	O
column	NN	O
is	VBZ	O
shown	VBN	O
above	IN	O
the	DT	O
elution	NN	O
profile	NN	O
.	.	O
FIG	NNP	O
.	.	O
26	CD	O
.	.	O
A.	NN	O
alternate	NN	O
xylanase	NN	O
was	VBD	O
PCR	NNP	O
amplified	VBD	O
using	VBG	O
genomic	JJ	O
DNA	NNP	O
as	IN	O
template	NN	O
.	.	O
PCR	NNP	O
product	NN	O
was	VBD	O
cloned	VBN	O
in	IN	O
pQE-30	JJ	O
UA	NNP	O
E.	NNP	O
coli	NNS	O
expression	NN	O
vector	NN	O
.	.	O
The	DT	O
vector	NN	O
was	VBD	O
transformed	VBN	O
into	IN	O
the	DT	O
E.	NNP	O
coli	NNS	O
M15	NNP	O
host	NN	O
strain	NN	O
using	VBG	O
electroporation	NN	O
and	CC	O
screened	VBD	O
for	IN	O
the	DT	O
6×-His	JJ	O
tag	NN	O
.	.	O
Strong	JJ	O
positive	JJ	O
colonies	NNS	O
were	VBD	O
selected	VBN	O
and	CC	O
grown	VBN	O
in	IN	O
one-liter	JJ	O
culture	NN	O
.	.	O
After	IN	O
induction	NN	O
with	IN	O
IPTG	NNP	O
,	,	O
proteins	NNS	O
were	VBD	O
purified	VBN	O
by	IN	O
a	DT	O
Ni-NTA	JJ	O
column	NN	O
.	.	O
M	NNP	O
;	:	O
marker	NN	O
,	,	O
1	CD	O
;	:	O
protein	NN	O
from	IN	O
uninduced	JJ	O
culture	NN	O
,	,	O
2	CD	O
;	:	O
protein	NN	O
from	IN	O
culture	NN	O
induced	VBN	O
with	IN	O
IPTG	NNP	O
,	,	O
3	CD	O
;	:	O
following	VBG	O
purification	NN	O
with	IN	O
Ni-NTA	NNP	O
column	NN	O
.	.	O
FIG	NNP	O
.	.	O
27	CD	O
.	.	O
Nucleic	NNP	O
acid	NN	O
sequence	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:1	NNP	O
)	)	O
encoding	VBG	O
a	DT	O
fungal	JJ	O
polypeptide	NN	O
having	VBG	O
the	DT	O
amino	NN	O
acid	JJ	O
sequence	NN	O
set	VBN	O
forth	NN	O
in	IN	O
SEQ	NNP	O
ID	NNP	O
NO:2	NNP	O
.	.	O
FIG	NNP	O
.	.	O
28	CD	O
.	.	O
Nucleic	NNP	O
acid	NN	O
sequence	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:3	NNP	O
)	)	O
encoding	VBG	O
a	DT	O
fungal	JJ	O
polypeptide	NN	O
having	VBG	O
the	DT	O
amino	NN	O
acid	JJ	O
sequence	NN	O
set	VBN	O
forth	NN	O
in	IN	O
SEQ	NNP	O
ID	NNP	O
NO:4	NNP	O
.	.	O
FIG	NNP	O
.	.	O
29	CD	O
.	.	O
Nucleic	NNP	O
acid	NN	O
sequence	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:5	NNP	O
)	)	O
encoding	VBG	O
a	DT	O
fungal	JJ	O
polypeptide	NN	O
having	VBG	O
the	DT	O
amino	NN	O
acid	JJ	O
sequence	NN	O
set	VBN	O
forth	NN	O
in	IN	O
SEQ	NNP	O
ID	NNP	O
NO:6	NNP	O
.	.	O
FIG	NNP	O
.	.	O
30	CD	O
.	.	O
Nucleic	NNP	O
acid	NN	O
sequence	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:7	NNP	O
)	)	O
encoding	VBG	O
a	DT	O
fungal	JJ	O
polypeptide	NN	O
having	VBG	O
the	DT	O
amino	NN	O
acid	JJ	O
sequence	NN	O
set	VBN	O
forth	NN	O
in	IN	O
SEQ	NNP	O
ID	NNP	O
NO:8	NNP	O
.	.	O
FIG	NNP	O
.	.	O
31	CD	O
.	.	O
Nucleic	NNP	O
acid	NN	O
sequence	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:9	NNP	O
)	)	O
encoding	VBG	O
a	DT	O
fungal	JJ	O
polypeptide	NN	O
having	VBG	O
the	DT	O
amino	NN	O
acid	JJ	O
sequence	NN	O
set	VBN	O
forth	NN	O
in	IN	O
SEQ	NNP	O
ID	NNP	O
NO:10	NNP	O
.	.	O
FIG	NNP	O
.	.	O
32	CD	O
.	.	O
Nucleic	NNP	O
acid	NN	O
sequence	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:11	NNP	O
)	)	O
encoding	VBG	O
a	DT	O
fungal	JJ	O
polypeptide	NN	O
having	VBG	O
the	DT	O
amino	NN	O
acid	JJ	O
sequence	NN	O
set	VBN	O
forth	NN	O
in	IN	O
SEQ	NNP	O
ID	NNP	O
NO:12	NNP	O
.	.	O
FIG	NNP	O
.	.	O
33	CD	O
.	.	O
Nucleic	NNP	O
acid	NN	O
sequence	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:13	NNP	O
)	)	O
encoding	VBG	O
a	DT	O
fungal	JJ	O
polypeptide	NN	O
having	VBG	O
the	DT	O
amino	NN	O
acid	JJ	O
sequence	NN	O
set	VBN	O
forth	NN	O
in	IN	O
SEQ	NNP	O
ID	NNP	O
NO:14	NNP	O
.	.	O
FIG	NNP	O
.	.	O
34	CD	O
.	.	O
Nucleic	NNP	O
acid	NN	O
sequence	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:15	NNP	O
)	)	O
encoding	VBG	O
a	DT	O
fungal	JJ	O
polypeptide	NN	O
having	VBG	O
the	DT	O
amino	NN	O
acid	JJ	O
sequence	NN	O
set	VBN	O
forth	NN	O
in	IN	O
SEQ	NNP	O
ID	NNP	O
NO:16	NNP	O
.	.	O
FIG	NNP	O
.	.	O
35	CD	O
.	.	O
Nucleic	NNP	O
acid	NN	O
sequence	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:17	NNP	O
)	)	O
encoding	VBG	O
a	DT	O
fungal	JJ	O
polypeptide	NN	O
having	VBG	O
the	DT	O
amino	NN	O
acid	JJ	O
sequence	NN	O
set	VBN	O
forth	NN	O
in	IN	O
SEQ	NNP	O
ID	NNP	O
NO:18	NNP	O
.	.	O
FIG	NNP	O
.	.	O
36	CD	O
.	.	O
Nucleic	NNP	O
acid	NN	O
sequence	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:19	NNP	O
)	)	O
encoding	VBG	O
a	DT	O
fungal	JJ	O
polypeptide	NN	O
having	VBG	O
the	DT	O
amino	NN	O
acid	JJ	O
sequence	NN	O
set	VBN	O
forth	NN	O
in	IN	O
SEQ	NNP	O
ID	NNP	O
NO:20	NNP	O
.	.	O
FIG	NNP	O
.	.	O
37	CD	O
.	.	O
Nucleic	NNP	O
acid	NN	O
sequence	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:21	NNP	O
)	)	O
encoding	VBG	O
a	DT	O
fungal	JJ	O
polypeptide	NN	O
having	VBG	O
the	DT	O
amino	NN	O
acid	JJ	O
sequence	NN	O
set	VBN	O
forth	NN	O
in	IN	O
SEQ	NNP	O
ID	NNP	O
NO:22	NNP	O
.	.	O
FIG	NNP	O
.	.	O
38	CD	O
.	.	O
Nucleic	NNP	O
acid	NN	O
sequence	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:23	NNP	O
)	)	O
encoding	VBG	O
a	DT	O
fungal	JJ	O
polypeptide	NN	O
having	VBG	O
the	DT	O
amino	NN	O
acid	JJ	O
sequence	NN	O
set	VBN	O
forth	NN	O
in	IN	O
SEQ	NNP	O
ID	NNP	O
NO:24	NNP	O
.	.	O
FIG	NNP	O
.	.	O
39	CD	O
.	.	O
Nucleic	NNP	O
acid	NN	O
sequence	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:25	NNP	O
)	)	O
encoding	VBG	O
a	DT	O
fungal	JJ	O
polypeptide	NN	O
having	VBG	O
the	DT	O
amino	NN	O
acid	JJ	O
sequence	NN	O
set	VBN	O
forth	NN	O
in	IN	O
SEQ	NNP	O
ID	NNP	O
NO:26	NNP	O
.	.	O
FIG	NNP	O
.	.	O
40	CD	O
.	.	O
Nucleic	NNP	O
acid	NN	O
sequence	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:27	NNP	O
)	)	O
encoding	VBG	O
a	DT	O
fungal	JJ	O
polypeptide	NN	O
having	VBG	O
the	DT	O
amino	NN	O
acid	JJ	O
sequence	NN	O
set	VBN	O
forth	NN	O
in	IN	O
SEQ	NNP	O
ID	NNP	O
NO:28	NNP	O
.	.	O
FIG	NNP	O
.	.	O
41	CD	O
.	.	O
Nucleic	NNP	O
acid	NN	O
sequence	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:29	NNP	O
)	)	O
encoding	VBG	O
a	DT	O
fungal	JJ	O
polypeptide	NN	O
having	VBG	O
the	DT	O
amino	NN	O
acid	JJ	O
sequence	NN	O
set	VBN	O
forth	NN	O
in	IN	O
SEQ	NNP	O
ID	NNP	O
NO:30	NNP	O
.	.	O
FIG	NNP	O
.	.	O
42	CD	O
.	.	O
Nucleic	NNP	O
acid	NN	O
sequence	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:31	NNP	O
)	)	O
encoding	VBG	O
a	DT	O
fungal	JJ	O
polypeptide	NN	O
having	VBG	O
the	DT	O
amino	NN	O
acid	JJ	O
sequence	NN	O
set	VBN	O
forth	NN	O
in	IN	O
SEQ	NNP	O
ID	NNP	O
NO:32	NNP	O
.	.	O
FIG	NNP	O
.	.	O
43	CD	O
.	.	O
Nucleic	NNP	O
acid	NN	O
sequence	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:33	NNP	O
)	)	O
encoding	VBG	O
a	DT	O
fungal	JJ	O
polypeptide	NN	O
having	VBG	O
the	DT	O
amino	NN	O
acid	JJ	O
sequence	NN	O
set	VBN	O
forth	NN	O
in	IN	O
SEQ	NNP	O
ID	NNP	O
NO:34	NNP	O
.	.	O
FIG	NNP	O
.	.	O
44	CD	O
.	.	O
PBMC	NNP	O
after	IN	O
challenge	NN	O
with	IN	O
isolated	JJ	O
Alternaria	NNP	O
protein	NN	O
fractions	NNS	O
30	CD	O
.	.	O
FIG	NNP	O
.	.	O
45	CD	O
.	.	O
PBMC	NNP	O
after	IN	O
challenge	NN	O
with	IN	O
isolated	JJ	O
Alternaria	NNP	O
protein	NN	O
fractions	NNS	O
32	CD	O
.	.	O
DETAILED	JJ	O
DESCRIPTION	NNP	O
This	DT	O
document	NN	O
relates	VBZ	O
to	TO	O
methods	NNS	O
and	CC	O
materials	NNS	O
involved	VBN	O
in	IN	O
fungus-induced	JJ	O
inflammation	NN	O
and	CC	O
eosinophil	JJ	O
degranulation	NN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
this	DT	O
document	NN	O
provides	VBZ	O
isolated	JJ	O
nucleic	JJ	O
acids	NNS	O
encoding	VBG	O
fungal	JJ	O
polypeptides	NNS	O
,	,	O
substantially	RB	O
pure	JJ	O
fungal	JJ	O
polypeptides	NNS	O
,	,	O
methods	NNS	O
for	IN	O
assessing	VBG	O
fungus-induced	JJ	O
inflammation	NN	O
,	,	O
methods	NNS	O
for	IN	O
assessing	VBG	O
eosinophil	JJ	O
degranulation	NN	O
,	,	O
and	CC	O
methods	NNS	O
for	IN	O
identifying	VBG	O
inhibitors	NNS	O
of	IN	O
fungus-induced	JJ	O
inflammation	NN	O
and/or	NN	O
eosinophil	JJ	O
degranulation	NN	O
.	.	O
This	DT	O
document	NN	O
also	RB	O
provides	VBZ	O
methods	NNS	O
and	CC	O
materials	NNS	O
for	IN	O
making	VBG	O
and	CC	O
using	VBG	O
an	DT	O
antibody	NN	O
that	WDT	O
can	MD	O
bind	VB	O
a	DT	O
fungal	JJ	O
polypeptide	NN	O
.	.	O
In	IN	O
addition	NN	O
,	,	O
this	DT	O
document	NN	O
provides	VBZ	O
methods	NNS	O
and	CC	O
materials	NNS	O
for	IN	O
treating	VBG	O
a	DT	O
mammal	JJ	O
having	VBG	O
a	DT	O
fungus-induced	JJ	O
inflammatory	JJ	O
condition	NN	O
(	(	O
e.g.	JJ	O
,	,	O
CRS	NNP	O
)	)	O
.	.	O
Fungal	NNP	O
Polypeptides	NNP	O
and	CC	O
Nucleic	NNP	O
Acids	NNP	O
Encoding	NNP	O
Fungal	NNP	O
Polypeptides	NNP	O
This	DT	O
document	NN	O
provides	VBZ	O
a	DT	O
substantially	RB	O
pure	JJ	O
fungal	JJ	O
polypeptide	NN	O
.	.	O
Such	JJ	O
fungal	JJ	O
polypeptides	NNS	O
can	MD	O
have	VB	O
the	DT	O
ability	NN	O
to	TO	O
stimulate	VB	O
eosinophil	JJ	O
degranulation	NN	O
and/or	NN	O
inflammation	NN	O
.	.	O
For	IN	O
example	NN	O
a	DT	O
fungal	JJ	O
polypeptide	NN	O
provided	VBD	O
herein	NN	O
can	MD	O
have	VB	O
the	DT	O
ability	NN	O
to	TO	O
stimulate	VB	O
eosinophil	JJ	O
degranulation	NN	O
in	IN	O
vitro	NN	O
,	,	O
can	MD	O
have	VB	O
the	DT	O
ability	NN	O
to	TO	O
stimulate	VB	O
inflammation	NN	O
in	IN	O
vivo	NN	O
,	,	O
or	CC	O
both	DT	O
.	.	O
The	DT	O
term	NN	O
“	NNP	O
substantially	RB	O
pure	VBZ	O
”	NN	O
with	IN	O
respect	NN	O
to	TO	O
a	DT	O
polypeptide	NN	O
refers	NNS	O
to	TO	O
a	DT	O
polypeptide	NN	O
that	WDT	O
has	VBZ	O
been	VBN	O
separated	VBN	O
from	IN	O
cellular	JJ	O
components	NNS	O
with	IN	O
which	WDT	O
it	PRP	O
is	VBZ	O
naturally	RB	O
accompanied	VBN	O
.	.	O
Typically	RB	O
,	,	O
a	DT	O
polypeptide	NN	O
provided	VBN	O
herein	NN	O
is	VBZ	O
substantially	RB	O
pure	JJ	O
when	WRB	O
it	PRP	O
is	VBZ	O
at	IN	O
least	JJS	O
60	CD	O
percent	NN	O
(	(	O
e.g.	UH	O
,	,	O
65	CD	O
,	,	O
70	CD	O
,	,	O
75	CD	O
,	,	O
80	CD	O
,	,	O
90	CD	O
,	,	O
95	CD	O
,	,	O
or	CC	O
99	CD	O
percent	NN	O
)	)	O
,	,	O
by	IN	O
weight	NN	O
,	,	O
free	JJ	O
from	IN	O
proteins	NNS	O
and	CC	O
naturally-occurring	JJ	O
organic	JJ	O
molecules	NNS	O
with	IN	O
which	WDT	O
it	PRP	O
is	VBZ	O
naturally	RB	O
associated	VBN	O
.	.	O
In	IN	O
general	JJ	O
,	,	O
a	DT	O
substantially	RB	O
pure	JJ	O
polypeptide	NN	O
will	MD	O
yield	VB	O
a	DT	O
single	JJ	O
major	JJ	O
band	NN	O
on	IN	O
a	DT	O
non-reducing	JJ	O
polyacrylamide	NN	O
gel	NN	O
.	.	O
In	IN	O
some	DT	O
cases	NNS	O
,	,	O
a	DT	O
substantially	RB	O
pure	JJ	O
polypeptide	NN	O
can	MD	O
be	VB	O
a	DT	O
polypeptide	JJ	O
preparation	NN	O
that	WDT	O
contains	VBZ	O
one	CD	O
of	IN	O
the	DT	O
polypeptides	NNS	O
set	VBD	O
forth	NN	O
in	IN	O
FIGS	NNP	O
.	.	O
27-39	JJ	O
or	CC	O
a	DT	O
polypeptide	NN	O
at	IN	O
least	JJS	O
about	IN	O
80	CD	O
percent	NN	O
identical	JJ	O
to	TO	O
such	PDT	O
a	DT	O
polypeptide	NN	O
,	,	O
while	IN	O
being	VBG	O
free	JJ	O
of	IN	O
at	IN	O
least	JJS	O
one	CD	O
of	IN	O
the	DT	O
other	JJ	O
polypeptides	NNS	O
set	VBP	O
forth	NN	O
in	IN	O
FIGS	NNP	O
.	.	O
27-39	JJ	O
.	.	O
The	DT	O
polypeptides	NNS	O
provided	VBD	O
herein	NN	O
can	MD	O
be	VB	O
at	IN	O
least	JJS	O
five	CD	O
amino	JJ	O
acids	NNS	O
in	IN	O
length	NN	O
(	(	O
e.g.	JJ	O
,	,	O
at	IN	O
least	JJS	O
6	CD	O
,	,	O
7	CD	O
,	,	O
10	CD	O
,	,	O
15	CD	O
,	,	O
30	CD	O
,	,	O
50	CD	O
,	,	O
70	CD	O
,	,	O
or	CC	O
100	CD	O
amino	JJ	O
acids	NNS	O
in	IN	O
length	NN	O
)	)	O
.	.	O
A	DT	O
substantially	RB	O
pure	JJ	O
polypeptide	NN	O
provided	VBD	O
herein	NN	O
can	MD	O
be	VB	O
a	DT	O
polypeptide	JJ	O
having	VBG	O
a	DT	O
sequence	NN	O
that	WDT	O
is	VBZ	O
at	IN	O
least	JJS	O
80	CD	O
percent	JJ	O
identical	JJ	O
to	TO	O
the	DT	O
amino	NN	O
acid	JJ	O
sequence	NN	O
set	VBN	O
forth	NN	O
in	IN	O
SEQ	NNP	O
ID	NNP	O
NO:2	NNP	O
,	,	O
4	CD	O
,	,	O
6	CD	O
,	,	O
8	CD	O
,	,	O
10	CD	O
,	,	O
12	CD	O
,	,	O
14	CD	O
,	,	O
16	CD	O
,	,	O
18	CD	O
,	,	O
20	CD	O
,	,	O
22	CD	O
,	,	O
24	CD	O
,	,	O
26	CD	O
,	,	O
28	CD	O
,	,	O
30	CD	O
,	,	O
32	CD	O
,	,	O
or	CC	O
34	CD	O
.	.	O
For	IN	O
example	NN	O
,	,	O
a	DT	O
polypeptide	NN	O
provided	VBD	O
herein	NN	O
can	MD	O
have	VB	O
at	IN	O
least	JJS	O
80	CD	O
,	,	O
85	CD	O
,	,	O
90	CD	O
,	,	O
95	CD	O
,	,	O
98	CD	O
,	,	O
or	CC	O
99	CD	O
percent	NN	O
identity	NN	O
to	TO	O
SEQ	NNP	O
ID	NNP	O
NO:2	NNP	O
,	,	O
4	CD	O
,	,	O
6	CD	O
,	,	O
8	CD	O
,	,	O
10	CD	O
,	,	O
12	CD	O
,	,	O
14	CD	O
,	,	O
16	CD	O
,	,	O
18	CD	O
,	,	O
20	CD	O
,	,	O
22	CD	O
,	,	O
24	CD	O
,	,	O
or	CC	O
26	CD	O
.	.	O
In	IN	O
some	DT	O
cases	NNS	O
,	,	O
a	DT	O
polypeptide	NN	O
provided	VBD	O
herein	NN	O
can	MD	O
have	VB	O
the	DT	O
exact	JJ	O
amino	NN	O
acid	JJ	O
sequence	NN	O
set	VBN	O
forth	NN	O
in	IN	O
SEQ	NNP	O
ID	NNP	O
NO:2	NNP	O
,	,	O
4	CD	O
,	,	O
6	CD	O
,	,	O
8	CD	O
,	,	O
10	CD	O
,	,	O
12	CD	O
,	,	O
14	CD	O
,	,	O
16	CD	O
,	,	O
18	CD	O
,	,	O
20	CD	O
,	,	O
22	CD	O
,	,	O
24	CD	O
,	,	O
26	CD	O
,	,	O
28	CD	O
,	,	O
30	CD	O
,	,	O
32	CD	O
,	,	O
or	CC	O
34	CD	O
.	.	O
The	DT	O
percent	NN	O
identity	NN	O
between	IN	O
a	DT	O
particular	JJ	O
amino	NN	O
acid	NN	O
sequence	NN	O
and	CC	O
the	DT	O
amino	NN	O
acid	JJ	O
sequence	NN	O
set	VBN	O
forth	NN	O
in	IN	O
SEQ	NNP	O
ID	NNP	O
NO:2	NNP	O
,	,	O
4	CD	O
,	,	O
6	CD	O
,	,	O
8	CD	O
,	,	O
10	CD	O
,	,	O
12	CD	O
,	,	O
14	CD	O
,	,	O
16	CD	O
,	,	O
18	CD	O
,	,	O
20	CD	O
,	,	O
22	CD	O
,	,	O
24	CD	O
,	,	O
26	CD	O
,	,	O
28	CD	O
,	,	O
30	CD	O
,	,	O
32	CD	O
,	,	O
or	CC	O
34	CD	O
is	VBZ	O
determined	VBN	O
as	IN	O
follows	VBZ	O
.	.	O
First	RB	O
,	,	O
the	DT	O
amino	NN	O
acid	NN	O
sequences	NNS	O
are	VBP	O
aligned	VBN	O
using	VBG	O
the	DT	O
BLAST	NNP	O
2	CD	O
Sequences	NNP	O
(	(	O
B12seq	NNP	O
)	)	O
program	NN	O
from	IN	O
the	DT	O
stand-alone	JJ	O
version	NN	O
of	IN	O
BLASTZ	NNP	O
containing	VBG	O
BLASTP	NNP	O
version	NN	O
2.0.14	CD	O
.	.	O
This	DT	O
stand-alone	JJ	O
version	NN	O
of	IN	O
BLASTZ	NNP	O
can	MD	O
be	VB	O
obtained	VBN	O
from	IN	O
Fish	NNP	O
&	CC	O
Richardson	NNP	O
's	POS	O
web	NN	O
site	NN	O
(	(	O
e.g.	JJ	O
,	,	O
www.fr.com/blast/	NN	O
)	)	O
or	CC	O
the	DT	O
State	NNP	O
University	NNP	O
of	IN	O
New	NNP	O
York-Old	NNP	O
Westbury	NNP	O
Library	NNP	O
(	(	O
call	JJ	O
number	NN	O
:	:	O
QH	NNP	O
447.M6714	CD	O
)	)	O
.	.	O
Instructions	NNS	O
explaining	VBG	O
how	WRB	O
to	TO	O
use	VB	O
the	DT	O
B12seq	NNP	O
program	NN	O
can	MD	O
be	VB	O
found	VBN	O
in	IN	O
the	DT	O
readme	NN	O
file	NN	O
accompanying	VBG	O
BLASTZ	NNP	O
.	.	O
B12seq	NNP	O
performs	VBZ	O
a	DT	O
comparison	NN	O
between	IN	O
two	CD	O
amino	NN	O
acid	NN	O
sequences	NNS	O
using	VBG	O
the	DT	O
BLASTP	NNP	O
algorithm	NN	O
.	.	O
To	TO	O
compare	VB	O
two	CD	O
amino	JJ	O
acid	NN	O
sequences	NNS	O
,	,	O
the	DT	O
options	NNS	O
of	IN	O
B12seq	NNP	O
are	VBP	O
set	VBN	O
as	IN	O
follows	VBZ	O
:	:	O
-i	NN	O
is	VBZ	O
set	VBN	O
to	TO	O
a	DT	O
file	NN	O
containing	VBG	O
the	DT	O
first	JJ	O
amino	NN	O
acid	NN	O
sequence	NN	O
to	TO	O
be	VB	O
compared	VBN	O
(	(	O
e.g.	NN	O
,	,	O
C	NNP	O
:	:	O
\seq1.txt	NN	O
)	)	O
;	:	O
-j	CC	O
is	VBZ	O
set	VBN	O
to	TO	O
a	DT	O
file	NN	O
containing	VBG	O
the	DT	O
second	JJ	O
amino	NN	O
acid	NN	O
sequence	NN	O
to	TO	O
be	VB	O
compared	VBN	O
(	(	O
e.g.	NN	O
,	,	O
C	NNP	O
:	:	O
\seq2.txt	NN	O
)	)	O
;	:	O
-p	CC	O
is	VBZ	O
set	VBN	O
to	TO	O
blastp	VB	O
;	:	O
-o	NNP	O
is	VBZ	O
set	VBN	O
to	TO	O
any	DT	O
desired	VBN	O
file	NN	O
name	NN	O
(	(	O
e.g.	UH	O
,	,	O
C	NNP	O
:	:	O
\output.txt	NN	O
)	)	O
;	:	O
and	CC	O
all	DT	O
other	JJ	O
options	NNS	O
are	VBP	O
left	VBN	O
at	IN	O
their	PRP$	O
default	NN	O
setting	NN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
the	DT	O
following	JJ	O
command	NN	O
can	MD	O
be	VB	O
used	VBN	O
to	TO	O
generate	VB	O
an	DT	O
output	NN	O
file	NN	O
containing	VBG	O
a	DT	O
comparison	NN	O
between	IN	O
two	CD	O
amino	NN	O
acid	JJ	O
sequences	NNS	O
:	:	O
C	NN	O
:	:	O
\B12seq	JJ	O
c	NN	O
:	:	O
\seq1.txt	JJ	O
-j	JJ	O
c	NN	O
:	:	O
\seq2.txt	JJ	O
-p	NNP	O
blastp	NN	O
-o	NNP	O
c	NN	O
:	:	O
\output.txt	NN	O
.	.	O
If	IN	O
the	DT	O
two	CD	O
compared	VBN	O
sequences	NNS	O
share	NN	O
homology	NN	O
,	,	O
then	RB	O
the	DT	O
designated	VBN	O
output	NN	O
file	NN	O
will	MD	O
present	VB	O
those	DT	O
regions	NNS	O
of	IN	O
homology	NN	O
as	IN	O
aligned	JJ	O
sequences	NNS	O
.	.	O
If	IN	O
the	DT	O
two	CD	O
compared	VBN	O
sequences	NNS	O
do	VBP	O
not	RB	O
share	NN	O
homology	NN	O
,	,	O
then	RB	O
the	DT	O
designated	VBN	O
output	NN	O
file	NN	O
will	MD	O
not	RB	O
present	VB	O
aligned	JJ	O
sequences	NNS	O
.	.	O
Once	RB	O
aligned	VBN	O
,	,	O
the	DT	O
number	NN	O
of	IN	O
matches	NNS	O
is	VBZ	O
determined	VBN	O
by	IN	O
counting	VBG	O
the	DT	O
number	NN	O
of	IN	O
positions	NNS	O
where	WRB	O
an	DT	O
identical	JJ	O
amino	NN	O
acid	NN	O
residue	NN	O
is	VBZ	O
presented	VBN	O
in	IN	O
both	DT	O
sequences	NNS	O
.	.	O
The	DT	O
percent	NN	O
identity	NN	O
is	VBZ	O
determined	VBN	O
by	IN	O
dividing	VBG	O
the	DT	O
number	NN	O
of	IN	O
matches	NNS	O
by	IN	O
the	DT	O
length	NN	O
of	IN	O
the	DT	O
full-length	JJ	O
amino	NN	O
acid	JJ	O
sequence	NN	O
set	VBN	O
forth	NN	O
in	IN	O
SEQ	NNP	O
ID	NNP	O
NO:2	NNP	O
,	,	O
4	CD	O
,	,	O
6	CD	O
,	,	O
8	CD	O
,	,	O
10	CD	O
,	,	O
12	CD	O
,	,	O
14	CD	O
,	,	O
16	CD	O
,	,	O
18	CD	O
,	,	O
20	CD	O
,	,	O
22	CD	O
,	,	O
24	CD	O
,	,	O
26	CD	O
,	,	O
28	CD	O
,	,	O
30	CD	O
,	,	O
32	CD	O
,	,	O
or	CC	O
34	CD	O
followed	VBN	O
by	IN	O
multiplying	VBG	O
the	DT	O
resulting	VBG	O
value	NN	O
by	IN	O
100	CD	O
.	.	O
For	IN	O
example	NN	O
,	,	O
an	DT	O
amino	NN	O
acid	NN	O
sequence	NN	O
that	WDT	O
has	VBZ	O
144	CD	O
matches	NNS	O
when	WRB	O
aligned	VBN	O
with	IN	O
the	DT	O
sequence	NN	O
set	VBN	O
forth	NN	O
in	IN	O
SEQ	NNP	O
ID	NNP	O
NO:26	NNP	O
is	VBZ	O
96.0	CD	O
percent	NN	O
identical	JJ	O
to	TO	O
the	DT	O
sequence	NN	O
set	VBN	O
forth	NN	O
in	IN	O
SEQ	NNP	O
ID	NNP	O
NO:26	NNP	O
(	(	O
i.e.	FW	O
,	,	O
144÷150*100=96.0	CD	O
)	)	O
.	.	O
It	PRP	O
is	VBZ	O
noted	VBN	O
that	IN	O
the	DT	O
percent	NN	O
identity	NN	O
value	NN	O
is	VBZ	O
rounded	VBN	O
to	TO	O
the	DT	O
nearest	JJS	O
tenth	NN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
78.11	CD	O
,	,	O
78.12	CD	O
,	,	O
78.13	CD	O
,	,	O
and	CC	O
78.14	CD	O
are	VBP	O
rounded	VBN	O
down	RB	O
to	TO	O
78.1	CD	O
,	,	O
while	IN	O
78.15	CD	O
,	,	O
78.16	CD	O
,	,	O
78.17	CD	O
,	,	O
78.18	CD	O
,	,	O
and	CC	O
78.19	CD	O
are	VBP	O
rounded	VBN	O
up	IN	O
to	TO	O
78.2	CD	O
.	.	O
It	PRP	O
also	RB	O
is	VBZ	O
noted	VBN	O
that	IN	O
the	DT	O
length	NN	O
value	NN	O
will	MD	O
always	RB	O
be	VB	O
an	DT	O
integer	NN	O
.	.	O
In	IN	O
some	DT	O
cases	NNS	O
,	,	O
a	DT	O
substantially	RB	O
pure	JJ	O
polypeptide	NN	O
provided	VBD	O
herein	NN	O
can	MD	O
have	VB	O
fewer	JJR	O
than	IN	O
10	CD	O
(	(	O
e.g.	NN	O
,	,	O
fewer	JJR	O
than	IN	O
9	CD	O
,	,	O
8	CD	O
,	,	O
7	CD	O
,	,	O
6	CD	O
,	,	O
5	CD	O
,	,	O
4	CD	O
,	,	O
3	CD	O
,	,	O
or	CC	O
2	CD	O
)	)	O
mismatches	NNS	O
as	IN	O
compared	VBN	O
to	TO	O
the	DT	O
amino	NN	O
acid	JJ	O
sequence	NN	O
set	VBN	O
forth	NN	O
in	IN	O
SEQ	NNP	O
ID	NNP	O
NO:2	NNP	O
,	,	O
4	CD	O
,	,	O
6	CD	O
,	,	O
8	CD	O
,	,	O
10	CD	O
,	,	O
12	CD	O
,	,	O
14	CD	O
,	,	O
16	CD	O
,	,	O
18	CD	O
,	,	O
20	CD	O
,	,	O
22	CD	O
,	,	O
24	CD	O
,	,	O
26	CD	O
,	,	O
28	CD	O
,	,	O
30	CD	O
,	,	O
32	CD	O
,	,	O
or	CC	O
34	CD	O
.	.	O
For	IN	O
example	NN	O
,	,	O
a	DT	O
polypeptide	NN	O
provided	VBD	O
herein	NN	O
can	MD	O
have	VB	O
4	CD	O
,	,	O
3	CD	O
,	,	O
2	CD	O
,	,	O
or	CC	O
1	CD	O
mismatches	NNS	O
as	IN	O
compared	VBN	O
to	TO	O
the	DT	O
amino	NN	O
acid	JJ	O
sequence	NN	O
set	VBN	O
forth	NN	O
in	IN	O
SEQ	NNP	O
ID	NNP	O
NO:2	NNP	O
,	,	O
4	CD	O
,	,	O
6	CD	O
,	,	O
8	CD	O
,	,	O
10	CD	O
,	,	O
12	CD	O
,	,	O
14	CD	O
,	,	O
16	CD	O
,	,	O
18	CD	O
,	,	O
20	CD	O
,	,	O
22	CD	O
,	,	O
24	CD	O
,	,	O
26	CD	O
,	,	O
28	CD	O
,	,	O
30	CD	O
,	,	O
32	CD	O
,	,	O
or	CC	O
34	CD	O
.	.	O
A	DT	O
substantially	RB	O
pure	JJ	O
polypeptide	NN	O
provided	VBD	O
herein	NN	O
can	MD	O
be	VB	O
obtained	VBN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
by	IN	O
extraction	NN	O
from	IN	O
a	DT	O
natural	JJ	O
source	NN	O
(	(	O
e.g.	NN	O
,	,	O
Alternaria	NNP	O
cells	NNS	O
)	)	O
,	,	O
chemical	JJ	O
synthesis	NN	O
,	,	O
or	CC	O
by	IN	O
recombinant	JJ	O
production	NN	O
in	IN	O
a	DT	O
host	NN	O
cell	NN	O
.	.	O
To	TO	O
recombinantly	RB	O
produce	VB	O
a	DT	O
polypeptide	NN	O
provided	VBD	O
herein	NN	O
,	,	O
a	DT	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
encoding	VBG	O
the	DT	O
polypeptide	NN	O
can	MD	O
be	VB	O
ligated	VBN	O
into	IN	O
an	DT	O
expression	NN	O
vector	NN	O
and	CC	O
used	VBD	O
to	TO	O
transform	VB	O
a	DT	O
bacterial	JJ	O
or	CC	O
eukaryotic	JJ	O
host	NN	O
cell	NN	O
(	(	O
e.g.	JJ	O
,	,	O
insect	JJ	O
,	,	O
yeast	RB	O
,	,	O
Alternaria	NNP	O
,	,	O
Pichia	NNP	O
,	,	O
or	CC	O
mammalian	JJ	O
cells	NNS	O
)	)	O
.	.	O
In	IN	O
general	JJ	O
,	,	O
nucleic	JJ	O
acid	NN	O
constructs	NNS	O
can	MD	O
include	VB	O
a	DT	O
regulatory	JJ	O
sequence	NN	O
operably	RB	O
linked	VBD	O
to	TO	O
a	DT	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
encoding	VBG	O
a	DT	O
polypeptide	NN	O
provided	VBD	O
herein	NN	O
.	.	O
Regulatory	NNP	O
sequences	NNS	O
do	VBP	O
not	RB	O
typically	RB	O
encode	VB	O
a	DT	O
gene	NN	O
product	NN	O
,	,	O
but	CC	O
instead	RB	O
affect	VB	O
the	DT	O
expression	NN	O
of	IN	O
the	DT	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
.	.	O
In	IN	O
bacterial	JJ	O
systems	NNS	O
,	,	O
a	DT	O
strain	NN	O
of	IN	O
Escherichia	NNP	O
coli	NNS	O
such	JJ	O
as	IN	O
BL-21	NNP	O
can	MD	O
be	VB	O
used	VBN	O
.	.	O
Suitable	JJ	O
E.	NNP	O
coli	NNS	O
vectors	NNS	O
include	VBP	O
the	DT	O
pGEX	JJ	O
series	NN	O
of	IN	O
vectors	NNS	O
(	(	O
Amersham	NNP	O
Biosciences	NNP	O
Corp.	NNP	O
,	,	O
Piscataway	NNP	O
,	,	O
N.J.	NNP	O
)	)	O
that	IN	O
produce	VBP	O
fusion	NN	O
proteins	NNS	O
with	IN	O
glutathione	JJ	O
S-transferase	NNP	O
(	(	O
GST	NNP	O
)	)	O
.	.	O
Transformed	NNP	O
E.	NNP	O
coli	NNS	O
typically	RB	O
are	VBP	O
grown	VBN	O
exponentially	RB	O
,	,	O
and	CC	O
then	RB	O
stimulated	VBD	O
with	IN	O
isopropylthio-galactopyranoside	JJ	O
(	(	O
IPTG	NNP	O
)	)	O
prior	RB	O
to	TO	O
harvesting	VBG	O
.	.	O
In	IN	O
general	JJ	O
,	,	O
such	JJ	O
fusion	NN	O
proteins	NNS	O
can	MD	O
be	VB	O
soluble	JJ	O
and	CC	O
can	MD	O
be	VB	O
purified	VBN	O
from	IN	O
lysed	VBN	O
cells	NNS	O
by	IN	O
adsorption	NN	O
to	TO	O
glutathione-agarose	JJ	O
beads	NNS	O
followed	VBN	O
by	IN	O
elution	NN	O
in	IN	O
the	DT	O
presence	NN	O
of	IN	O
free	JJ	O
glutathione	NN	O
.	.	O
The	DT	O
pGEX	NN	O
vectors	NNS	O
can	MD	O
be	VB	O
designed	VBN	O
to	TO	O
include	VB	O
thrombin	NN	O
or	CC	O
factor	NN	O
Xa	JJ	O
protease	NN	O
cleavage	NN	O
sites	VBZ	O
so	RB	O
that	IN	O
the	DT	O
cloned	VBN	O
target	NN	O
gene	NN	O
product	NN	O
can	MD	O
be	VB	O
released	VBN	O
from	IN	O
the	DT	O
GST	NNP	O
moiety	NN	O
.	.	O
In	IN	O
some	DT	O
cases	NNS	O
,	,	O
fungi	NNS	O
can	MD	O
be	VB	O
grown	VBN	O
in	IN	O
large	JJ	O
quantities	NNS	O
in	IN	O
vitro	NN	O
,	,	O
and	CC	O
a	DT	O
polypeptide	NN	O
provided	VBD	O
herein	NN	O
that	WDT	O
is	VBZ	O
endogenously	RB	O
produced	VBN	O
can	MD	O
be	VB	O
separated	VBN	O
and	CC	O
purified	VBN	O
using	VBG	O
chromatographic	JJ	O
methods	NNS	O
(	(	O
e.g.	NN	O
,	,	O
HPL	NNP	O
and/or	VBZ	O
FPLC	NNP	O
with	IN	O
a	DT	O
variety	NN	O
of	IN	O
separation	NN	O
matrices	NNS	O
)	)	O
.	.	O
In	IN	O
order	NN	O
to	TO	O
produce	VB	O
recombinant	JJ	O
,	,	O
highly	RB	O
purified	JJ	O
forms	NNS	O
of	IN	O
a	DT	O
polypeptide	NN	O
provided	VBD	O
herein	NN	O
,	,	O
one	CD	O
method	NN	O
would	MD	O
be	VB	O
to	TO	O
engineer	VB	O
an	DT	O
affinity	NN	O
tag	NN	O
(	(	O
e.g	NN	O
.	.	O
6×	CD	O
Histidine	NNP	O
tag	NN	O
)	)	O
either	CC	O
on	IN	O
the	DT	O
N-	NNP	O
or	CC	O
C-terminus	NNP	O
of	IN	O
the	DT	O
polypeptide	NN	O
(	(	O
either	CC	O
via	IN	O
manipulation	NN	O
of	IN	O
the	DT	O
cDNA	NN	O
nucleic	JJ	O
acid	JJ	O
sequence	NN	O
with	IN	O
PCR	NNP	O
mutagenesis	NN	O
,	,	O
or	CC	O
use	NN	O
of	IN	O
expression	NN	O
vectors	NNS	O
containing	VBG	O
an	DT	O
affinity	NN	O
tag	NN	O
sequence	NN	O
)	)	O
to	TO	O
aid	NN	O
in	IN	O
purification	NN	O
.	.	O
Existing	VBG	O
Pichia	NNP	O
pastoris	NN	O
expression	NN	O
vectors	NNS	O
and	CC	O
purification	NN	O
systems	NNS	O
like	IN	O
those	DT	O
from	IN	O
Invitrogen	NNP	O
(	(	O
Carlsbad	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
can	MD	O
be	VB	O
used	VBN	O
for	IN	O
production	NN	O
of	IN	O
recombinant	JJ	O
fungal	JJ	O
polypeptides	NNS	O
.	.	O
Moreover	RB	O
,	,	O
yeast	NN	O
and	CC	O
fungi	NNS	O
are	VBP	O
closely	RB	O
related	JJ	O
organisms	NNS	O
and	CC	O
thus	RB	O
recombinantly	RB	O
produced	VBN	O
fungal	JJ	O
polypeptides	NNS	O
in	IN	O
P.	NNP	O
pastoris	NN	O
can	MD	O
have	VB	O
an	DT	O
increased	VBN	O
chance	NN	O
of	IN	O
being	VBG	O
properly	RB	O
folded	VBN	O
and	CC	O
retain	VBP	O
post	NN	O
translation	NN	O
(	(	O
e.g.	JJ	O
,	,	O
glycosylation	NN	O
)	)	O
modifications	NNS	O
involved	VBN	O
in	IN	O
activity	NN	O
.	.	O
P.	NNP	O
pastoris	NN	O
can	MD	O
be	VB	O
used	VBN	O
as	IN	O
described	NN	O
elsewhere	RB	O
(	(	O
Reichard	NNP	B
et	VBZ	I
al.	NN	I
,	,	I
Appl	NNP	I
.	.	I
Environ	NNP	I
.	.	I
Microbiol.	NNP	I
,	,	I
72	CD	I
(	(	I
3	CD	I
)	)	I
:1739-48	NN	I
(	(	I
2006	CD	I
)	)	I
)	)	O
.	.	O
Another	DT	O
method	NN	O
can	MD	O
involve	VB	O
using	VBG	O
Alternaria	NNP	O
itself	PRP	O
as	IN	O
a	DT	O
production	NN	O
system	NN	O
.	.	O
This	DT	O
can	MD	O
be	VB	O
accomplished	VBN	O
by	IN	O
engineering	NN	O
an	DT	O
affinity	NN	O
tag	NN	O
on	IN	O
the	DT	O
desired	VBN	O
polypeptide	NN	O
and	CC	O
then	RB	O
employing	VBG	O
the	DT	O
LME	NNP	O
fungal	JJ	O
transformation	NN	O
approaches	NNS	O
as	IN	O
described	VBN	O
elsewhere	RB	O
(	(	O
Cho	NNP	B
et	RB	I
al.	RB	I
,	,	I
Molecular	JJ	I
Plant-Microbe	NNP	I
Interact.	NNP	I
,	,	I
19:7-15	CD	I
(	(	I
2006	CD	I
)	)	I
)	)	O
.	.	O
In	IN	O
eukaryotic	JJ	O
host	NN	O
cells	NNS	O
,	,	O
a	DT	O
number	NN	O
of	IN	O
viral-based	JJ	O
expression	NN	O
systems	NNS	O
can	MD	O
be	VB	O
utilized	VBN	O
to	TO	O
express	VB	O
polypeptides	NNS	O
provided	VBN	O
herein	NN	O
.	.	O
A	DT	O
nucleic	JJ	O
acid	NN	O
encoding	VBG	O
a	DT	O
polypeptide	NN	O
provided	VBD	O
herein	NN	O
can	MD	O
be	VB	O
cloned	VBN	O
into	IN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
a	DT	O
baculoviral	JJ	O
vector	NN	O
such	JJ	O
as	IN	O
pBlueBac	NN	O
(	(	O
Invitrogen	NNP	O
,	,	O
Carlsbad	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
and	CC	O
then	RB	O
used	VBD	O
to	TO	O
co-transfect	JJ	O
insect	JJ	O
cells	NNS	O
such	JJ	O
as	IN	O
Spodoptera	NNP	O
frugiperda	NN	O
(	(	O
Sf9	NNP	O
)	)	O
cells	NNS	O
with	IN	O
wild	JJ	O
type	NN	O
DNA	NN	O
from	IN	O
Autographa	NNP	O
californica	NN	O
multiply	NN	O
enveloped	VBD	O
nuclear	JJ	O
polyhedrosis	NN	O
virus	NN	O
(	(	O
AcMNPV	NNP	O
)	)	O
.	.	O
Recombinant	JJ	O
viruses	NNS	O
producing	VBG	O
polypeptides	NNS	O
provided	VBD	O
herein	NN	O
can	MD	O
be	VB	O
identified	VBN	O
by	IN	O
standard	JJ	O
methodology	NN	O
.	.	O
In	IN	O
some	DT	O
cases	NNS	O
,	,	O
a	DT	O
nucleic	JJ	O
acid	NN	O
encoding	VBG	O
a	DT	O
polypeptide	NN	O
provided	VBD	O
herein	NN	O
can	MD	O
be	VB	O
introduced	VBN	O
into	IN	O
a	DT	O
SV40	NNP	O
,	,	O
retroviral	JJ	O
,	,	O
or	CC	O
vaccinia	NNS	O
based	VBN	O
viral	JJ	O
vector	NN	O
and	CC	O
used	VBD	O
to	TO	O
infect	VB	O
suitable	JJ	O
host	NN	O
cells	NNS	O
.	.	O
Mammalian	JJ	O
cell	NN	O
lines	NNS	O
that	WDT	O
stably	RB	O
express	VBP	O
a	DT	O
polypeptide	NN	O
provided	VBD	O
herein	NN	O
can	MD	O
be	VB	O
produced	VBN	O
using	VBG	O
expression	NN	O
vectors	NNS	O
with	IN	O
the	DT	O
appropriate	JJ	O
control	NN	O
elements	NNS	O
and	CC	O
a	DT	O
selectable	JJ	O
marker	NN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
the	DT	O
eukaryotic	JJ	O
expression	NN	O
vectors	NNS	O
pCR3.1	VBP	O
(	(	O
Invitrogen	NNP	O
)	)	O
and	CC	O
p91023	NN	O
(	(	O
B	NNP	O
)	)	O
(	(	O
see	VB	O
Wong	NNP	B
et	FW	I
al.	NN	I
,	,	I
Science	NNP	I
,	,	I
228:810-815	CD	I
(	(	I
1985	CD	I
)	)	I
)	)	O
can	MD	O
be	VB	O
used	VBN	O
to	TO	O
express	VB	O
a	DT	O
polypeptide	NN	O
provided	VBD	O
herein	NN	O
in	IN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
Chinese	JJ	O
hamster	NN	O
ovary	JJ	O
(	(	O
CHO	NNP	O
)	)	O
cells	NNS	O
,	,	O
COS-1	NNP	O
cells	NNS	O
,	,	O
human	JJ	O
embryonic	JJ	O
kidney	NN	O
293	CD	O
cells	NNS	O
,	,	O
NIH3T3	NNP	O
cells	NNS	O
,	,	O
BHK21	NNP	O
cells	NNS	O
,	,	O
MDCK	NNP	O
cells	NNS	O
,	,	O
and	CC	O
human	JJ	O
vascular	JJ	O
endothelial	NN	O
cells	NNS	O
(	(	O
HUVEC	NNP	O
)	)	O
.	.	O
Following	VBG	O
introduction	NN	O
of	IN	O
the	DT	O
expression	NN	O
vector	NN	O
by	IN	O
electroporation	NN	O
,	,	O
lipofection	NN	O
,	,	O
calcium	NN	O
phosphate	NN	O
or	CC	O
calcium	NN	O
chloride	JJ	O
co-precipitation	NN	O
,	,	O
DEAE	NNP	O
dextran	NN	O
,	,	O
or	CC	O
other	JJ	O
suitable	JJ	O
transfection	NN	O
method	NN	O
,	,	O
stable	JJ	O
cell	NN	O
lines	NNS	O
can	MD	O
be	VB	O
selected	VBN	O
,	,	O
e.g.	FW	O
,	,	O
by	IN	O
antibiotic	JJ	O
resistance	NN	O
to	TO	O
G418	NNP	O
,	,	O
kanamycin	NN	O
,	,	O
or	CC	O
hygromycin	NN	O
.	.	O
In	IN	O
some	DT	O
cases	NNS	O
,	,	O
amplified	JJ	O
sequences	NNS	O
can	MD	O
be	VB	O
ligated	VBN	O
into	IN	O
a	DT	O
mammalian	JJ	O
expression	NN	O
vector	NN	O
such	JJ	O
as	IN	O
pcDNA3	NN	O
(	(	O
Invitrogen	NNP	O
)	)	O
and	CC	O
then	RB	O
transcribed	VBD	O
and	CC	O
translated	VBN	O
in	IN	O
vitro	NN	O
using	VBG	O
wheat	JJ	O
germ	JJ	O
extract	NN	O
or	CC	O
rabbit	NN	O
reticulocyte	JJ	O
lysate	NN	O
.	.	O
Polypeptides	NNS	O
provided	VBD	O
herein	NN	O
can	MD	O
be	VB	O
purified	VBN	O
by	IN	O
known	JJ	O
chromatographic	JJ	O
methods	NNS	O
including	VBG	O
DEAE	NNP	O
ion	NN	O
exchange	NN	O
,	,	O
gel	JJ	O
filtration	NN	O
,	,	O
and	CC	O
hydroxylapatite	JJ	O
chromatography	NN	O
.	.	O
See	VB	O
,	,	O
e.g.	VB	O
,	,	O
Van	NNP	B
Loon	NNP	I
and	CC	I
Weinshilboum	NNP	I
,	,	I
Drug	NNP	I
Metab	NNP	I
.	.	I
Dispos.	NNP	I
,	,	I
18:632-638	CD	I
(	(	I
1990	CD	I
)	)	I
;	:	O
and	CC	O
Van	NNP	B
Loon	NNP	I
et	FW	I
al.	NN	I
,	,	I
Biochem	NNP	I
.	.	I
Pharmacol.	NNP	I
,	,	I
44:775-785	CD	I
(	(	I
1992	CD	I
)	)	I
.	.	O
Polypeptides	NNS	O
provided	VBD	O
herein	NN	O
can	MD	O
be	VB	O
modified	VBN	O
to	TO	O
contain	VB	O
an	DT	O
amino	NN	O
acid	NN	O
sequence	NN	O
that	WDT	O
allows	VBZ	O
the	DT	O
polypeptide	NN	O
to	TO	O
be	VB	O
captured	VBN	O
onto	IN	O
an	DT	O
affinity	NN	O
matrix	NN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
a	DT	O
tag	NN	O
such	JJ	O
as	IN	O
c-myc	NN	O
,	,	O
hemagglutinin	NN	O
,	,	O
polyhistidine	NN	O
,	,	O
or	CC	O
Flag™	NNP	O
(	(	O
Kodak	NNP	O
)	)	O
can	MD	O
be	VB	O
used	VBN	O
to	TO	O
aid	VB	O
polypeptide	JJ	O
purification	NN	O
.	.	O
Such	JJ	O
tags	NNS	O
can	MD	O
be	VB	O
inserted	VBN	O
anywhere	RB	O
within	IN	O
a	DT	O
polypeptide	JJ	O
including	VBG	O
at	IN	O
either	CC	O
the	DT	O
carboxyl	NN	O
or	CC	O
amino	NN	O
terminus	NN	O
.	.	O
Other	JJ	O
fusions	NNS	O
that	WDT	O
can	MD	O
be	VB	O
useful	JJ	O
include	VBP	O
enzymes	NNS	O
that	WDT	O
aid	VBP	O
in	IN	O
the	DT	O
detection	NN	O
of	IN	O
a	DT	O
polypeptide	NN	O
,	,	O
such	JJ	O
as	IN	O
alkaline	JJ	O
phosphatase	NN	O
.	.	O
Immunoaffinity	NNP	O
chromatography	NN	O
also	RB	O
can	MD	O
be	VB	O
used	VBN	O
to	TO	O
purify	VB	O
polypeptides	NNS	O
provided	VBN	O
herein	NN	O
.	.	O
Any	DT	O
suitable	JJ	O
method	NN	O
,	,	O
such	JJ	O
as	IN	O
PCR	NNP	O
,	,	O
can	MD	O
be	VB	O
used	VBN	O
to	TO	O
obtain	VB	O
an	DT	O
isolated	JJ	O
nucleic	NN	O
acid	NN	O
encoding	VBG	O
a	DT	O
polypeptide	NN	O
provided	VBD	O
herein	NN	O
.	.	O
The	DT	O
term	NN	O
“	NNP	O
nucleic	CC	O
acid	RB	O
”	NNP	O
as	IN	O
used	VBN	O
herein	NN	O
encompasses	VBZ	O
both	DT	O
RNA	NNP	O
and	CC	O
DNA	NNP	O
,	,	O
including	VBG	O
cDNA	NN	O
,	,	O
genomic	JJ	O
DNA	NNP	O
,	,	O
and	CC	O
synthetic	JJ	O
(	(	O
e.g.	JJ	O
,	,	O
chemically	RB	O
synthesized	VBN	O
)	)	O
DNA	NN	O
.	.	O
The	DT	O
nucleic	JJ	O
acid	NN	O
can	MD	O
be	VB	O
double-stranded	JJ	O
or	CC	O
single-stranded	JJ	O
.	.	O
Where	WRB	O
single-stranded	JJ	O
,	,	O
the	DT	O
nucleic	JJ	O
acid	NN	O
can	MD	O
be	VB	O
the	DT	O
sense	NN	O
strand	NN	O
or	CC	O
the	DT	O
antisense	JJ	O
strand	NN	O
.	.	O
In	IN	O
addition	NN	O
,	,	O
nucleic	JJ	O
acid	NN	O
can	MD	O
be	VB	O
circular	JJ	O
or	CC	O
linear	JJ	O
.	.	O
The	DT	O
term	NN	O
“	NNP	O
isolated	VBD	O
”	NNP	O
as	IN	O
used	VBN	O
herein	NN	O
with	IN	O
reference	NN	O
to	TO	O
nucleic	VB	O
acid	JJ	O
refers	NNS	O
to	TO	O
a	DT	O
naturally-occurring	JJ	O
nucleic	NN	O
acid	NN	O
that	WDT	O
is	VBZ	O
not	RB	O
immediately	RB	O
contiguous	JJ	O
with	IN	O
both	DT	O
of	IN	O
the	DT	O
sequences	NNS	O
with	IN	O
which	WDT	O
it	PRP	O
is	VBZ	O
immediately	RB	O
contiguous	JJ	O
(	(	O
one	CD	O
on	IN	O
the	DT	O
5′	CD	O
end	NN	O
and	CC	O
one	CD	O
on	IN	O
the	DT	O
3′	CD	O
end	NN	O
)	)	O
in	IN	O
the	DT	O
naturally-occurring	JJ	O
genome	NN	O
of	IN	O
the	DT	O
organism	NN	O
from	IN	O
which	WDT	O
it	PRP	O
is	VBZ	O
derived	VBN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
an	DT	O
isolated	JJ	O
nucleic	JJ	O
acid	NN	O
can	MD	O
be	VB	O
,	,	O
without	IN	O
limitation	NN	O
,	,	O
a	DT	O
recombinant	JJ	O
DNA	NNP	O
molecule	NN	O
of	IN	O
any	DT	O
length	NN	O
,	,	O
provided	VBD	O
one	CD	O
of	IN	O
the	DT	O
nucleic	JJ	O
acid	NN	O
sequences	NNS	O
normally	RB	O
found	VBD	O
immediately	RB	O
flanking	VBG	O
that	IN	O
recombinant	JJ	O
DNA	NNP	O
molecule	NN	O
in	IN	O
a	DT	O
naturally-occurring	JJ	O
genome	NN	O
is	VBZ	O
removed	VBN	O
or	CC	O
absent	NN	O
.	.	O
Thus	RB	O
,	,	O
an	DT	O
isolated	JJ	O
nucleic	JJ	O
acid	NN	O
includes	VBZ	O
,	,	O
without	IN	O
limitation	NN	O
,	,	O
a	DT	O
recombinant	JJ	O
DNA	NN	O
that	WDT	O
exists	VBZ	O
as	IN	O
a	DT	O
separate	JJ	O
molecule	NN	O
(	(	O
e.g.	NN	O
,	,	O
a	DT	O
cDNA	NN	O
or	CC	O
a	DT	O
genomic	JJ	O
DNA	NNP	O
fragment	NN	O
produced	VBN	O
by	IN	O
PCR	NNP	O
or	CC	O
restriction	NN	O
endonuclease	FW	O
treatment	NN	O
)	)	O
independent	JJ	O
of	IN	O
other	JJ	O
sequences	NNS	O
as	RB	O
well	RB	O
as	IN	O
recombinant	JJ	O
DNA	NN	O
that	WDT	O
is	VBZ	O
incorporated	VBN	O
into	IN	O
a	DT	O
vector	NN	O
,	,	O
an	DT	O
autonomously	RB	O
replicating	VBG	O
plasmid	NN	O
,	,	O
a	DT	O
virus	NN	O
(	(	O
e.g.	NN	O
,	,	O
a	DT	O
retrovirus	NN	O
,	,	O
adenovirus	NN	O
,	,	O
or	CC	O
herpes	NNS	O
virus	NN	O
)	)	O
,	,	O
or	CC	O
into	IN	O
the	DT	O
genomic	JJ	O
DNA	NN	O
of	IN	O
a	DT	O
prokaryote	NN	O
or	CC	O
eukaryote	NN	O
.	.	O
In	IN	O
addition	NN	O
,	,	O
an	DT	O
isolated	JJ	O
nucleic	JJ	O
acid	NN	O
can	MD	O
include	VB	O
a	DT	O
recombinant	JJ	O
DNA	NN	O
molecule	NN	O
that	WDT	O
is	VBZ	O
part	NN	O
of	IN	O
a	DT	O
hybrid	NN	O
or	CC	O
fusion	NN	O
nucleic	JJ	O
acid	JJ	O
sequence	NN	O
.	.	O
The	DT	O
term	NN	O
“	NNP	O
isolated	VBD	O
”	NNP	O
as	IN	O
used	VBN	O
herein	NN	O
with	IN	O
reference	NN	O
to	TO	O
nucleic	VB	O
acid	NN	O
also	RB	O
includes	VBZ	O
any	DT	O
non-naturally-occurring	JJ	O
nucleic	NN	O
acid	NN	O
since	IN	O
non-naturally-occurring	JJ	O
nucleic	JJ	O
acid	NN	O
sequences	NNS	O
are	VBP	O
not	RB	O
found	VBN	O
in	IN	O
nature	NN	O
and	CC	O
do	VBP	O
not	RB	O
have	VB	O
immediately	RB	O
contiguous	JJ	O
sequences	NNS	O
in	IN	O
a	DT	O
naturally-occurring	JJ	O
genome	NN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
non-naturally-occurring	JJ	O
nucleic	JJ	O
acid	NN	O
such	JJ	O
as	IN	O
an	DT	O
engineered	JJ	O
nucleic	NN	O
acid	NN	O
is	VBZ	O
considered	VBN	O
to	TO	O
be	VB	O
isolated	VBN	O
nucleic	JJ	O
acid	NN	O
.	.	O
Engineered	NNP	O
nucleic	CC	O
acid	NN	O
can	MD	O
be	VB	O
made	VBN	O
using	VBG	O
common	JJ	O
molecular	JJ	O
cloning	NN	O
or	CC	O
chemical	NN	O
nucleic	JJ	O
acid	JJ	O
synthesis	NN	O
techniques	NNS	O
.	.	O
Isolated	VBN	O
non-naturally-occurring	JJ	O
nucleic	JJ	O
acid	NN	O
can	MD	O
be	VB	O
independent	JJ	O
of	IN	O
other	JJ	O
sequences	NNS	O
,	,	O
or	CC	O
incorporated	VBN	O
into	IN	O
a	DT	O
vector	NN	O
,	,	O
an	DT	O
autonomously	RB	O
replicating	VBG	O
plasmid	NN	O
,	,	O
a	DT	O
virus	NN	O
(	(	O
e.g.	NN	O
,	,	O
a	DT	O
retrovirus	NN	O
,	,	O
adenovirus	NN	O
,	,	O
or	CC	O
herpes	NNS	O
virus	NN	O
)	)	O
,	,	O
or	CC	O
the	DT	O
genomic	JJ	O
DNA	NN	O
of	IN	O
a	DT	O
prokaryote	NN	O
or	CC	O
eukaryote	NN	O
.	.	O
In	IN	O
addition	NN	O
,	,	O
a	DT	O
non-naturally-occurring	JJ	O
nucleic	JJ	O
acid	NN	O
can	MD	O
include	VB	O
a	DT	O
nucleic	JJ	O
acid	NN	O
molecule	NN	O
that	WDT	O
is	VBZ	O
part	NN	O
of	IN	O
a	DT	O
hybrid	NN	O
or	CC	O
fusion	NN	O
nucleic	JJ	O
acid	JJ	O
sequence	NN	O
.	.	O
It	PRP	O
will	MD	O
be	VB	O
apparent	JJ	O
to	TO	O
those	DT	O
of	IN	O
skill	NN	O
in	IN	O
the	DT	O
art	NN	O
that	IN	O
a	DT	O
nucleic	JJ	O
acid	NN	O
existing	VBG	O
among	IN	O
hundreds	NNS	O
to	TO	O
millions	NNS	O
of	IN	O
other	JJ	O
nucleic	JJ	O
acid	NN	O
molecules	NNS	O
within	IN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
cDNA	NN	O
or	CC	O
genomic	JJ	O
libraries	NNS	O
,	,	O
or	CC	O
gel	NN	O
slices	NNS	O
containing	VBG	O
a	DT	O
genomic	JJ	O
DNA	NNP	O
restriction	NN	O
digest	NN	O
is	VBZ	O
not	RB	O
to	TO	O
be	VB	O
considered	VBN	O
an	DT	O
isolated	JJ	O
nucleic	NN	O
acid	NN	O
.	.	O
A	DT	O
nucleic	JJ	O
acid	NN	O
provided	VBD	O
herein	NN	O
can	MD	O
be	VB	O
at	IN	O
least	JJS	O
about	IN	O
ten	JJ	O
nucleotides	NNS	O
in	IN	O
length	NN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
the	DT	O
nucleic	JJ	O
acid	NN	O
can	MD	O
be	VB	O
about	RB	O
10	CD	O
,	,	O
11	CD	O
,	,	O
15-20	JJ	O
(	(	O
e.g.	JJ	O
,	,	O
11	CD	O
,	,	O
12	CD	O
,	,	O
13	CD	O
,	,	O
14	CD	O
,	,	O
15	CD	O
,	,	O
16	CD	O
,	,	O
17	CD	O
,	,	O
18	CD	O
,	,	O
19	CD	O
,	,	O
or	CC	O
20	CD	O
nucleotides	NNS	O
in	IN	O
length	NN	O
)	)	O
,	,	O
20-50	JJ	O
,	,	O
50-100	JJ	O
or	CC	O
greater	JJR	O
than	IN	O
100	CD	O
nucleotides	NNS	O
in	IN	O
length	NN	O
(	(	O
e.g.	NN	O
,	,	O
greater	JJR	O
than	IN	O
150	CD	O
,	,	O
200	CD	O
,	,	O
250	CD	O
,	,	O
300	CD	O
,	,	O
350	CD	O
,	,	O
400	CD	O
,	,	O
450	CD	O
,	,	O
500	CD	O
,	,	O
750	CD	O
,	,	O
or	CC	O
1000	CD	O
nucleotides	NNS	O
in	IN	O
length	NN	O
)	)	O
.	.	O
Nucleic	NNP	O
acids	NNS	O
provided	VBD	O
herein	NN	O
can	MD	O
be	VB	O
in	IN	O
a	DT	O
sense	NN	O
or	CC	O
antisense	NN	O
orientation	NN	O
,	,	O
can	MD	O
be	VB	O
identical	JJ	O
or	CC	O
complementary	JJ	O
to	TO	O
the	DT	O
nucleotide	JJ	O
sequence	NN	O
set	VBN	O
forth	NN	O
in	IN	O
SEQ	NNP	O
ID	NNP	O
NO:1	NNP	O
,	,	O
3	CD	O
,	,	O
5	CD	O
,	,	O
7	CD	O
,	,	O
9	CD	O
,	,	O
11	CD	O
,	,	O
13	CD	O
,	,	O
15	CD	O
,	,	O
17	CD	O
,	,	O
19	CD	O
,	,	O
21	CD	O
,	,	O
23	CD	O
,	,	O
25	CD	O
,	,	O
27	CD	O
,	,	O
29	CD	O
,	,	O
31	CD	O
,	,	O
or	CC	O
33	CD	O
,	,	O
and	CC	O
can	MD	O
be	VB	O
DNA	NNP	O
,	,	O
RNA	NNP	O
,	,	O
or	CC	O
nucleic	JJ	O
acid	JJ	O
analogs	NNS	O
.	.	O
Nucleic	NNP	O
acid	JJ	O
analogs	NNS	O
can	MD	O
be	VB	O
modified	VBN	O
at	IN	O
the	DT	O
base	NN	O
moiety	NN	O
,	,	O
sugar	NN	O
moiety	NN	O
,	,	O
or	CC	O
phosphate	VB	O
backbone	NN	O
to	TO	O
improve	VB	O
,	,	O
for	IN	O
example	NN	O
,	,	O
stability	NN	O
,	,	O
hybridization	NN	O
,	,	O
or	CC	O
solubility	NN	O
of	IN	O
the	DT	O
nucleic	JJ	O
acid	NN	O
.	.	O
Modifications	NNS	O
at	IN	O
the	DT	O
base	NN	O
moiety	NN	O
include	VBP	O
deoxyuridine	NN	O
for	IN	O
deoxythymidine	NN	O
,	,	O
and	CC	O
5-methyl-2′-deoxycytidine	JJ	O
and	CC	O
5-bromo-2′-deoxycytidine	JJ	O
for	IN	O
deoxycytidine	NN	O
.	.	O
Modifications	NNS	O
of	IN	O
the	DT	O
sugar	NN	O
moiety	NN	O
can	MD	O
include	VB	O
modification	NN	O
of	IN	O
the	DT	O
2′	CD	O
hydroxyl	NN	O
of	IN	O
the	DT	O
ribose	NN	O
sugar	NN	O
to	TO	O
form	VB	O
2′-O-methyl	JJ	O
or	CC	O
2′-O-allyl	JJ	O
sugars	NNS	O
.	.	O
The	DT	O
deoxyribose	JJ	O
phosphate	NN	O
backbone	NN	O
can	MD	O
be	VB	O
modified	VBN	O
to	TO	O
produce	VB	O
morpholino	NN	O
nucleic	JJ	O
acids	NNS	O
,	,	O
in	IN	O
which	WDT	O
each	DT	O
base	NN	O
moiety	NN	O
is	VBZ	O
linked	VBN	O
to	TO	O
a	DT	O
six	CD	O
membered	VBN	O
,	,	O
morpholino	NN	O
ring	NN	O
,	,	O
or	CC	O
peptide	VB	O
nucleic	JJ	O
acids	NNS	O
,	,	O
in	IN	O
which	WDT	O
the	DT	O
deoxyphosphate	NN	O
backbone	NN	O
is	VBZ	O
replaced	VBN	O
by	IN	O
a	DT	O
pseudopeptide	NN	O
backbone	NN	O
and	CC	O
the	DT	O
four	CD	O
bases	NNS	O
are	VBP	O
retained	VBN	O
.	.	O
See	VB	O
,	,	O
for	IN	O
example	NN	O
,	,	O
Summerton	NNP	B
and	CC	I
Weller	NNP	I
,	,	I
Antisense	NNP	I
Nucleic	NNP	I
Acid	NNP	I
Drug	NNP	I
Dev.	NNP	I
,	,	I
7:187-195	NNP	I
(	(	I
1997	CD	I
)	)	I
;	:	O
and	CC	O
Hyrup	NNP	B
,	,	I
et	FW	I
al.	NN	I
,	,	I
Bioorgan	NNP	I
.	.	I
Med	NNP	I
.	.	I
Chem.	NNP	I
,	,	I
4:5-23	CD	I
(	(	I
1996	CD	I
)	)	I
.	.	O
In	IN	O
addition	NN	O
,	,	O
the	DT	O
deoxyphosphate	NN	O
backbone	NN	O
can	MD	O
be	VB	O
replaced	VBN	O
with	IN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
a	DT	O
phosphorothioate	NN	O
or	CC	O
phosphorodithioate	VB	O
backbone	NN	O
,	,	O
a	DT	O
phosphoroamidite	NN	O
,	,	O
or	CC	O
an	DT	O
alkyl	JJ	O
phosphotriester	NN	O
backbone	NN	O
.	.	O
Nucleic	NNP	O
acids	NNS	O
provided	VBD	O
herein	NN	O
can	MD	O
hybridize	VB	O
,	,	O
under	IN	O
hybridization	NN	O
conditions	NNS	O
,	,	O
to	TO	O
the	DT	O
sense	NN	O
or	CC	O
antisense	JJ	O
strand	NN	O
of	IN	O
a	DT	O
nucleic	JJ	O
acid	NN	O
having	VBG	O
the	DT	O
nucleotide	JJ	O
sequence	NN	O
set	VBN	O
forth	NN	O
in	IN	O
SEQ	NNP	O
ID	NNP	O
NO:1	NNP	O
,	,	O
3	CD	O
,	,	O
5	CD	O
,	,	O
7	CD	O
,	,	O
9	CD	O
,	,	O
11	CD	O
,	,	O
13	CD	O
,	,	O
15	CD	O
,	,	O
17	CD	O
,	,	O
19	CD	O
,	,	O
21	CD	O
,	,	O
23	CD	O
,	,	O
25	CD	O
,	,	O
27	CD	O
,	,	O
29	CD	O
,	,	O
31	CD	O
,	,	O
or	CC	O
33	CD	O
.	.	O
The	DT	O
hybridization	NN	O
conditions	NNS	O
can	MD	O
be	VB	O
moderately	RB	O
or	CC	O
highly	RB	O
stringent	JJ	O
hybridization	NN	O
conditions	NNS	O
.	.	O
As	IN	O
used	VBN	O
herein	NN	O
,	,	O
moderately	RB	O
stringent	JJ	O
hybridization	NN	O
conditions	NNS	O
mean	VBP	O
the	DT	O
hybridization	NN	O
is	VBZ	O
performed	VBN	O
at	IN	O
about	RB	O
42°	CD	O
C.	NNP	O
in	IN	O
a	DT	O
hybridization	NN	O
solution	NN	O
containing	VBG	O
25	CD	O
mM	JJ	O
KPO4	NNP	O
(	(	O
pH	VB	O
7.4	CD	O
)	)	O
,	,	O
5×SSC	CD	O
,	,	O
5×Denhart	CD	O
's	POS	O
solution	NN	O
,	,	O
50	CD	O
μg/mL	NN	O
denatured	VBN	O
,	,	O
sonicated	VBD	O
salmon	JJ	O
sperm	NN	O
DNA	NNP	O
,	,	O
50	CD	O
%	NN	O
formamide	NN	O
,	,	O
10	CD	O
%	NN	O
Dextran	NNP	O
sulfate	NN	O
,	,	O
and	CC	O
1-15	JJ	O
ng/mL	NN	O
probe	NN	O
(	(	O
about	IN	O
5×107	CD	O
cpm/μg	NN	O
)	)	O
,	,	O
while	IN	O
the	DT	O
washes	NNS	O
are	VBP	O
performed	VBN	O
at	IN	O
about	RB	O
50°	CD	O
C.	NNP	O
with	IN	O
a	DT	O
wash	JJ	O
solution	NN	O
containing	VBG	O
2×SSC	CD	O
and	CC	O
0.1	CD	O
%	NN	O
sodium	NN	O
dodecyl	NN	O
sulfate	NN	O
.	.	O
Highly	NNP	O
stringent	JJ	O
hybridization	NN	O
conditions	NNS	O
mean	VBP	O
the	DT	O
hybridization	NN	O
is	VBZ	O
performed	VBN	O
at	IN	O
about	RB	O
42°	CD	O
C.	NNP	O
in	IN	O
a	DT	O
hybridization	NN	O
solution	NN	O
containing	VBG	O
25	CD	O
mM	JJ	O
KPO4	NNP	O
(	(	O
pH	VB	O
7.4	CD	O
)	)	O
,	,	O
5×SSC	CD	O
,	,	O
5×Denhart	CD	O
's	POS	O
solution	NN	O
,	,	O
50	CD	O
μg/mL	NN	O
denatured	VBN	O
,	,	O
sonicated	VBD	O
salmon	JJ	O
sperm	NN	O
DNA	NNP	O
,	,	O
50	CD	O
%	NN	O
formamide	NN	O
,	,	O
10	CD	O
%	NN	O
Dextran	NNP	O
sulfate	NN	O
,	,	O
and	CC	O
1-15	JJ	O
ng/mL	NN	O
probe	NN	O
(	(	O
about	IN	O
5×107	CD	O
cpm/μg	NN	O
)	)	O
,	,	O
while	IN	O
the	DT	O
washes	NNS	O
are	VBP	O
performed	VBN	O
at	IN	O
about	RB	O
65°	CD	O
C.	NNP	O
with	IN	O
a	DT	O
wash	JJ	O
solution	NN	O
containing	VBG	O
0.2×SSC	CD	O
and	CC	O
0.1	CD	O
%	NN	O
sodium	NN	O
dodecyl	NN	O
sulfate	NN	O
.	.	O
Hybridization	NN	O
can	MD	O
be	VB	O
done	VBN	O
by	IN	O
Southern	NNP	O
or	CC	O
Northern	NNP	O
analysis	NN	O
to	TO	O
identify	VB	O
a	DT	O
DNA	NN	O
or	CC	O
RNA	NNP	O
sequence	NN	O
,	,	O
respectively	RB	O
,	,	O
that	WDT	O
hybridizes	VBZ	O
to	TO	O
a	DT	O
probe	NN	O
.	.	O
The	DT	O
DNA	NN	O
or	CC	O
RNA	NNP	O
to	TO	O
be	VB	O
analyzed	VBN	O
can	MD	O
be	VB	O
electrophoretically	RB	O
separated	VBN	O
on	IN	O
an	DT	O
agarose	NN	O
or	CC	O
polyacrylamide	NN	O
gel	NN	O
,	,	O
transferred	VBN	O
to	TO	O
nitrocellulose	VB	O
,	,	O
nylon	NN	O
,	,	O
or	CC	O
other	JJ	O
suitable	JJ	O
membrane	NN	O
,	,	O
and	CC	O
hybridized	VBN	O
with	IN	O
a	DT	O
probe	NN	O
using	VBG	O
standard	JJ	O
techniques	NNS	O
well	RB	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
such	JJ	O
as	IN	O
those	DT	O
described	VBN	O
in	IN	O
sections	NNS	O
7.39-7.52	CD	O
of	IN	O
Sambrook	NNP	B
et	FW	I
al.	NN	I
,	,	I
(	(	I
1989	CD	I
)	)	I
Molecular	NNP	I
Cloning	NNP	I
,	,	I
second	JJ	I
edition	NN	I
,	,	I
Cold	NNP	I
Spring	NNP	I
harbor	NN	I
Laboratory	NNP	I
,	,	I
Plainview	NNP	I
,	,	I
N.Y	NNP	I
.	.	O
Typically	RB	O
,	,	O
a	DT	O
probe	NN	O
is	VBZ	O
at	IN	O
least	JJS	O
about	IN	O
20	CD	O
nucleotides	NNS	O
in	IN	O
length	NN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
a	DT	O
probe	NN	O
corresponding	VBG	O
to	TO	O
a	DT	O
20	CD	O
nucleotide	JJ	O
sequence	NN	O
set	VBN	O
forth	NN	O
in	IN	O
SEQ	NNP	O
ID	NNP	O
NO:1	NNP	O
,	,	O
3	CD	O
,	,	O
5	CD	O
,	,	O
7	CD	O
,	,	O
9	CD	O
,	,	O
11	CD	O
,	,	O
13	CD	O
,	,	O
15	CD	O
,	,	O
17	CD	O
,	,	O
19	CD	O
,	,	O
21	CD	O
,	,	O
23	CD	O
,	,	O
25	CD	O
,	,	O
27	CD	O
,	,	O
29	CD	O
,	,	O
31	CD	O
,	,	O
or	CC	O
33	CD	O
can	MD	O
be	VB	O
used	VBN	O
to	TO	O
identify	VB	O
an	DT	O
identical	JJ	O
or	CC	O
similar	JJ	O
nucleic	JJ	O
acid	NN	O
.	.	O
In	IN	O
addition	NN	O
,	,	O
probes	RB	O
longer	RBR	O
or	CC	O
shorter	JJR	O
than	IN	O
20	CD	O
nucleotides	NNS	O
can	MD	O
be	VB	O
used	VBN	O
.	.	O
A	DT	O
probe	NN	O
can	MD	O
be	VB	O
labeled	VBN	O
with	IN	O
a	DT	O
biotin	NN	O
,	,	O
digoxygenin	NN	O
,	,	O
an	DT	O
enzyme	NN	O
,	,	O
or	CC	O
a	DT	O
radioisotope	NN	O
such	JJ	O
as	IN	O
32P	CD	O
.	.	O
Isolated	VBN	O
nucleic	JJ	O
acids	NNS	O
provided	VBD	O
herein	NN	O
also	RB	O
can	MD	O
be	VB	O
chemically	RB	O
synthesized	VBN	O
,	,	O
either	RB	O
as	IN	O
a	DT	O
single	JJ	O
nucleic	NN	O
acid	NN	O
molecule	NN	O
(	(	O
e.g.	NN	O
,	,	O
using	VBG	O
automated	VBN	O
DNA	NNP	O
synthesis	NN	O
in	IN	O
the	DT	O
3′	CD	O
to	TO	O
5′	CD	O
direction	NN	O
using	VBG	O
phosphoramidite	JJ	O
technology	NN	O
)	)	O
or	CC	O
as	IN	O
a	DT	O
series	NN	O
of	IN	O
oligonucleotides	NNS	O
.	.	O
For	IN	O
example	NN	O
,	,	O
one	CD	O
or	CC	O
more	JJR	O
pairs	NNS	O
of	IN	O
long	JJ	O
oligonucleotides	NNS	O
(	(	O
e.g.	NN	O
,	,	O
>	VBZ	O
100	CD	O
nucleotides	NNS	O
)	)	O
can	MD	O
be	VB	O
synthesized	VBN	O
that	IN	O
contain	VBP	O
the	DT	O
desired	JJ	O
sequence	NN	O
,	,	O
with	IN	O
each	DT	O
pair	NN	O
containing	VBG	O
a	DT	O
short	JJ	O
segment	NN	O
of	IN	O
complementarity	NN	O
(	(	O
e.g.	JJ	O
,	,	O
about	RB	O
15	CD	O
nucleotides	NNS	O
)	)	O
such	PDT	O
that	IN	O
a	DT	O
duplex	NN	O
is	VBZ	O
formed	VBN	O
when	WRB	O
the	DT	O
oligonucleotide	NN	O
pair	NN	O
is	VBZ	O
annealed	VBN	O
.	.	O
DNA	NN	O
polymerase	NN	O
is	VBZ	O
used	VBN	O
to	TO	O
extend	VB	O
the	DT	O
oligonucleotides	NNS	O
,	,	O
resulting	VBG	O
in	IN	O
a	DT	O
single	JJ	O
,	,	O
double-stranded	JJ	O
nucleic	JJ	O
acid	NN	O
molecule	NN	O
per	IN	O
oligonucleotide	NN	O
pair	NN	O
,	,	O
which	WDT	O
then	RB	O
can	MD	O
be	VB	O
ligated	VBN	O
into	IN	O
a	DT	O
vector	NN	O
.	.	O
Antibodies	NNS	O
An	DT	O
antibody	NN	O
that	WDT	O
can	MD	O
bind	VB	O
to	TO	O
a	DT	O
polypeptide	NN	O
provided	VBD	O
herein	NN	O
can	MD	O
be	VB	O
made	VBN	O
and	CC	O
purified	VBN	O
using	VBG	O
methods	NNS	O
known	VBN	O
to	TO	O
those	DT	O
skilled	VBN	O
in	IN	O
the	DT	O
art	NN	O
(	(	O
e.g.	NN	O
,	,	O
the	DT	O
methods	NNS	O
described	VBD	O
herein	NN	O
)	)	O
.	.	O
For	IN	O
example	NN	O
,	,	O
an	DT	O
antibody	NN	O
that	WDT	O
can	MD	O
bind	VB	O
to	TO	O
a	DT	O
polypeptide	NN	O
provided	VBD	O
herein	NN	O
can	MD	O
be	VB	O
affinity	JJ	O
purified	VBN	O
from	IN	O
the	DT	O
serum	NN	O
of	IN	O
an	DT	O
animal	NN	O
(	(	O
e.g.	JJ	O
,	,	O
a	DT	O
mouse	NN	O
,	,	O
rat	NN	O
,	,	O
rabbit	NN	O
,	,	O
goat	NN	O
,	,	O
donkey	NN	O
,	,	O
horse	NN	O
,	,	O
duck	NN	O
,	,	O
or	CC	O
chicken	NN	O
)	)	O
that	WDT	O
received	VBD	O
a	DT	O
substantially	RB	O
pure	JJ	O
polypeptide	NN	O
provided	VBD	O
herein	JJ	O
under	IN	O
conditions	NNS	O
that	WDT	O
illicit	VBP	O
an	DT	O
immune	JJ	O
response	NN	O
to	TO	O
the	DT	O
polypeptide	NN	O
.	.	O
In	IN	O
some	DT	O
cases	NNS	O
,	,	O
an	DT	O
antibody	NN	O
that	WDT	O
can	MD	O
bind	VB	O
to	TO	O
a	DT	O
polypeptide	NN	O
provided	VBD	O
herein	NN	O
can	MD	O
be	VB	O
purified	VBN	O
from	IN	O
the	DT	O
supernatant	NN	O
of	IN	O
a	DT	O
B	NNP	O
cell	NN	O
hybridoma	NN	O
that	WDT	O
produces	VBZ	O
such	PDT	O
an	DT	O
antibody	NN	O
.	.	O
An	DT	O
antibody	NN	O
that	WDT	O
can	MD	O
bind	VB	O
to	TO	O
a	DT	O
polypeptide	NN	O
provided	VBD	O
herein	NN	O
can	MD	O
be	VB	O
monoclonal	JJ	O
or	CC	O
polyclonal	JJ	O
and	CC	O
can	MD	O
be	VB	O
,	,	O
for	IN	O
example	NN	O
,	,	O
a	DT	O
single	JJ	O
chain	NN	O
Fv	NNP	O
,	,	O
chimeric	JJ	O
antibody	NN	O
,	,	O
or	CC	O
an	DT	O
Fab	JJ	O
fragment	NN	O
.	.	O
Fungus-Induced	JJ	O
Eosinophil	NNP	O
Degranulation	NNP	O
Eosinophils	NNP	O
belong	NN	O
to	TO	O
the	DT	O
granulocyte	JJ	O
class	NN	O
of	IN	O
white	JJ	O
blood	NN	O
cells	NNS	O
,	,	O
and	CC	O
contain	VBP	O
cytoplasmic	JJ	O
granules	NNS	O
that	WDT	O
stain	VBP	O
with	IN	O
the	DT	O
acidic	JJ	O
dye	NN	O
eosin	NN	O
.	.	O
Eosinophils	NNS	O
are	VBP	O
the	DT	O
main	JJ	O
effectors	NNS	O
of	IN	O
antibody-dependent	JJ	O
cell-mediated	JJ	O
cytotoxicity	NN	O
against	IN	O
multicellular	JJ	O
parasites	NNS	O
that	IN	O
provoke	VBD	O
IgE	NNP	O
antibodies	NNS	O
.	.	O
Their	PRP$	O
role	NN	O
seems	VBZ	O
to	TO	O
be	VB	O
to	TO	O
engulf	VB	O
and	CC	O
destroy	VB	O
the	DT	O
precipitated	JJ	O
antigen-antibody	NN	O
complexes	NNS	O
produced	VBN	O
in	IN	O
humorally	RB	O
based	VBN	O
immune	JJ	O
reactions	NNS	O
.	.	O
An	DT	O
elevated	JJ	O
eosinophil	NN	O
count	NN	O
usually	RB	O
is	VBZ	O
seen	VBN	O
in	IN	O
allergic	JJ	O
reactions	NNS	O
,	,	O
and	CC	O
numerous	JJ	O
eosinophils	NNS	O
are	VBP	O
chemotactically	RB	O
aggregated	VBN	O
at	IN	O
sites	NNS	O
where	WRB	O
antigen-antibody	NN	O
complexes	NNS	O
are	VBP	O
found	VBN	O
.	.	O
As	IN	O
used	VBN	O
herein	NN	O
,	,	O
“	JJ	O
fungus-induced	JJ	O
eosinophil	NN	O
degranulation	NN	O
”	VBZ	O
refers	NNS	O
to	TO	O
eosinophil	VB	O
degranulation	NN	O
in	IN	O
response	NN	O
to	TO	O
one	CD	O
or	CC	O
more	JJR	O
antigens	NNS	O
from	IN	O
fungal	JJ	O
cells	NNS	O
(	(	O
e.g.	NN	O
,	,	O
from	IN	O
fungal	JJ	O
cell	NN	O
extracts	NNS	O
or	CC	O
fungal	JJ	O
culture	NN	O
supernatants	NNS	O
)	)	O
.	.	O
Degranulation	NN	O
is	VBZ	O
the	DT	O
release	NN	O
of	IN	O
toxic	JJ	O
molecules	NNS	O
such	JJ	O
as	IN	O
eosinophil	JJ	O
cationic	JJ	O
protein	NN	O
(	(	O
ECP	NNP	O
)	)	O
,	,	O
eosinophil	JJ	O
peroxidase	NN	O
(	(	O
EPO	NNP	O
)	)	O
,	,	O
and	CC	O
MBP	NNP	O
that	WDT	O
are	VBP	O
contained	VBN	O
within	IN	O
eosinophil	JJ	O
granules	NNS	O
;	:	O
this	DT	O
release	NN	O
typically	RB	O
causes	VBZ	O
damage	NN	O
to	TO	O
or	CC	O
death	NN	O
of	IN	O
cells	NNS	O
in	IN	O
the	DT	O
vicinity	NN	O
of	IN	O
the	DT	O
degranulating	NN	O
eosinophils	NNS	O
.	.	O
Eosinophil	NNP	O
degranulation	NN	O
can	MD	O
be	VB	O
achieved	VBN	O
in	IN	O
vitro	NN	O
as	IN	O
described	VBN	O
in	IN	O
the	DT	O
example	NN	O
section	NN	O
herein	NN	O
.	.	O
In	IN	O
some	DT	O
cases	NNS	O
,	,	O
a	DT	O
fungal	JJ	O
preparation	NN	O
(	(	O
e.g.	NN	O
,	,	O
a	DT	O
fungal	JJ	O
cell	NN	O
extract	NN	O
or	CC	O
fungal	JJ	O
culture	NN	O
supernatant	NN	O
)	)	O
can	MD	O
be	VB	O
added	VBN	O
to	TO	O
an	DT	O
eosinophil	NN	O
to	TO	O
induce	VB	O
degranulation	NN	O
.	.	O
As	IN	O
used	VBN	O
herein	NN	O
,	,	O
a	DT	O
“	JJ	O
fungal	NN	O
cell	NN	O
extract	JJ	O
”	NNP	O
is	VBZ	O
a	DT	O
preparation	NN	O
that	WDT	O
contains	VBZ	O
factors	NNS	O
(	(	O
e.g.	NN	O
,	,	O
polypeptides	NNS	O
)	)	O
found	VBD	O
within	IN	O
a	DT	O
fungal	JJ	O
cell	NN	O
(	(	O
e.g.	JJ	O
,	,	O
in	IN	O
the	DT	O
cytoplasm	NN	O
,	,	O
membranes	NNS	O
,	,	O
or	CC	O
organelles	NNS	O
of	IN	O
a	DT	O
fungal	JJ	O
cell	NN	O
)	)	O
.	.	O
The	DT	O
term	NN	O
“	NNP	O
fungal	JJ	O
culture	NN	O
supernatant	NN	O
”	NN	O
refers	NNS	O
to	TO	O
media	NNS	O
obtained	VBN	O
from	IN	O
culturing	VBG	O
fungal	JJ	O
cells	NNS	O
.	.	O
A	DT	O
fungal	JJ	O
culture	NN	O
supernatant	NN	O
can	MD	O
be	VB	O
manipulated	VBN	O
to	TO	O
form	VB	O
solid	JJ	O
material	NN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
a	DT	O
fungal	JJ	O
culture	NN	O
supernatant	NN	O
can	MD	O
be	VB	O
obtained	VBN	O
by	IN	O
removing	VBG	O
fungal	JJ	O
organisms	NNS	O
from	IN	O
a	DT	O
fungal	JJ	O
culture	NN	O
.	.	O
The	DT	O
resulting	VBG	O
supernatant	JJ	O
then	RB	O
can	MD	O
be	VB	O
concentrated	VBN	O
such	JJ	O
that	IN	O
any	DT	O
remaining	VBG	O
material	NN	O
(	(	O
e.g.	JJ	O
,	,	O
fungal	JJ	O
polypeptides	NNS	O
)	)	O
form	NN	O
concentrated	VBN	O
liquid	NN	O
or	CC	O
dry	JJ	O
material	NN	O
.	.	O
This	DT	O
dry	JJ	O
material	NN	O
can	MD	O
be	VB	O
a	DT	O
fungal	JJ	O
culture	NN	O
extract	NN	O
.	.	O
A	DT	O
cell	NN	O
extract	NN	O
or	CC	O
culture	NN	O
supernatant	NN	O
from	IN	O
any	DT	O
suitable	JJ	O
type	NN	O
of	IN	O
fungus	NN	O
can	MD	O
be	VB	O
used	VBN	O
to	TO	O
induce	VB	O
degranulation	NN	O
,	,	O
including	VBG	O
extracts	NNS	O
and	CC	O
supernatants	NNS	O
from	IN	O
those	DT	O
fungi	NNS	O
listed	VBN	O
above	IN	O
(	(	O
e.g.	NN	O
,	,	O
Alternaria	NNP	O
,	,	O
Candida	NNP	O
,	,	O
Aspergillus	NNP	O
,	,	O
or	CC	O
Cladisporium	NNP	O
)	)	O
.	.	O
Alternaria	NNP	O
cell	NN	O
extracts	NNS	O
and	CC	O
culture	NN	O
supernatants	NNS	O
are	VBP	O
particularly	RB	O
useful	JJ	O
.	.	O
These	DT	O
can	MD	O
be	VB	O
obtained	VBN	O
by	IN	O
standard	JJ	O
laboratory	NN	O
cell	NN	O
culture	NN	O
and	CC	O
extract	JJ	O
preparation	NN	O
techniques	NNS	O
.	.	O
Alternatively	RB	O
,	,	O
fungal	JJ	O
cell	NN	O
extracts	NNS	O
and	CC	O
culture	NN	O
supernatants	NNS	O
are	VBP	O
commercially	RB	O
available	JJ	O
(	(	O
e.g.	JJ	O
,	,	O
from	IN	O
Greer	NNP	O
Laboratories	NNPS	O
,	,	O
Lenoir	NNP	O
,	,	O
N.C.	NNP	O
)	)	O
.	.	O
Eosinophils	NNS	O
can	MD	O
be	VB	O
obtained	VBN	O
by	IN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
purification	NN	O
from	IN	O
an	DT	O
individual	NN	O
's	POS	O
blood	NN	O
.	.	O
Methods	NNS	O
for	IN	O
such	JJ	O
purification	NN	O
are	VBP	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
Eosinophil	NNP	O
degranulation	NN	O
can	MD	O
be	VB	O
stimulated	VBN	O
in	IN	O
vitro	NN	O
by	IN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
incubating	VBG	O
a	DT	O
fungal	JJ	O
preparation	NN	O
(	(	O
e.g.	NN	O
,	,	O
a	DT	O
volume	NN	O
of	IN	O
Alternaria	NNP	O
culture	NN	O
supernatant	NN	O
or	CC	O
50	CD	O
μg/mL	NN	O
of	IN	O
an	DT	O
Alternaria	NNP	O
culture	NN	O
supernatant	NN	O
extract	NN	O
)	)	O
with	IN	O
an	DT	O
eosinophil	NN	O
(	(	O
e.g.	JJ	O
,	,	O
purified	JJ	O
eosinophils	NNS	O
)	)	O
.	.	O
Any	DT	O
incubation	NN	O
time	NN	O
(	(	O
e.g.	UH	O
,	,	O
1	CD	O
,	,	O
2	CD	O
,	,	O
3	CD	O
,	,	O
4	CD	O
,	,	O
5	CD	O
,	,	O
6	CD	O
,	,	O
7	CD	O
,	,	O
or	CC	O
more	JJR	O
hours	NNS	O
)	)	O
can	MD	O
be	VB	O
used	VBN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
an	DT	O
incubation	NN	O
time	NN	O
from	IN	O
about	RB	O
2	CD	O
to	TO	O
about	IN	O
6	CD	O
hours	NNS	O
can	MD	O
be	VB	O
used	VBN	O
.	.	O
Any	DT	O
amount	NN	O
of	IN	O
a	DT	O
fungal	JJ	O
preparation	NN	O
can	MD	O
be	VB	O
used	VBN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
the	DT	O
amount	NN	O
of	IN	O
a	DT	O
fungal	JJ	O
extract	NN	O
can	MD	O
range	VB	O
from	IN	O
about	IN	O
10	CD	O
μg/mL	NNS	O
to	TO	O
about	IN	O
100	CD	O
mg/mL	NNS	O
(	(	O
e.g.	NN	O
,	,	O
about	RB	O
50	CD	O
,	,	O
100	CD	O
,	,	O
200	CD	O
,	,	O
300	CD	O
,	,	O
or	CC	O
more	JJR	O
μg/mL	NNS	O
)	)	O
.	.	O
Degranulation	NN	O
can	MD	O
be	VB	O
measured	VBN	O
by	IN	O
a	DT	O
number	NN	O
of	IN	O
methods	NNS	O
,	,	O
including	VBG	O
those	DT	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
Degranulation	NN	O
can	MD	O
be	VB	O
assessed	VBN	O
by	IN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
measuring	VBG	O
the	DT	O
release	NN	O
of	IN	O
markers	NNS	O
such	JJ	O
as	IN	O
ECP	NNP	O
,	,	O
EPO	NNP	O
,	,	O
MBP	NNP	O
,	,	O
or	CC	O
EDN	NNP	O
.	.	O
Non-limiting	JJ	O
examples	NNS	O
of	IN	O
methods	NNS	O
for	IN	O
measuring	VBG	O
marker	NN	O
levels	NNS	O
include	VBP	O
protein-based	JJ	O
methods	NNS	O
such	JJ	O
as	IN	O
ELISA	NNP	O
assays	NNS	O
and	CC	O
western	JJ	O
blotting	NN	O
.	.	O
Alternatively	RB	O
,	,	O
degranulation	NN	O
can	MD	O
be	VB	O
assessed	VBN	O
by	IN	O
visual	JJ	O
inspection	NN	O
of	IN	O
eosinophils	NNS	O
by	IN	O
microscopy	NN	O
(	(	O
e.g.	NN	O
,	,	O
using	VBG	O
an	DT	O
electron	NN	O
microscope	NN	O
)	)	O
to	TO	O
detect	VB	O
the	DT	O
presence	NN	O
of	IN	O
empty	JJ	O
granules	NNS	O
.	.	O
Identifying	VBG	O
an	DT	O
Inhibitor	NN	O
of	IN	O
Fungus-Induced	NNP	O
Eosinophil	NNP	O
Degranulation	NNP	O
and/or	POS	O
Inflammation	NNP	O
This	DT	O
document	NN	O
provides	VBZ	O
methods	NNS	O
and	CC	O
materials	NNS	O
that	WDT	O
can	MD	O
be	VB	O
used	VBN	O
to	TO	O
identify	VB	O
an	DT	O
agent	NN	O
that	IN	O
inhibits	VBZ	O
fungus-induced	JJ	O
eosinophil	JJ	O
degranulation	NN	O
and/or	NN	O
inflammation	NN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
an	DT	O
inhibitor	NN	O
of	IN	O
fungus-induced	JJ	O
eosinophil	JJ	O
degranulation	NN	O
can	MD	O
be	VB	O
identified	VBN	O
by	IN	O
contacting	VBG	O
an	DT	O
eosinophil	NN	O
with	IN	O
a	DT	O
polypeptide	NN	O
provided	VBD	O
herein	NN	O
in	IN	O
the	DT	O
presence	NN	O
and	CC	O
absence	NN	O
of	IN	O
a	DT	O
test	NN	O
agent	NN	O
,	,	O
and	CC	O
measuring	VBG	O
levels	NNS	O
of	IN	O
degranulation	NN	O
(	(	O
e.g.	NN	O
,	,	O
by	IN	O
measuring	VBG	O
EDN	NNP	O
output	NN	O
or	CC	O
MBP	NNP	O
output	NN	O
,	,	O
or	CC	O
by	IN	O
observing	VBG	O
empty	JJ	O
granules	NNS	O
within	IN	O
eosinophils	NNS	O
viewed	VBN	O
by	IN	O
microscopy	NN	O
)	)	O
.	.	O
A	DT	O
test	NN	O
agent	NN	O
can	MD	O
be	VB	O
identified	VBN	O
as	IN	O
an	DT	O
inhibitor	NN	O
of	IN	O
eosinophil	JJ	O
degranulation	NN	O
if	IN	O
the	DT	O
level	NN	O
of	IN	O
degranulation	NN	O
is	VBZ	O
reduced	VBN	O
in	IN	O
the	DT	O
presence	NN	O
of	IN	O
the	DT	O
test	NN	O
agent	NN	O
as	IN	O
compared	VBN	O
to	TO	O
the	DT	O
level	NN	O
of	IN	O
degranulation	NN	O
observed	VBN	O
in	IN	O
the	DT	O
absence	NN	O
of	IN	O
the	DT	O
test	NN	O
agent	NN	O
.	.	O
By	IN	O
“	NNP	O
reduced	VBD	O
”	NNP	O
is	VBZ	O
meant	VBN	O
that	IN	O
the	DT	O
level	NN	O
of	IN	O
degranulation	NN	O
in	IN	O
the	DT	O
presence	NN	O
of	IN	O
the	DT	O
test	NN	O
agent	NN	O
is	VBZ	O
less	RBR	O
(	(	O
e.g.	NN	O
,	,	O
1	CD	O
%	NN	O
less	JJR	O
,	,	O
5	CD	O
%	NN	O
less	JJR	O
,	,	O
10	CD	O
%	NN	O
less	JJR	O
,	,	O
50	CD	O
%	NN	O
less	JJR	O
,	,	O
90	CD	O
%	NN	O
less	JJR	O
,	,	O
or	CC	O
100	CD	O
%	NN	O
less	JJR	O
)	)	O
than	IN	O
the	DT	O
level	NN	O
observed	VBD	O
without	IN	O
the	DT	O
test	NN	O
agent	NN	O
.	.	O
Molecules	NNS	O
belonging	VBG	O
to	TO	O
any	DT	O
of	IN	O
a	DT	O
number	NN	O
of	IN	O
classes	NNS	O
can	MD	O
be	VB	O
used	VBN	O
as	IN	O
test	NN	O
agents	NNS	O
.	.	O
For	IN	O
example	NN	O
,	,	O
molecules	NNS	O
that	WDT	O
are	VBP	O
polypeptides	NNS	O
(	(	O
i.e.	FW	O
,	,	O
amino	JJ	O
acid	NN	O
chains	NNS	O
of	IN	O
any	DT	O
length	NN	O
,	,	O
regardless	RB	O
of	IN	O
modification	NN	O
such	JJ	O
as	IN	O
phosphorylation	NN	O
or	CC	O
glycosylation	NN	O
)	)	O
,	,	O
oligonucleotides	UH	O
,	,	O
esters	NNS	O
,	,	O
lipids	NNS	O
,	,	O
carbohydrates	NNS	O
,	,	O
and	CC	O
steroids	NNS	O
can	MD	O
be	VB	O
used	VBN	O
as	IN	O
test	NN	O
agents	NNS	O
.	.	O
Molecules	NNS	O
that	WDT	O
are	VBP	O
protease	JJ	O
inhibitors	NNS	O
may	MD	O
be	VB	O
particularly	RB	O
useful	JJ	O
.	.	O
Such	JJ	O
protease	NN	O
inhibitors	NNS	O
can	MD	O
be	VB	O
included	VBN	O
within	IN	O
a	DT	O
cocktail	NN	O
of	IN	O
inhibitors	NNS	O
(	(	O
e.g.	NN	O
,	,	O
inhibitor	NN	O
cocktails	NNS	O
that	WDT	O
are	VBP	O
commercially	RB	O
available	JJ	O
from	IN	O
Roche	NNP	O
Molecular	NNP	O
Biochemicals	NNP	O
,	,	O
Indianapolis	NNP	O
,	,	O
Ind	NNP	O
.	.	O
)	)	O
or	CC	O
can	MD	O
be	VB	O
individual	JJ	O
protease	NN	O
inhibitors	NNS	O
(	(	O
e.g.	NN	O
,	,	O
a	DT	O
single	JJ	O
serine	NN	O
protease	NN	O
inhibitor	NN	O
such	JJ	O
as	IN	O
AEBSF	NNP	O
)	)	O
.	.	O
In	IN	O
some	DT	O
cases	NNS	O
,	,	O
an	DT	O
inhibitor	NN	O
of	IN	O
fungus-induced	JJ	O
inflammation	NN	O
can	MD	O
be	VB	O
identified	VBN	O
by	IN	O
contacting	VBG	O
an	DT	O
animal	JJ	O
model	NN	O
(	(	O
e.g.	JJ	O
,	,	O
a	DT	O
mouse	NN	O
model	NN	O
)	)	O
with	IN	O
a	DT	O
polypeptide	NN	O
provided	VBD	O
herein	NN	O
in	IN	O
the	DT	O
presence	NN	O
and	CC	O
absence	NN	O
of	IN	O
a	DT	O
test	NN	O
agent	NN	O
,	,	O
and	CC	O
measuring	VBG	O
levels	NNS	O
of	IN	O
inflammation	NN	O
.	.	O
A	DT	O
test	NN	O
agent	NN	O
can	MD	O
be	VB	O
identified	VBN	O
as	IN	O
an	DT	O
inhibitor	NN	O
of	IN	O
inflammation	NN	O
if	IN	O
the	DT	O
level	NN	O
of	IN	O
inflammation	NN	O
is	VBZ	O
reduced	VBN	O
in	IN	O
the	DT	O
presence	NN	O
of	IN	O
the	DT	O
test	NN	O
agent	NN	O
as	IN	O
compared	VBN	O
to	TO	O
the	DT	O
level	NN	O
of	IN	O
inflammation	NN	O
observed	VBN	O
in	IN	O
the	DT	O
absence	NN	O
of	IN	O
the	DT	O
test	NN	O
agent	NN	O
.	.	O
The	DT	O
invention	NN	O
will	MD	O
be	VB	O
further	JJ	O
described	VBN	O
in	IN	O
the	DT	O
following	JJ	O
examples	NNS	O
,	,	O
which	WDT	O
do	VBP	O
not	RB	O
limit	VB	O
the	DT	O
scope	NN	O
of	IN	O
the	DT	O
invention	NN	O
described	VBN	O
in	IN	O
the	DT	O
claims	NNS	O
.	.	O
EXAMPLES	NNP	O
Example	NNP	O
1	CD	O
The	DT	O
Abnormal	NNP	O
Immunologic	NNP	O
Response	NNP	O
of	IN	O
CRS	NNP	O
Patients	NNPS	O
to	TO	O
Fungal	NNP	O
Antigens	NNP	O
The	DT	O
responses	NNS	O
of	IN	O
peripheral	JJ	O
blood	NN	O
mononuclear	NN	O
cells	NNS	O
(	(	O
PBMC	NNP	O
)	)	O
from	IN	O
CRS	NNP	O
patients	NNS	O
to	TO	O
fungal	VB	O
antigens	NNS	O
were	VBD	O
characterized	VBN	O
.	.	O
The	DT	O
cytokine	NN	O
responses	NNS	O
from	IN	O
CRS	NNP	O
patients	NNS	O
and	CC	O
normal	JJ	O
volunteers	NNS	O
,	,	O
when	WRB	O
stimulated	VBN	O
with	IN	O
extracts	NNS	O
from	IN	O
four	CD	O
common	JJ	O
environmental	JJ	O
fungal	JJ	O
species—including	VBG	O
Alternaria	NNP	O
,	,	O
Aspergillus	NNP	O
,	,	O
Cladosporium	NNP	O
,	,	O
and	CC	O
Penicillium	NNP	O
,	,	O
were	VBD	O
examined	VBN	O
.	.	O
In	IN	O
the	DT	O
Examples	NNP	O
section	NN	O
,	,	O
Alternaria	NNP	O
refers	NNS	O
to	TO	O
Alternaria	NNP	O
alternate	NN	O
unless	IN	O
specified	VBN	O
otherwise	NN	O
.	.	O
In	IN	O
FIG	NNP	O
.	.	O
1	CD	O
,	,	O
PBMC	NNP	O
from	IN	O
about	RB	O
90	CD	O
%	NN	O
of	IN	O
the	DT	O
CRS	NNP	O
patients	NNS	O
,	,	O
but	CC	O
not	RB	O
those	DT	O
from	IN	O
normal	JJ	O
individuals	NNS	O
,	,	O
produced	VBD	O
both	DT	O
IL-5	NNP	O
and	CC	O
IL-13	NNP	O
when	WRB	O
exposed	VBN	O
to	TO	O
Alternaria	NNP	O
,	,	O
Aspergillus	NNP	O
,	,	O
or	CC	O
Cladosporium	NNP	O
,	,	O
but	CC	O
there	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
in	IN	O
the	DT	O
amounts	NNS	O
of	IN	O
these	DT	O
cytokines	NNS	O
between	IN	O
allergic	JJ	O
and	CC	O
non-allergic	JJ	O
CRS	NNP	O
patients	NNS	O
.	.	O
In	IN	O
response	NN	O
to	TO	O
Alternaria	NNP	O
,	,	O
PBMC	NNP	O
from	IN	O
CRS	NNP	O
patients	NNS	O
produced	VBD	O
about	IN	O
5-times	NNS	O
more	RBR	O
IFN-γ	JJ	O
than	IN	O
PBMC	NNP	O
from	IN	O
normal	JJ	O
individuals	NNS	O
.	.	O
Furthermore	RB	O
,	,	O
levels	NNS	O
of	IN	O
serum	NN	O
IgG	NNP	O
antibodies	VBZ	O
to	TO	O
Alternaria	NNP	O
and	CC	O
Cladosporium	NNP	O
were	VBD	O
increased	VBN	O
in	IN	O
CRS	NNP	O
patients	NNS	O
compared	VBN	O
to	TO	O
normal	JJ	O
individuals	NNS	O
(	(	O
p	NN	O
<	RB	O
0.01	CD	O
)	)	O
,	,	O
and	CC	O
the	DT	O
increased	VBN	O
humoral	NN	O
(	(	O
serum	JJ	O
IgG	NNP	O
antibody	NN	O
)	)	O
response	NN	O
strongly	RB	O
correlated	VBN	O
with	IN	O
the	DT	O
increased	VBN	O
cellular	NN	O
(	(	O
IL-5	NNP	O
production	NN	O
)	)	O
response	NN	O
to	TO	O
Alternaria	NNP	O
(	(	O
r=0.619	NN	O
,	,	O
p	NN	O
<	NNP	O
0.01	CD	O
)	)	O
(	(	O
FIG	NNP	O
.	.	O
2	CD	O
)	)	O
.	.	O
In	IN	O
contrast	NN	O
,	,	O
<	VBP	O
30	CD	O
%	NN	O
of	IN	O
patients	NNS	O
had	VBD	O
elevated	VBN	O
serum	NN	O
levels	NNS	O
of	IN	O
IgE	NNP	O
antibody	NN	O
to	TO	O
Alternaria	NNP	O
,	,	O
and	CC	O
there	EX	O
was	VBD	O
no	DT	O
correlation	NN	O
between	IN	O
the	DT	O
serum	NN	O
levels	NNS	O
IgE	NNP	O
antibody	NN	O
and	CC	O
the	DT	O
cellular	JJ	O
response	NN	O
to	TO	O
Alternaria	NNP	O
.	.	O
Overall	JJ	O
,	,	O
CRS	NNP	O
patients	NNS	O
likely	JJ	O
exhibit	NN	O
exaggerated	JJ	O
humoral	JJ	O
and	CC	O
cellular	JJ	O
responses	NNS	O
,	,	O
both	DT	O
Th1	NNP	O
and	CC	O
Th2	NNP	O
types	NNS	O
,	,	O
to	TO	O
common	JJ	O
airborne	JJ	O
fungi	NNS	O
,	,	O
particularly	RB	O
Alternaria	NNP	O
.	.	O
The	DT	O
following	NN	O
was	VBD	O
performed	VBN	O
to	TO	O
determine	VB	O
why	WRB	O
<	JJ	O
30	CD	O
%	NN	O
of	IN	O
the	DT	O
CRS	NNP	O
patients	NNS	O
have	VBP	O
IgE	NNP	O
antibodies	NNS	O
to	TO	O
fungi	VB	O
,	,	O
while	IN	O
about	RB	O
90	CD	O
%	NN	O
of	IN	O
them	PRP	O
exhibit	VBP	O
Th2-like	JJ	O
PBMC	NNP	O
responses	NNS	O
.	.	O
Production	NN	O
of	IN	O
IgE	NNP	O
occurs	VBZ	O
through	IN	O
sequential	JJ	O
switching	VBG	O
events	NNS	O
from	IN	O
μ	NN	O
to	TO	O
γ4	VB	O
to	TO	O
ε	VB	O
.	.	O
With	IN	O
chronic	JJ	O
antigen	NN	O
exposure	NN	O
,	,	O
IgG4-switched	NNP	O
B	NNP	O
memory	NN	O
cells	NNS	O
are	VBP	O
induced	VBN	O
,	,	O
and	CC	O
these	DT	O
IgG4-switched	JJ	O
B	NNP	O
memory	NN	O
cells	NNS	O
may	MD	O
undergo	VB	O
a	DT	O
secondary	JJ	O
switch	NN	O
to	TO	O
IgE	NNP	O
.	.	O
FIG	NNP	O
.	.	O
3	CD	O
shows	NNS	O
that	IN	O
60	CD	O
%	NN	O
of	IN	O
the	DT	O
patients	NNS	O
with	IN	O
CRS	NNP	O
had	VBD	O
specific	JJ	O
IgG4	NNP	O
antibodies	NNS	O
to	TO	O
Alternaria	NNP	O
;	:	O
20	CD	O
%	NN	O
of	IN	O
patients	NNS	O
with	IN	O
seasonal	JJ	O
allergic	JJ	O
rhinitis	NN	O
(	(	O
AR	NNP	O
)	)	O
had	VBD	O
anti-Alternaria	JJ	O
IgG4	NNP	O
,	,	O
and	CC	O
none	NN	O
of	IN	O
the	DT	O
normal	JJ	O
individuals	NNS	O
did	VBD	O
.	.	O
In	IN	O
contrast	NN	O
,	,	O
there	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
the	DT	O
levels	NNS	O
of	IN	O
IgG4	NNP	O
antibodies	NNS	O
to	TO	O
Aspergillus	NNP	O
among	IN	O
the	DT	O
three	CD	O
groups	NNS	O
.	.	O
Thus	RB	O
,	,	O
patients	NNS	O
with	IN	O
CRS	NNP	O
may	MD	O
have	VB	O
had	VBD	O
an	DT	O
increased	VBN	O
exposure	NN	O
to	TO	O
Alternaria	NNP	O
,	,	O
but	CC	O
not	RB	O
to	TO	O
Aspergillus	NNP	O
,	,	O
or	CC	O
they	PRP	O
may	MD	O
have	VB	O
had	VBD	O
an	DT	O
enhanced	VBN	O
“	NN	O
modified	VBD	O
Th2	NNP	O
response	NN	O
”	NN	O
to	TO	O
Alternaria	NNP	O
,	,	O
or	CC	O
both	DT	O
.	.	O
Epithelial	JJ	O
cells	NNS	O
are	VBP	O
likely	JJ	O
participants	NNS	O
among	IN	O
the	DT	O
important	JJ	O
cellular	JJ	O
network	NN	O
of	IN	O
immune	NN	O
and	CC	O
inflammatory	JJ	O
responses	NNS	O
in	IN	O
the	DT	O
airways	NNS	O
.	.	O
It	PRP	O
was	VBD	O
found	VBN	O
that	IN	O
nasal	JJ	O
polyp	JJ	O
epithelial	JJ	O
cells	NNS	O
obtained	VBN	O
from	IN	O
CRS	NNP	O
patients	NNS	O
produce	VBP	O
large	JJ	O
quantities	NNS	O
of	IN	O
IL-8	NNP	O
and	CC	O
GM-CSF	NNP	O
.	.	O
Conditioned	VBN	O
media	NNS	O
containing	VBG	O
GM-CSF	NNP	O
markedly	RB	O
enhanced	VBD	O
activation	NN	O
of	IN	O
blood	NN	O
eosinophils	NNS	O
,	,	O
suggesting	VBG	O
that	IN	O
the	DT	O
products	NNS	O
of	IN	O
not	RB	O
only	RB	O
lymphocytes	VBZ	O
,	,	O
but	CC	O
also	RB	O
epithelial	JJ	O
cells	NNS	O
activate	VBP	O
airway	RB	O
eosinophils	NNS	O
in	IN	O
nasal	JJ	O
polyps	NNS	O
.	.	O
Example	RB	O
2	CD	O
Eosinophil	NNP	O
Activation	NNP	O
and	CC	O
Degranulation	NNP	O
in	IN	O
CRS	NNP	O
Asthma	NNP	O
and	CC	O
CRS	NNP	O
coexist	VBP	O
clinically	RB	O
in	IN	O
>	JJ	O
50	CD	O
%	NN	O
of	IN	O
patients	NNS	O
with	IN	O
CRS	NNP	O
.	.	O
Histologic	NNP	O
specimens	VBZ	O
from	IN	O
refractory	NN	O
CRS	NNP	O
patients	NNS	O
undergoing	VBG	O
endoscopic	JJ	O
sinus	NN	O
surgery	NN	O
were	VBD	O
examined	VBN	O
.	.	O
Specimens	NNS	O
from	IN	O
all	DT	O
CRS	NNP	O
patients	NNS	O
(	(	O
22/22	CD	O
)	)	O
revealed	VBD	O
epithelial	JJ	O
changes	NNS	O
including	VBG	O
shedding	VBG	O
and	CC	O
basement	JJ	O
membrane	NN	O
thickening	NN	O
.	.	O
Striking	VBG	O
eosinophilic	JJ	O
inflammation	NN	O
,	,	O
which	WDT	O
did	VBD	O
not	RB	O
differ	VB	O
between	IN	O
allergic	JJ	O
and	CC	O
non-allergic	JJ	O
patients	NNS	O
,	,	O
was	VBD	O
also	RB	O
detected	VBN	O
in	IN	O
all	DT	O
CRS	NNP	O
patients	NNS	O
.	.	O
These	DT	O
findings	NNS	O
,	,	O
coupled	VBN	O
with	IN	O
the	DT	O
clinical	JJ	O
coexistence	NN	O
of	IN	O
both	DT	O
diseases	NNS	O
,	,	O
suggest	VBP	O
that	IN	O
the	DT	O
same	JJ	O
pathologic	JJ	O
disease	NN	O
process	NN	O
is	VBZ	O
manifest	RBS	O
as	IN	O
CRS	NNP	O
in	IN	O
the	DT	O
upper	JJ	O
airway	NN	O
and	CC	O
as	IN	O
asthma	NN	O
in	IN	O
the	DT	O
lower	JJR	O
airway	NN	O
.	.	O
Eosinophilic	JJ	O
inflammation	NN	O
in	IN	O
CRS	NNP	O
patients	NNS	O
was	VBD	O
characterized	VBN	O
using	VBG	O
specific	JJ	O
immunological	JJ	O
probes	NNS	O
.	.	O
Conventionally	RB	O
,	,	O
Grocott-methenamine	NNP	O
silver	NN	O
(	(	O
GMS	NNP	O
)	)	O
staining	NN	O
can	MD	O
detect	VB	O
fungi	NNS	O
in	IN	O
pathologic	JJ	O
specimens	NNS	O
;	:	O
however	RB	O
,	,	O
this	DT	O
technique	NN	O
can	MD	O
be	VB	O
inconsistent	JJ	O
because	IN	O
it	PRP	O
lacks	VBZ	O
sensitivity	NN	O
and	CC	O
specificity	NN	O
.	.	O
Chitinase	NNP	O
is	VBZ	O
an	DT	O
enzyme	NN	O
,	,	O
which	WDT	O
selectively	RB	O
and	CC	O
specifically	RB	O
binds	NNS	O
to	TO	O
chitin	VB	O
in	IN	O
fungal	JJ	O
cell	NN	O
walls	NNS	O
.	.	O
Fluorescein-labeled	JJ	O
chitinase	NN	O
was	VBD	O
used	VBN	O
and	CC	O
detected	VBN	O
one	CD	O
or	CC	O
more	JJR	O
fungal	JJ	O
hyphae	NN	O
within	IN	O
the	DT	O
sinus	JJ	O
mucus	NN	O
of	IN	O
54/54	CD	O
(	(	O
100	CD	O
%	NN	O
)	)	O
of	IN	O
consecutive	JJ	O
surgical	JJ	O
patients	NNS	O
with	IN	O
CRS	NNP	O
.	.	O
Fungi	NNS	O
were	VBD	O
in	IN	O
the	DT	O
airway	JJ	O
lumen	NNS	O
but	CC	O
not	RB	O
within	IN	O
the	DT	O
airway	NN	O
tissues	NNS	O
,	,	O
suggesting	VBG	O
that	IN	O
CRS	NNP	O
is	VBZ	O
not	RB	O
an	DT	O
invasive	JJ	O
fungal	JJ	O
infection	NN	O
.	.	O
Because	IN	O
PBMC	NNP	O
from	IN	O
CRS	NNP	O
patients	NNS	O
exhibited	VBD	O
vigorous	JJ	O
cytokine	NN	O
responses	NNS	O
to	TO	O
Alternaria	NNP	O
(	(	O
FIG	NNP	O
.	.	O
1	CD	O
)	)	O
,	,	O
a	DT	O
polyclonal	JJ	O
antibody	NN	O
to	TO	O
Alternaria	NNP	O
was	VBD	O
used	VBN	O
to	TO	O
investigate	VB	O
the	DT	O
presence	NN	O
of	IN	O
fungi	NNS	O
in	IN	O
sinus	NN	O
specimens	NNS	O
from	IN	O
CRS	NNP	O
patients	NNS	O
.	.	O
Rabbits	NNS	O
were	VBD	O
immunized	VBN	O
with	IN	O
crude	NN	O
Alternaria	NNP	O
extract	NN	O
,	,	O
and	CC	O
as	IN	O
expected	VBN	O
,	,	O
this	DT	O
anti-Alternaria	JJ	O
cross-reacted	JJ	O
with	IN	O
other	JJ	O
fungi	NNS	O
,	,	O
including	VBG	O
Aspergillus	NNP	O
,	,	O
Cladosporium	NNP	O
,	,	O
and	CC	O
Penicillium	NNP	O
,	,	O
but	CC	O
not	RB	O
with	IN	O
bacteria	NNS	O
.	.	O
In	IN	O
FIG	NNP	O
.	.	O
4C	CD	O
,	,	O
anti-Alternaria	JJ	O
antibody	NN	O
clearly	RB	O
visualized	JJ	O
fungal	JJ	O
hyphae	NN	O
and	CC	O
fungal	JJ	O
products	NNS	O
in	IN	O
the	DT	O
clusters	NNS	O
of	IN	O
inflammatory	JJ	O
cells	NNS	O
(	(	O
i.e.	FW	O
,	,	O
eosinophils	NNS	O
)	)	O
within	IN	O
the	DT	O
sinus	JJ	O
lumen	NNS	O
.	.	O
To	TO	O
characterize	VB	O
the	DT	O
extent	NN	O
and	CC	O
location	NN	O
of	IN	O
eosinophilic	JJ	O
inflammation	NN	O
,	,	O
antibody	NN	O
to	TO	O
eosinophil	VB	O
major	JJ	O
basic	JJ	O
protein	NN	O
(	(	O
MBP	NNP	O
)	)	O
were	VBD	O
used	VBN	O
.	.	O
All	DT	O
tissue	NN	O
specimens	VBZ	O
from	IN	O
CRS	NNP	O
patients	NNS	O
exhibited	VBD	O
intact	JJ	O
eosinophils	NNS	O
,	,	O
but	CC	O
diffuse	IN	O
extracellular	JJ	O
MBP	NNP	O
deposition	NN	O
,	,	O
as	IN	O
a	DT	O
marker	NN	O
of	IN	O
eosinophil	JJ	O
degranulation	NN	O
,	,	O
was	VBD	O
rare	JJ	O
.	.	O
In	IN	O
contrast	NN	O
,	,	O
all	DT	O
mucus	NN	O
specimens	NNS	O
exhibited	VBD	O
abundant	JJ	O
diffuse	NN	O
extracellular	JJ	O
MBP	NNP	O
deposition	NN	O
within	IN	O
or	CC	O
around	IN	O
the	DT	O
clusters	NNS	O
of	IN	O
eosinophils	NNS	O
(	(	O
FIG	NNP	O
.	.	O
4D	CD	O
)	)	O
.	.	O
Thus	RB	O
,	,	O
release	NN	O
and	CC	O
deposition	NN	O
of	IN	O
the	DT	O
toxic	JJ	O
MBP	NNP	O
from	IN	O
eosinophils	NNS	O
seem	VBP	O
to	TO	O
occur	VB	O
mainly	RB	O
within	IN	O
the	DT	O
airway	JJ	O
lumen	NNS	O
,	,	O
but	CC	O
not	RB	O
in	IN	O
airway	RB	O
tissues	NNS	O
.	.	O
This	DT	O
observation	NN	O
and	CC	O
the	DT	O
presence	NN	O
of	IN	O
fungal	JJ	O
hyphae	NN	O
and	CC	O
fungal	JJ	O
products	NNS	O
within	IN	O
the	DT	O
airway	JJ	O
lumen	NNS	O
suggested	VBD	O
that	IN	O
the	DT	O
eosinophilic	JJ	O
inflammation	NN	O
of	IN	O
CRS	NNP	O
may	MD	O
be	VB	O
part	NN	O
of	IN	O
a	DT	O
normal	JJ	O
,	,	O
but	CC	O
clearly	RB	O
exaggerated	JJ	O
,	,	O
immune	JJ	O
response	NN	O
to	TO	O
environmental	JJ	O
and	CC	O
airborne	JJ	O
fungal	JJ	O
organisms	NNS	O
.	.	O
The	DT	O
activation	NN	O
mechanisms	NN	O
of	IN	O
eosinophils	NNS	O
in	IN	O
vivo	NN	O
in	IN	O
CRS	NNP	O
and	CC	O
asthma	NNS	O
have	VBP	O
been	VBN	O
poorly	RB	O
understood	JJ	O
.	.	O
The	DT	O
following	NN	O
was	VBD	O
performed	VBN	O
to	TO	O
determine	VB	O
whether	IN	O
human	JJ	O
eosinophils	NNS	O
have	VBP	O
an	DT	O
innate	NN	O
capacity	NN	O
to	TO	O
respond	VB	O
to	TO	O
environmental	JJ	O
fungal	JJ	O
organisms	NNS	O
.	.	O
Human	NNP	O
eosinophils	NNS	O
were	VBD	O
incubated	VBN	O
with	IN	O
extracts	NNS	O
from	IN	O
common	JJ	O
environmental	JJ	O
airborne	JJ	O
fungi	NNS	O
.	.	O
As	IN	O
shown	VBN	O
in	IN	O
FIG	NNP	O
.	.	O
5	CD	O
,	,	O
Alternaria	NNP	O
and	CC	O
Penicillium	NNP	O
induced	VBD	O
remarkable	JJ	O
degranulation	NN	O
(	(	O
e.g.	JJ	O
,	,	O
eosinophil-derived	JJ	O
neurotoxin	NN	O
(	(	O
EDN	NNP	O
)	)	O
release	NN	O
)	)	O
of	IN	O
eosinophils	NNS	O
from	IN	O
normal	JJ	O
healthy	JJ	O
individuals	NNS	O
.	.	O
No	DT	O
opsonization	NN	O
or	CC	O
sensitization	NN	O
with	IN	O
IgE	NNP	O
or	CC	O
IgG	NNP	O
antibodies	NNS	O
was	VBD	O
necessary	JJ	O
.	.	O
Alternaria	NNP	O
also	RB	O
strongly	RB	O
induced	VBD	O
other	JJ	O
activation	NN	O
events	NNS	O
in	IN	O
eosinophils	NNS	O
from	IN	O
healthy	JJ	O
individuals	NNS	O
,	,	O
including	VBG	O
increases	NNS	O
in	IN	O
intracellular	JJ	O
calcium	NN	O
concentration	NN	O
(	(	O
[	JJ	O
Ca2+	NNP	O
]	NNP	O
i	NN	O
)	)	O
,	,	O
cell	VBP	O
surface	JJ	O
expression	NN	O
of	IN	O
CD63	NNP	O
and	CC	O
CD11b	NNP	O
,	,	O
and	CC	O
production	NN	O
of	IN	O
IL-8	NNP	O
.	.	O
Alternaria	NNP	O
did	VBD	O
not	RB	O
induce	VB	O
neutrophil	JJ	O
activation	NN	O
,	,	O
suggesting	VBG	O
cellular	JJ	O
specificity	NN	O
of	IN	O
the	DT	O
Alternaria	NNP	O
response	NN	O
.	.	O
The	DT	O
Alternaria-induced	NNP	O
eosinophil	NN	O
[	NNP	O
Ca2+	NNP	O
]	NNP	O
i	NN	O
response	NN	O
and	CC	O
degranulation	NN	O
was	VBD	O
pertussis	NN	O
toxin	NN	O
(	(	O
PTX	NNP	O
)	)	O
-sensitive	NN	O
.	.	O
The	DT	O
eosinophil-stimulating	JJ	O
activity	NN	O
in	IN	O
Alternaria	NNP	O
extract	NN	O
was	VBD	O
heat-labile	JJ	O
,	,	O
inactivated	VBN	O
by	IN	O
heat	NN	O
treatment	NN	O
at	IN	O
56°	CD	O
C.	NNP	O
for	IN	O
30	CD	O
minutes	NNS	O
,	,	O
and	CC	O
had	VBD	O
a	DT	O
molecular	JJ	O
mass	NN	O
about	IN	O
30-50	JJ	O
kDa	NN	O
(	(	O
FIG	NNP	O
.	.	O
6	CD	O
)	)	O
.	.	O
Thus	RB	O
,	,	O
eosinophils	NNS	O
,	,	O
but	CC	O
not	RB	O
neutrophils	NNS	O
,	,	O
likely	JJ	O
possess	NN	O
G	NNP	O
protein-dependent	JJ	O
cellular	JJ	O
activation	NN	O
machinery	NN	O
that	WDT	O
directly	RB	O
responds	VBZ	O
to	TO	O
an	DT	O
Alternaria	NNP	O
protein	NN	O
or	CC	O
glycoprotein	JJ	O
product	NN	O
(	(	O
s	JJ	O
)	)	O
.	.	O
The	DT	O
following	NN	O
was	VBD	O
performed	VBN	O
to	TO	O
examine	VB	O
whether	IN	O
eosinophils	NNS	O
can	MD	O
respond	VB	O
to	TO	O
proteases	NNS	O
.	.	O
Protease-activated	JJ	O
receptors	NNS	O
(	(	O
PARs	NNP	O
)	)	O
are	VBP	O
a	DT	O
unique	JJ	O
class	NN	O
of	IN	O
G	NNP	O
protein-coupled	JJ	O
seven	CD	O
transmembrane	NN	O
receptors	NNS	O
,	,	O
which	WDT	O
are	VBP	O
activated	VBN	O
by	IN	O
proteolytic	JJ	O
cleavage	NN	O
of	IN	O
the	DT	O
amino	NN	O
terminus	NN	O
of	IN	O
the	DT	O
receptor	NN	O
itself	PRP	O
(	(	O
FIG	NNP	O
.	.	O
7	CD	O
)	)	O
.	.	O
Four	CD	O
members	NNS	O
of	IN	O
this	DT	O
family	NN	O
,	,	O
including	VBG	O
PAR-1	NNP	O
,	,	O
-2	NNP	O
,	,	O
-3	NNP	O
,	,	O
and	CC	O
-4	NNP	O
,	,	O
have	VBP	O
been	VBN	O
described	VBN	O
elsewhere	RB	O
.	.	O
In	IN	O
the	DT	O
case	NN	O
of	IN	O
PAR-2	NNP	O
(	(	O
FIG	NNP	O
.	.	O
7	CD	O
)	)	O
,	,	O
proteolytic	JJ	O
cleavage	NN	O
by	IN	O
a	DT	O
certain	JJ	O
protease	NN	O
(	(	O
e.g.	JJ	O
,	,	O
trypsin	NN	O
)	)	O
exposes	VBZ	O
its	PRP$	O
new	JJ	O
N-terminus	NNP	O
(	(	O
SLIGKV	NNP	O
;	:	O
SEQ	NNP	O
ID	NNP	O
NO:38	NNP	O
)	)	O
,	,	O
which	WDT	O
binds	VBZ	O
to	TO	O
the	DT	O
ligand-binding	JJ	O
site	NN	O
in	IN	O
the	DT	O
second	JJ	O
extracellular	JJ	O
loop	NN	O
and	CC	O
results	NNS	O
in	IN	O
activation	NN	O
of	IN	O
downstream	NN	O
events	NNS	O
.	.	O
Human	NNP	O
eosinophils	NNS	O
were	VBD	O
found	VBN	O
to	TO	O
express	VB	O
PAR-2	NNP	O
constitutively	RB	O
and	CC	O
found	VBD	O
to	TO	O
be	VB	O
activated	VBN	O
by	IN	O
serine	NN	O
and	CC	O
cysteine	NN	O
proteases	NNS	O
,	,	O
such	JJ	O
as	IN	O
trypsin	NN	O
and	CC	O
papain	NN	O
,	,	O
through	IN	O
this	DT	O
receptor	NN	O
.	.	O
Eosinophils	NNS	O
were	VBD	O
also	RB	O
activated	VBN	O
by	IN	O
a	DT	O
natural	JJ	O
mite	NN	O
allergen	NN	O
protease	NN	O
,	,	O
Der	NNP	O
f1	NN	O
.	.	O
PAR-2	NN	O
may	MD	O
serve	VB	O
as	IN	O
an	DT	O
eosinophil	NN	O
receptor	NN	O
to	TO	O
recognize	VB	O
and	CC	O
respond	VB	O
to	TO	O
proteases	NNS	O
from	IN	O
allergens	NNS	O
,	,	O
resulting	VBG	O
in	IN	O
active	JJ	O
release	NN	O
of	IN	O
pro-inflammatory	JJ	O
mediators	NNS	O
.	.	O
Example	RB	O
3	CD	O
Test	NNP	O
Hypothesis	NN	O
that	WDT	O
Fungi	NNP	O
Colonized	NNP	O
in	IN	O
Paranasal	NNP	O
Sinus	NNP	O
and	CC	O
Nasal	NNP	O
Cavities	NNP	O
are	VBP	O
Involved	VBN	O
in	IN	O
Persistent	NNP	O
Eosinophilic	NNP	O
Inflammation	NNP	O
in	IN	O
CRS	NNP	O
To	TO	O
examine	VB	O
the	DT	O
clinical	JJ	O
significance	NN	O
of	IN	O
fungal	JJ	O
colonization	NN	O
in	IN	O
CRS	NNP	O
,	,	O
two	CD	O
clinical	JJ	O
trials	NNS	O
were	VBD	O
performed	VBN	O
to	TO	O
examine	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
anti-fungal	JJ	O
agents	NNS	O
.	.	O
It	PRP	O
was	VBD	O
hypothesized	VBN	O
that	IN	O
anti-fungal	JJ	O
agents	NNS	O
will	MD	O
reduce	VB	O
the	DT	O
fungal	JJ	O
burden	NN	O
in	IN	O
the	DT	O
upper	JJ	O
airways	NNS	O
,	,	O
resulting	VBG	O
in	IN	O
less	JJR	O
antigenic	JJ	O
stimulation	NN	O
of	IN	O
immune	JJ	O
cells	NNS	O
,	,	O
less	JJR	O
airway	JJ	O
inflammation	NN	O
,	,	O
and	CC	O
improved	JJ	O
clinical	JJ	O
outcomes	NNS	O
.	.	O
The	DT	O
first	JJ	O
aim	NN	O
was	VBD	O
to	TO	O
establish	VB	O
the	DT	O
safety	NN	O
and	CC	O
demonstrate	VB	O
potential	JJ	O
clinical	JJ	O
efficacy	NN	O
of	IN	O
intranasal	JJ	O
antifungal	JJ	O
drug	NN	O
therapy	NN	O
in	IN	O
patients	NNS	O
with	IN	O
CRS	NNP	O
in	IN	O
a	DT	O
pilot	NN	O
trial	NN	O
.	.	O
This	DT	O
prospective	JJ	O
,	,	O
open-label	JJ	O
trial	NN	O
used	VBN	O
amphotericin	RB	O
B	NNP	O
as	IN	O
a	DT	O
medical	JJ	O
treatment	NN	O
in	IN	O
51	CD	O
randomly	RB	O
selected	VBN	O
CRS	NNP	O
patients	NNS	O
.	.	O
The	DT	O
antifungal	NN	O
was	VBD	O
applied	VBN	O
intranasally	RB	O
using	VBG	O
20	CD	O
mL	NN	O
of	IN	O
a	DT	O
100	CD	O
μg/mL	JJ	O
solution	NN	O
twice	RB	O
daily	RB	O
for	IN	O
a	DT	O
mean	NN	O
of	IN	O
11	CD	O
months	NNS	O
(	(	O
minimum	NN	O
of	IN	O
3	CD	O
months	NNS	O
)	)	O
.	.	O
Using	VBG	O
amphotericin	NN	O
B	NNP	O
,	,	O
improvement	NN	O
of	IN	O
sinusitis	NN	O
symptoms	NNS	O
was	VBD	O
observed	VBN	O
in	IN	O
38/51	CD	O
(	(	O
75	CD	O
%	NN	O
)	)	O
of	IN	O
patients	NNS	O
.	.	O
Endoscopically	RB	O
,	,	O
18/51	CD	O
(	(	O
35	CD	O
%	NN	O
)	)	O
patients	NNS	O
became	VBD	O
disease	JJ	O
free	JJ	O
and	CC	O
an	DT	O
additional	JJ	O
20/51	CD	O
(	(	O
39	CD	O
%	NN	O
)	)	O
improved	VBN	O
by	IN	O
at	IN	O
least	JJS	O
one	CD	O
stage	NN	O
.	.	O
No	DT	O
effect	NN	O
was	VBD	O
seen	VBN	O
in	IN	O
13/51	CD	O
(	(	O
25	CD	O
%	NN	O
)	)	O
patients	NNS	O
.	.	O
The	DT	O
available	JJ	O
CT	NNP	O
scans	VBZ	O
pre-	JJ	O
and	CC	O
post-treatment	JJ	O
(	(	O
n=12	JJ	O
)	)	O
demonstrated	VBD	O
a	DT	O
significant	JJ	O
reduction	NN	O
in	IN	O
the	DT	O
inflammatory	NN	O
mucosal	NN	O
thickening	NN	O
.	.	O
Thus	RB	O
,	,	O
this	DT	O
open-label	JJ	O
pilot	NN	O
trial	NN	O
demonstrated	VBD	O
that	IN	O
direct	JJ	O
muco-administration	NN	O
of	IN	O
an	DT	O
antifungal	JJ	O
drug	NN	O
is	VBZ	O
both	DT	O
safe	JJ	O
and	CC	O
potentially	RB	O
effective	JJ	O
to	TO	O
treat	VB	O
patients	NNS	O
with	IN	O
CRS	NNP	O
.	.	O
Second	JJ	O
,	,	O
to	TO	O
address	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
intranasal	JJ	O
antifungal	JJ	O
agents	NNS	O
more	RBR	O
objectively	RB	O
,	,	O
a	DT	O
randomized	VBN	O
,	,	O
placebo-controlled	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
single	JJ	O
center	NN	O
trial	NN	O
was	VBD	O
performed	VBN	O
to	TO	O
treat	VB	O
30	CD	O
randomly	RB	O
selected	VBN	O
CRS	NNP	O
patients	NNS	O
.	.	O
Patients	NNS	O
instilled	VBD	O
20	CD	O
mL	NN	O
amphotericin	NN	O
B	NNP	O
(	(	O
250	CD	O
μg/mL	NN	O
)	)	O
or	CC	O
placebo	NN	O
to	TO	O
each	DT	O
nostril	JJ	O
twice	RB	O
daily	RB	O
for	IN	O
6	CD	O
months	NNS	O
.	.	O
Twenty-four	JJ	O
patients	NNS	O
completed	VBD	O
the	DT	O
6	CD	O
months	NNS	O
of	IN	O
treatment	NN	O
.	.	O
Patients	NNS	O
receiving	VBG	O
amphotericin	NN	O
B	NNP	O
showed	VBD	O
reduced	VBN	O
mucosal	NN	O
thickening	VBG	O
on	IN	O
CT	NNP	O
scans	NNS	O
compared	VBN	O
to	TO	O
placebo	VB	O
(	(	O
p=0.030	NN	O
)	)	O
.	.	O
Between	NNP	O
group	NN	O
comparisons	NNS	O
of	IN	O
the	DT	O
changes	NNS	O
in	IN	O
the	DT	O
intranasal	NN	O
mucus	NN	O
levels	NNS	O
of	IN	O
EDN	NNP	O
,	,	O
as	IN	O
a	DT	O
marker	NN	O
of	IN	O
eosinophilic	JJ	O
inflammation	NN	O
,	,	O
showed	VBD	O
a	DT	O
reduction	NN	O
in	IN	O
the	DT	O
amphotericin	NN	O
B	NNP	O
group	NN	O
and	CC	O
an	DT	O
increase	NN	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
(	(	O
p=0.046	NN	O
)	)	O
.	.	O
The	DT	O
changes	NNS	O
in	IN	O
the	DT	O
endoscopic	NN	O
scores	VBZ	O
improved	VBN	O
in	IN	O
the	DT	O
amphotericin	NN	O
B	NNP	O
group	NN	O
compared	VBN	O
to	TO	O
placebo	VB	O
(	(	O
p=0.038	NN	O
)	)	O
.	.	O
While	IN	O
the	DT	O
group	NN	O
comparison	NN	O
showed	VBD	O
statistically	RB	O
significant	JJ	O
differences	NNS	O
,	,	O
careful	JJ	O
examination	NN	O
of	IN	O
individual	JJ	O
patient	NN	O
data	NNS	O
in	IN	O
the	DT	O
amphotericin	NN	O
B	NNP	O
group	NN	O
showed	VBD	O
a	DT	O
spectrum	NN	O
of	IN	O
efficacy	NN	O
.	.	O
Some	DT	O
patients	NNS	O
responded	VBD	O
well	RB	O
to	TO	O
the	DT	O
treatment	NN	O
,	,	O
but	CC	O
others	NNS	O
not	RB	O
as	RB	O
well	RB	O
.	.	O
Thus	RB	O
,	,	O
fungi	NNS	O
may	MD	O
be	VB	O
important	JJ	O
in	IN	O
the	DT	O
development	NN	O
of	IN	O
CRS	NNP	O
in	IN	O
certain	JJ	O
patients	NNS	O
.	.	O
Example	RB	O
4	CD	O
Mechanisms	NNP	O
and	CC	O
Molecules	NNP	O
Involved	NNP	O
in	IN	O
Eosinophil	NNP	O
Degranulation	NNP	O
in	IN	O
Response	NNP	O
to	TO	O
Alternaria	VB	O
The	DT	O
majority	NN	O
of	IN	O
previous	JJ	O
studies	NNS	O
in	IN	O
anti-fungal	JJ	O
immune	JJ	O
responses	NNS	O
used	VBD	O
the	DT	O
following	JJ	O
models	NNS	O
:	:	O
animal	JJ	O
infection	NN	O
in	IN	O
in	IN	O
vivo	JJ	O
systems	NNS	O
(	(	O
e.g.	JJ	O
,	,	O
Candida	NNP	O
albicans	VBZ	O
,	,	O
Aspergillus	NNP	O
fumigatus	NN	O
)	)	O
,	,	O
or	CC	O
entire	JJ	O
fungal	JJ	O
hyphae	NN	O
or	CC	O
conidia	NN	O
(	(	O
e.g.	JJ	O
,	,	O
C.	NNP	O
albicans	VBZ	O
,	,	O
A.	NNP	O
fumigatus	NN	O
)	)	O
,	,	O
a	DT	O
yeast	NN	O
model	NN	O
(	(	O
e.g.	JJ	O
,	,	O
zymosan	NNP	O
)	)	O
,	,	O
and	CC	O
isolated	JJ	O
fungal	JJ	O
carbohydrate	NN	O
macromolecules	NNS	O
(	(	O
e.g.	NN	O
,	,	O
β-glucan	JJ	O
,	,	O
mannan	NN	O
)	)	O
in	IN	O
in	IN	O
vitro	JJ	O
systems	NNS	O
.	.	O
These	DT	O
studies	NNS	O
pointed	VBD	O
to	TO	O
roles	NNS	O
for	IN	O
TLRs	NNP	O
,	,	O
in	IN	O
particular	JJ	O
TLR2	NNP	O
and	CC	O
TLR4	NNP	O
,	,	O
and	CC	O
to	TO	O
other	JJ	O
pattern	JJ	O
recognition	NN	O
receptors	NNS	O
that	IN	O
immune	JJ	O
cells	NNS	O
,	,	O
such	JJ	O
as	IN	O
macrophages	NNS	O
and	CC	O
neutrophils	NNS	O
,	,	O
use	NN	O
to	TO	O
recognize	VB	O
fungi	NNS	O
.	.	O
Because	IN	O
eosinophils	NNS	O
express	RB	O
little	JJ	O
TLR2	NNP	O
or	CC	O
TLR4	NNP	O
and	CC	O
the	DT	O
active	JJ	O
component	NN	O
(	(	O
s	NN	O
)	)	O
in	IN	O
Alternaria	NNP	O
extract	NN	O
was	VBD	O
a	DT	O
heat-labile	JJ	O
molecule	NN	O
(	(	O
s	NN	O
)	)	O
with	IN	O
an	DT	O
approximate	JJ	O
30-50	JJ	O
kDa	NN	O
molecular	JJ	O
mass	NN	O
(	(	O
FIG	NNP	O
.	.	O
6	CD	O
)	)	O
,	,	O
it	PRP	O
was	VBD	O
speculated	VBN	O
that	IN	O
an	DT	O
Alternaria-derived	JJ	O
protease	NN	O
(	(	O
s	NN	O
)	)	O
(	(	O
not	RB	O
carbohydrates	VBZ	O
)	)	O
,	,	O
interacting	VBG	O
with	IN	O
eosinophil	JJ	O
PAR-2	NNP	O
,	,	O
may	MD	O
be	VB	O
involved	VBN	O
in	IN	O
the	DT	O
eosinophils	NNS	O
'	POS	O
responses	NNS	O
to	TO	O
Alternaria	NNP	O
.	.	O
Sine	NNP	O
no	DT	O
specific	JJ	O
small	JJ	O
molecule	NN	O
inhibitor	NN	O
for	IN	O
PAR-2	NNP	O
is	VBZ	O
available	JJ	O
,	,	O
a	DT	O
desensitization	NN	O
approach	NN	O
was	VBD	O
used	VBN	O
.	.	O
As	IN	O
shown	VBN	O
in	IN	O
FIG	NNP	O
.	.	O
8	CD	O
,	,	O
pre-incubation	NN	O
of	IN	O
eosinophils	NNS	O
with	IN	O
the	DT	O
PAR-2	NNP	O
agonistic	JJ	O
peptide	NN	O
,	,	O
SLIGKV	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:38	NNP	O
)	)	O
,	,	O
significantly	RB	O
inhibited	VBD	O
the	DT	O
eosinophils	NNS	O
'	POS	O
calcium	NN	O
response	NN	O
to	TO	O
Alternaria	NNP	O
extract	NN	O
.	.	O
Similarly	RB	O
,	,	O
an	DT	O
N-terminal	JJ	O
reversed	JJ	O
peptide	NN	O
(	(	O
LSIGKV	NNP	O
;	:	O
SEQ	NNP	O
ID	NNP	O
NO:35	NNP	O
)	)	O
,	,	O
which	WDT	O
is	VBZ	O
known	VBN	O
to	TO	O
inhibit	VB	O
activation	NN	O
of	IN	O
PAR-2	NNP	O
,	,	O
also	RB	O
inhibited	VBD	O
the	DT	O
eosinophils	NNS	O
'	POS	O
calcium	NN	O
response	NN	O
to	TO	O
Alternaria	NNP	O
;	:	O
a	DT	O
control	NN	O
scramble	JJ	O
peptide	NN	O
(	(	O
GLIVKS	NNP	O
;	:	O
SEQ	NNP	O
ID	NNP	O
NO:36	NNP	O
)	)	O
showed	VBD	O
no	DT	O
effects	NNS	O
.	.	O
Eosinophil	NNP	O
degranulation	NN	O
induced	VBN	O
by	IN	O
Alternaria	NNP	O
extract	NN	O
was	VBD	O
also	RB	O
significantly	RB	O
and	CC	O
specifically	RB	O
inhibited	VBN	O
by	IN	O
the	DT	O
LSIGKV	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:35	NNP	O
)	)	O
peptide	NN	O
(	(	O
FIG	NNP	O
.	.	O
8	CD	O
,	,	O
panel	NN	O
B	NNP	O
)	)	O
.	.	O
In	IN	O
contrast	NN	O
,	,	O
degranulation	NN	O
induced	VBN	O
by	IN	O
PAF	NNP	O
or	CC	O
PMA	NNP	O
was	VBD	O
not	RB	O
affected	VBN	O
by	IN	O
the	DT	O
LSIGKV	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NP:35	NNP	O
)	)	O
peptide	NN	O
.	.	O
Thus	RB	O
,	,	O
PAR-2	NNP	O
is	VBZ	O
likely	JJ	O
involved	VBN	O
in	IN	O
the	DT	O
eosinophils	NNS	O
'	POS	O
calcium	NN	O
and	CC	O
degranulation	NN	O
responses	NNS	O
to	TO	O
Alternaria	NNP	O
extract	NN	O
.	.	O
A	DT	O
search	NN	O
through	IN	O
a	DT	O
current	JJ	O
database	NN	O
of	IN	O
known	VBN	O
Alternaria	NNP	O
allergens	NNS	O
did	VBD	O
not	RB	O
reveal	VB	O
any	DT	O
relevant	JJ	O
proteases	NNS	O
.	.	O
A	DT	O
fluorescent	NN	O
quenched	VBN	O
peptide	RB	O
substrate	JJ	O
(	(	O
Abz-SKGRSLIGK	NNP	O
(	(	O
Dnp	NNP	O
)	)	O
D	NNP	O
)	)	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:37	NNP	O
)	)	O
,	,	O
which	WDT	O
spans	VBZ	O
the	DT	O
trypsin-cleavage	JJ	O
site	NN	O
(	(	O
between	IN	O
R	NNP	O
and	CC	O
S	NNP	O
)	)	O
of	IN	O
PAR-2	NNP	O
was	VBD	O
synthesized	VBN	O
,	,	O
and	CC	O
used	VBD	O
it	PRP	O
in	IN	O
an	DT	O
in	IN	O
vitro	NN	O
assay	NN	O
for	IN	O
PAR-2	NNP	O
cleavage	NN	O
and	CC	O
activation	NN	O
.	.	O
As	IN	O
shown	VBN	O
in	IN	O
FIG	NNP	O
.	.	O
9	CD	O
,	,	O
trypsin	NN	O
,	,	O
as	IN	O
positive	JJ	O
control	NN	O
,	,	O
clearly	RB	O
cleaved	VBD	O
this	DT	O
peptide	NN	O
,	,	O
and	CC	O
a	DT	O
serine	JJ	O
protease	NN	O
inhibitor	NN	O
,	,	O
APMSF	NNP	O
,	,	O
inhibited	VBD	O
the	DT	O
activity	NN	O
.	.	O
Alternaria	NNP	O
extract	NN	O
also	RB	O
potently	RB	O
cleaved	VBN	O
this	DT	O
peptide	NN	O
,	,	O
but	CC	O
it	PRP	O
was	VBD	O
insensitive	JJ	O
to	TO	O
APMSF	NNP	O
.	.	O
Alternaria	NNP	O
's	POS	O
activity	NN	O
was	VBD	O
abolished	VBN	O
when	WRB	O
aspartate	JJ	O
protease	NN	O
(	(	O
s	NN	O
)	)	O
was	VBD	O
removed	VBN	O
from	IN	O
the	DT	O
extract	NN	O
by	IN	O
pepstatin	NN	O
A	NNP	O
agarose	NN	O
(	(	O
FIG	NNP	O
.	.	O
9	CD	O
)	)	O
;	:	O
pepstatin	VB	O
A	DT	O
is	VBZ	O
a	DT	O
highly	RB	O
specific	JJ	O
inhibitor	NN	O
for	IN	O
aspartate	JJ	O
protease	NN	O
.	.	O
Furthermore	RB	O
,	,	O
eosinophil	JJ	O
degranulation	NN	O
induced	VBN	O
by	IN	O
Alternaria	NNP	O
extract	NN	O
was	VBD	O
significantly	RB	O
inhibited	VBN	O
by	IN	O
pepstatin	NN	O
A	NNP	O
agarose	NN	O
,	,	O
but	CC	O
not	RB	O
by	IN	O
control	NN	O
agarose	NN	O
or	CC	O
APMSF	NNP	O
.	.	O
Thus	RB	O
,	,	O
an	DT	O
aspartate	JJ	O
protease	NN	O
(	(	O
s	NN	O
)	)	O
in	IN	O
Alternaria	NNP	O
extract	NN	O
,	,	O
but	CC	O
not	RB	O
a	DT	O
serine	JJ	O
protease	NN	O
(	(	O
s	NN	O
)	)	O
,	,	O
may	MD	O
be	VB	O
involved	VBN	O
in	IN	O
the	DT	O
activation	NN	O
of	IN	O
eosinophils	NNS	O
through	IN	O
PAR-2	NNP	O
.	.	O
this	DT	O
observation	NN	O
was	VBD	O
confirmed	VBN	O
by	IN	O
using	VBG	O
other	JJ	O
aspartate	JJ	O
protease	NN	O
inhibitors	NNS	O
,	,	O
including	VBG	O
alkalo-thermophilic	JJ	O
bacillus	NN	O
inhibitor	NN	O
(	(	O
ATBI	NNP	O
)	)	O
,	,	O
nelfinavir	UH	O
,	,	O
and	CC	O
ritonavir	NN	O
.	.	O
Eosinophils	NNS	O
may	MD	O
be	VB	O
the	DT	O
only	JJ	O
cell	NN	O
that	WDT	O
can	MD	O
recognize	VB	O
Alternaria	NNP	O
.	.	O
In	IN	O
FIG	NNP	O
.	.	O
10	CD	O
,	,	O
an	DT	O
airway	JJ	O
epithelial	JJ	O
cell	NN	O
line	NN	O
,	,	O
BEAS-2B	NNP	O
,	,	O
produced	VBD	O
and	CC	O
released	VBN	O
IL-6	NNP	O
when	WRB	O
incubated	VBN	O
with	IN	O
Alternaria	NNP	O
extract	NN	O
for	IN	O
24	CD	O
hours	NNS	O
.	.	O
Extracts	NNS	O
of	IN	O
Aspergillus	NNP	O
,	,	O
Candida	NNP	O
,	,	O
and	CC	O
Penicillium	NNP	O
,	,	O
did	VBD	O
not	RB	O
induce	VB	O
IL-6	NNP	O
production	NN	O
;	:	O
rather	RB	O
,	,	O
both	DT	O
Aspergillus	NNP	O
and	CC	O
Penicillium	NNP	O
inhibited	VBD	O
the	DT	O
baseline	NN	O
production	NN	O
of	IN	O
IL-6	NNP	O
.	.	O
BEAS-2B	NNP	O
stimulated	VBD	O
with	IN	O
Alternaria	NNP	O
also	RB	O
produced	VBD	O
other	JJ	O
pro-inflammatory	JJ	O
factors	NNS	O
such	JJ	O
as	IN	O
IL-8	NNP	O
and	CC	O
GM-CSF	NNP	O
.	.	O
This	DT	O
Alternaria-induced	JJ	O
IL-6	JJ	O
production	NN	O
was	VBD	O
inhibited	VBN	O
by	IN	O
ATBI	NNP	O
,	,	O
nelfinavir	RB	O
,	,	O
ritonavir	NN	O
or	CC	O
pepstatin	JJ	O
A-agarose	JJ	O
treatment	NN	O
of	IN	O
Alternaria	NNP	O
extract	NN	O
by	IN	O
about	IN	O
60	CD	O
%	NN	O
to	TO	O
90	CD	O
%	NN	O
;	:	O
ritonavir	JJ	O
results	NNS	O
are	VBP	O
shown	VBN	O
in	IN	O
FIG	NNP	O
.	.	O
11	CD	O
.	.	O
In	IN	O
contrast	NN	O
,	,	O
TNF-α-induced	JJ	O
IL-6	JJ	O
production	NN	O
was	VBD	O
not	RB	O
affected	VBN	O
by	IN	O
these	DT	O
treatments	NNS	O
.	.	O
Furthermore	RB	O
,	,	O
a	DT	O
peptide	JJ	O
antagonist	NN	O
for	IN	O
PAR-2	NNP	O
,	,	O
LSIGKV	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:35	NNP	O
)	)	O
,	,	O
partially	RB	O
(	(	O
˜40	CD	O
%	NN	O
)	)	O
but	CC	O
significantly	RB	O
inhibited	VBD	O
Alternaria-induced	JJ	O
IL-6	JJ	O
production	NN	O
by	IN	O
BEAS-2B	NNP	O
cells	NNS	O
.	.	O
Thus	RB	O
,	,	O
through	IN	O
its	PRP$	O
aspartate	JJ	O
protease	NN	O
activity	NN	O
,	,	O
Alternaria	NNP	O
may	MD	O
activate	VB	O
airway	RP	O
epithelial	JJ	O
cells	NNS	O
;	:	O
this	DT	O
activation	NN	O
is	VBZ	O
partially	RB	O
mediated	VBN	O
by	IN	O
PAR-2	NNP	O
.	.	O
A	DT	O
series	NN	O
of	IN	O
efforts	NNS	O
have	VBP	O
been	VBN	O
initiated	VBN	O
to	TO	O
identify	VB	O
and	CC	O
isolate	VB	O
protease	NN	O
(	(	O
s	PRP	O
)	)	O
from	IN	O
Alternaria	NNP	O
.	.	O
A	DT	O
preliminary	JJ	O
biochemical	JJ	O
characterization	NN	O
showed	VBD	O
that	IN	O
,	,	O
at	IN	O
pH	JJ	O
7.5	CD	O
,	,	O
the	DT	O
Alternaria	NNP	O
activity	NN	O
towards	NNS	O
eosinophils	VBZ	O
binds	NNS	O
to	TO	O
hydroxyapatite	VB	O
,	,	O
DEAE	NNP	O
Sepharose	NNP	O
,	,	O
and	CC	O
phenyl-Sepharose	JJ	O
,	,	O
but	CC	O
not	RB	O
to	TO	O
a	DT	O
variety	NN	O
of	IN	O
cation	NN	O
exchange	NN	O
or	CC	O
lectin	NN	O
columns	NN	O
.	.	O
In	IN	O
FIG	NNP	O
.	.	O
12	CD	O
,	,	O
DEAE	NNP	O
fractionation	NN	O
of	IN	O
an	DT	O
Alternaria	NNP	O
extract	NN	O
showed	VBD	O
a	DT	O
single	JJ	O
peak	NN	O
with	IN	O
strong	JJ	O
aspartate	JJ	O
protease	NN	O
activity	NN	O
,	,	O
as	IN	O
detected	VBN	O
by	IN	O
a	DT	O
malaria	NN	O
aspartate	NN	O
protease	NN	O
substrate	NN	O
.	.	O
The	DT	O
peak	NN	O
of	IN	O
aspartate	JJ	O
protease	NN	O
activity	NN	O
coincided	VBN	O
with	IN	O
the	DT	O
peak	NN	O
of	IN	O
the	DT	O
PAR-2	NNP	O
cleavage	NN	O
activity	NN	O
,	,	O
and	CC	O
the	DT	O
aspartate	JJ	O
protease	NN	O
activity	NN	O
paralleled	VBD	O
each	DT	O
fraction	NN	O
's	POS	O
ability	NN	O
to	TO	O
induce	VB	O
eosinophil	JJ	O
degranulation	NN	O
.	.	O
Partial	JJ	O
characterization	NN	O
of	IN	O
Alternaria	NNP	O
extract	NN	O
.	.	O
Three	CD	O
strategies	NNS	O
were	VBD	O
used	VBN	O
to	TO	O
begin	VB	O
characterizing	VBG	O
the	DT	O
Alternaria	NNP	O
products	NNS	O
involved	VBN	O
in	IN	O
eosinophil	JJ	O
degranulation	NN	O
.	.	O
First	RB	O
,	,	O
the	DT	O
Alternaria	NNP	O
extract	NN	O
was	VBD	O
subjected	VBN	O
to	TO	O
membrane	VB	O
filtration	NN	O
.	.	O
After	IN	O
filtration	NN	O
with	IN	O
a	DT	O
YM100	NNP	O
Centricon®	NNP	O
membrane	NN	O
,	,	O
the	DT	O
filtrate	NN	O
stimulated	VBD	O
eosinophil	JJ	O
degranulation	NN	O
,	,	O
but	CC	O
the	DT	O
retentate	NN	O
did	VBD	O
not	RB	O
.	.	O
After	IN	O
filtration	NN	O
with	IN	O
a	DT	O
YM10	NNP	O
Centricon®	NNP	O
membrane	NN	O
,	,	O
the	DT	O
retentate	NN	O
stimulated	VBD	O
eosinophils	NNS	O
,	,	O
but	CC	O
the	DT	O
filtrate	NN	O
did	VBD	O
not	RB	O
.	.	O
Thus	RB	O
,	,	O
the	DT	O
eosinophil-stimulatory	JJ	O
activity	NN	O
in	IN	O
the	DT	O
Alternaria	NNP	O
extract	NN	O
is	VBZ	O
likely	JJ	O
between	IN	O
10	CD	O
and	CC	O
100	CD	O
kDa	NN	O
.	.	O
Second	JJ	O
,	,	O
Alternaria	NNP	O
extracts	VBZ	O
,	,	O
which	WDT	O
had	VBD	O
been	VBN	O
treated	VBN	O
at	IN	O
56°	CD	O
C.	NNP	O
or	CC	O
100°	CD	O
C.	NNP	O
for	IN	O
30	CD	O
min	NNS	O
,	,	O
did	VBD	O
not	RB	O
induce	VB	O
EDN	NNP	O
release	NN	O
(	(	O
FIG	NNP	O
.	.	O
25A	CD	O
)	)	O
,	,	O
but	CC	O
extracts	VBZ	O
treated	VBN	O
at	IN	O
4°	CD	O
C.	NNP	O
or	CC	O
37°	CD	O
C.	NNP	O
for	IN	O
30	CD	O
min	NNS	O
did	VBD	O
induce	VB	O
EDN	NNP	O
release	NN	O
,	,	O
suggesting	VBG	O
that	IN	O
it	PRP	O
is	VBZ	O
a	DT	O
heat-labile	JJ	O
protein	NN	O
(	(	O
s	JJ	O
)	)	O
or	CC	O
glycoprotein	NN	O
(	(	O
s	NN	O
)	)	O
.	.	O
The	DT	O
activity	NN	O
of	IN	O
a	DT	O
cytokine	NN	O
,	,	O
IL-5	NNP	O
,	,	O
to	TO	O
induce	VB	O
EDN	NNP	O
release	NN	O
was	VBD	O
abolished	VBN	O
by	IN	O
treatment	NN	O
at	IN	O
100°	CD	O
C.	NNP	O
,	,	O
but	CC	O
not	RB	O
by	IN	O
treatment	NN	O
at	IN	O
56°	CD	O
C.	NNP	O
or	CC	O
lower	JJR	O
temperatures	NNS	O
.	.	O
Third	NNP	O
,	,	O
size	NN	O
exclusion	NN	O
chromatography	NN	O
was	VBD	O
used	VBN	O
(	(	O
FIG	NNP	O
.	.	O
25B	CD	O
)	)	O
,	,	O
and	CC	O
the	DT	O
column	NN	O
fractions	NNS	O
tested	VBN	O
for	IN	O
their	PRP$	O
abilities	NNS	O
to	TO	O
induce	VB	O
eosinophil	JJ	O
degranulation	NN	O
.	.	O
Although	IN	O
the	DT	O
absorbance	NN	O
profile	NN	O
shows	VBZ	O
a	DT	O
broad	JJ	O
peak	NN	O
from	IN	O
fractions	NNS	O
32	CD	O
though	IN	O
37	CD	O
,	,	O
the	DT	O
most	RBS	O
potent	JJ	O
eosinophil	JJ	O
degranulation	NN	O
activity	NN	O
appeared	VBD	O
in	IN	O
fraction	NN	O
32	CD	O
with	IN	O
a	DT	O
molecular	JJ	O
mass	NN	O
about	IN	O
60	CD	O
kDa	NNS	O
.	.	O
PBMCs	NNP	O
obtained	VBD	O
from	IN	O
a	DT	O
CRS	NNP	O
patient	NN	O
were	VBD	O
incubated	VBN	O
with	IN	O
fractions	NNS	O
30	CD	O
or	CC	O
32	CD	O
,	,	O
and	CC	O
the	DT	O
level	NN	O
of	IN	O
cytokine	JJ	O
production	NN	O
was	VBD	O
measured	VBN	O
(	(	O
FIGS	NNP	O
.	.	O
44	CD	O
and	CC	O
45	CD	O
)	)	O
.	.	O
Polypeptides	NNS	O
(	(	O
e.g.	NN	O
,	,	O
enzymes	RB	O
)	)	O
implicated	VBN	O
in	IN	O
the	DT	O
activation	NN	O
of	IN	O
eosinophils	NNS	O
and	CC	O
promotion	NN	O
of	IN	O
eosinophillic	JJ	O
inflammation	NN	O
in	IN	O
a	DT	O
murine	JJ	O
model	NN	O
were	VBD	O
identified	VBN	O
.	.	O
Proteins	NNS	O
in	IN	O
HPLC	NNP	O
DEAE	NNP	O
fraction	NN	O
#	#	O
18	CD	O
and	CC	O
the	DT	O
eluate	NN	O
from	IN	O
pepstatin	NN	O
A	NNP	O
agarose	NN	O
were	VBD	O
trypsin	RB	O
digested	VBN	O
,	,	O
and	CC	O
the	DT	O
resulting	VBG	O
peptides	NNS	O
were	VBD	O
subjected	VBN	O
to	TO	O
nLC-microESI-MS/MS	JJ	O
analysis	NN	O
using	VBG	O
a	DT	O
Finnigan	NNP	O
LTQ	NNP	O
system	NN	O
(	(	O
Thermo	NNP	O
Electron	NNP	O
Corporation	NNP	O
,	,	O
Waltham	NNP	O
,	,	O
Mass	NNP	O
.	.	O
)	)	O
.	.	O
Peptide	NNP	O
mass	NN	O
fingerprinting	VBG	O
with	IN	O
SEQUEST	NNP	O
software	NN	O
(	(	O
distributed	VBN	O
by	IN	O
Thermo	NNP	O
Electron	NNP	O
Corporation	NNP	O
,	,	O
Waltham	NNP	O
,	,	O
Mass	NNP	O
.	.	O
)	)	O
was	VBD	O
used	VBN	O
to	TO	O
identify	VB	O
peptides	NNS	O
existing	VBG	O
in	IN	O
these	DT	O
fractions	NNS	O
using	VBG	O
the	DT	O
resulting	VBG	O
peptide	JJ	O
mass	NN	O
data	NNS	O
and	CC	O
a	DT	O
database	NN	O
of	IN	O
predicted	JJ	O
Alternaria	NNP	O
brassicicola	NN	O
proteins	NNS	O
derived	VBN	O
from	IN	O
expressed	VBN	O
sequence	NN	O
tags	NN	O
(	(	O
ESTs	NNP	O
)	)	O
and	CC	O
the	DT	O
A.	NNP	O
brassicola	NNP	O
whole	JJ	O
genome	NN	O
shotgun	NN	O
sequence	NN	O
information	NN	O
.	.	O
SEQUEST	NNP	O
correlates	NNS	O
uninterpreted	VBD	O
tandem	JJ	O
mass	NN	O
spectra	NN	O
of	IN	O
peptides	NNS	O
with	IN	O
amino	JJ	O
acid	JJ	O
sequences	NNS	O
from	IN	O
protein	NN	O
and	CC	O
nucleotide	JJ	O
databases	NNS	O
.	.	O
SEQUEST	NN	O
will	MD	O
determine	VB	O
the	DT	O
amino	NN	O
acid	JJ	O
sequence	NN	O
of	IN	O
the	DT	O
peptide	NN	O
fragments	NNS	O
,	,	O
and	CC	O
thus	RB	O
the	DT	O
full	JJ	O
length	NN	O
protein	NN	O
(	(	O
s	PRP	O
)	)	O
can	MD	O
be	VB	O
identified	VBN	O
.	.	O
Proteins	NNS	O
in	IN	O
the	DT	O
database	NN	O
were	VBD	O
predicted	VBN	O
using	VBG	O
ab	JJ	O
initio	JJ	O
gene	NN	O
finding	NN	O
and	CC	O
protein	NN	O
prediction	NN	O
software	NN	O
FgeneSH	NNP	O
(	(	O
Softberry	NNP	O
,	,	O
Inc.	NNP	O
,	,	O
Mount	NNP	O
Kisco	NNP	O
,	,	O
N.Y.	NNP	O
)	)	O
.	.	O
SEQUEST	NNP	O
is	VBZ	O
a	DT	O
registered	JJ	O
trademark	NN	O
of	IN	O
the	DT	O
University	NNP	O
of	IN	O
Washington	NNP	O
.	.	O
SEQUEST	JJ	O
uses	NNS	O
algorithms	VBP	O
described	VBN	O
in	IN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
Nos	NNP	O
.	.	O
6,017,693	CD	O
and	CC	O
5,538,897	CD	O
.	.	O
The	DT	O
fungal	JJ	O
genes	NNS	O
encoding	VBG	O
these	DT	O
immunostimulatory	JJ	O
proteins	NNS	O
were	VBD	O
identified	VBN	O
using	VBG	O
the	DT	O
above	NN	O
described	VBD	O
approach	NN	O
.	.	O
The	DT	O
implicated	JJ	O
immunostimulatory	NN	O
proteins	NNS	O
identified	VBN	O
in	IN	O
these	DT	O
fractions	NNS	O
were	VBD	O
then	RB	O
further	RB	O
annotated	VBN	O
by	IN	O
BlastP	NNP	O
analysis	NN	O
against	IN	O
the	DT	O
GenbankNR	NNP	O
database	NN	O
and	CC	O
the	DT	O
MEROPS	NNP	O
peptidase	NN	O
database	NN	O
.	.	O
The	DT	O
MEROPS	NNP	O
database	NN	O
is	VBZ	O
an	DT	O
information	NN	O
resource	NN	O
for	IN	O
peptidases	NNS	O
(	(	O
also	RB	O
termed	VBN	O
proteases	NNS	O
,	,	O
proteinases	NNS	O
and	CC	O
proteolytic	JJ	O
enzymes	NNS	O
)	)	O
and	CC	O
the	DT	O
proteins	NNS	O
that	WDT	O
inhibit	VBP	O
them	PRP	O
and	CC	O
was	VBD	O
developed	VBN	O
and	CC	O
web	RBR	O
accessible	JJ	O
at	IN	O
the	DT	O
Sanger	NNP	O
Institute	NNP	O
,	,	O
UK	NNP	O
.	.	O
Furthermore	RB	O
,	,	O
all	DT	O
candidate	VBP	O
proteins	NNS	O
were	VBD	O
subjected	VBN	O
to	TO	O
Interpro	NNP	O
analysis	NN	O
.	.	O
InterPro	NNP	O
is	VBZ	O
a	DT	O
database	NN	O
of	IN	O
protein	NN	O
families	NNS	O
,	,	O
domains	NNS	O
and	CC	O
functional	JJ	O
sites	NNS	O
in	IN	O
which	WDT	O
identifiable	JJ	O
features	NNS	O
found	VBN	O
in	IN	O
known	JJ	O
proteins	NNS	O
can	MD	O
be	VB	O
applied	VBN	O
to	TO	O
unknown	JJ	O
protein	NN	O
sequences	NNS	O
.	.	O
Interpro	NNP	O
analysis	NN	O
is	VBZ	O
web	JJ	O
accessible	JJ	O
and	CC	O
a	DT	O
public	JJ	O
service	NN	O
available	JJ	O
at	IN	O
the	DT	O
European	JJ	O
Bioinformatics	NNP	O
Institute	NNP	O
(	(	O
EMBL-EBI	NNP	O
)	)	O
.	.	O
The	DT	O
annotated	JJ	O
proteins	NNS	O
include	VBP	O
several	JJ	O
proteases	NNS	O
belonging	VBG	O
to	TO	O
S53	NNP	O
and	CC	O
M38families	NNP	O
,	,	O
several	JJ	O
predicted	VBD	O
glycolytic	JJ	O
enzymes	NNS	O
,	,	O
superoxide	JJ	O
dismutase	NN	O
,	,	O
a	DT	O
ribosomal	JJ	O
protein	NN	O
,	,	O
S-adenosyl-homocysteine	JJ	O
lyase	NN	O
,	,	O
and	CC	O
several	JJ	O
others	NNS	O
(	(	O
Table	JJ	O
1	CD	O
)	)	O
.	.	O
The	DT	O
Alternaria	NNP	O
brassicicola	NN	O
nucleic	NN	O
acid	NN	O
sequence	NN	O
for	IN	O
each	DT	O
identified	VBN	O
Alternaria	NNP	O
alternata	JJ	O
candidate	NN	O
along	IN	O
with	IN	O
the	DT	O
predicted	JJ	O
Alternaria	NNP	O
brassicicola	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
is	VBZ	O
set	VBN	O
forth	NN	O
in	IN	O
FIGS	NNP	O
.	.	O
27-39	JJ	O
.	.	O
Example	JJ	O
5	CD	O
Production	NN	O
of	IN	O
Immunostimulatory	NNP	O
Molecules	NNP	O
by	IN	O
Live	NNP	O
Alternaria	NNP	O
Spores	NNP	O
of	IN	O
A.	NNP	O
alternata	NNS	O
were	VBD	O
obtained	VBN	O
,	,	O
and	CC	O
the	DT	O
effects	NNS	O
of	IN	O
the	DT	O
fungus	NN	O
itself	PRP	O
on	IN	O
eosinophil	NN	O
activation	NN	O
were	VBD	O
examined	VBN	O
.	.	O
Various	JJ	O
numbers	NNS	O
of	IN	O
spores	NNS	O
were	VBD	O
suspended	VBN	O
in	IN	O
RPMI	NNP	O
medium	NN	O
with	IN	O
10	CD	O
%	NN	O
FCS	NNP	O
and	CC	O
incubated	VBN	O
in	IN	O
tissue	NN	O
culture	NN	O
wells	VBZ	O
for	IN	O
12	CD	O
hours	NNS	O
to	TO	O
induce	VB	O
germination	NN	O
.	.	O
A	DT	O
fixed	JJ	O
number	NN	O
of	IN	O
isolated	JJ	O
human	JJ	O
eosinophils	NNS	O
were	VBD	O
added	VBN	O
to	TO	O
the	DT	O
wells	NNS	O
and	CC	O
incubated	VBN	O
for	IN	O
an	DT	O
additional	JJ	O
4	CD	O
hours	NNS	O
.	.	O
These	DT	O
eosinophils	NNS	O
showed	VBD	O
strong	JJ	O
conjugate	NN	O
formation	NN	O
with	IN	O
the	DT	O
germinating	VBG	O
Alternaria	NNP	O
fungal	JJ	O
spores	NNS	O
(	(	O
FIG	NNP	O
.	.	O
13A	CD	O
)	)	O
.	.	O
Furthermore	RB	O
,	,	O
these	DT	O
eosinophils	NNS	O
became	VBD	O
activated	JJ	O
and	CC	O
released	VBN	O
their	PRP$	O
granule	NN	O
proteins	VBZ	O
into	IN	O
the	DT	O
supernatants	NNS	O
(	(	O
FIG	NNP	O
.	.	O
13B	CD	O
)	)	O
.	.	O
To	TO	O
characterize	VB	O
the	DT	O
growth	NN	O
pattern	NN	O
and	CC	O
production	NN	O
of	IN	O
immunostimulatory	JJ	O
molecules	NNS	O
by	IN	O
Alternaria	NNP	O
further	RB	O
,	,	O
GFP-transformed	NNP	O
A.	NN	O
alternata	NNS	O
were	VBD	O
used	VBN	O
(	(	O
FIG	NNP	O
.	.	O
14	CD	O
)	)	O
.	.	O
Currently	RB	O
,	,	O
there	EX	O
is	VBZ	O
no	DT	O
standardized	JJ	O
scientific	JJ	O
method	NN	O
to	TO	O
quantitate	VB	O
fungal	JJ	O
growth	NN	O
.	.	O
However	RB	O
,	,	O
these	DT	O
transformed	VBN	O
fungi	NNS	O
have	VBP	O
a	DT	O
technical	JJ	O
advantage	NN	O
;	:	O
fungal	JJ	O
growth	NN	O
can	MD	O
be	VB	O
quantitated	VBN	O
by	IN	O
measuring	VBG	O
the	DT	O
fluorescence	NN	O
intensity	NN	O
using	VBG	O
a	DT	O
plate	NN	O
reader	NN	O
or	CC	O
spectrophotometer	NN	O
.	.	O
Production	NN	O
of	IN	O
so-called	JJ	O
“	NN	O
allergens	NNS	O
”	VBN	O
by	IN	O
fungi	NNS	O
can	MD	O
be	VB	O
significantly	RB	O
increased	VBN	O
during	IN	O
and	CC	O
after	IN	O
their	PRP$	O
germination	NN	O
.	.	O
FIG	NNP	O
.	.	O
15B	CD	O
shows	NNS	O
that	IN	O
the	DT	O
PAR-2-stimulating	NNP	O
enzymatic	JJ	O
activity	NN	O
(	(	O
ies	NNS	O
)	)	O
is	VBZ	O
clearly	RB	O
produced	VBN	O
by	IN	O
A.	NNP	O
alternata	NNS	O
during	IN	O
their	PRP$	O
germination	NN	O
and	CC	O
hyphal	JJ	O
growth	NN	O
.	.	O
The	DT	O
growth	NN	O
of	IN	O
fungi	NN	O
(	(	O
FIG	NNP	O
.	.	O
15A	CD	O
)	)	O
and	CC	O
production	NN	O
of	IN	O
PAR-2	NNP	O
activating	VBG	O
enzymes	NNS	O
(	(	O
FIG	NNP	O
.	.	O
15B	CD	O
)	)	O
dramatically	RB	O
increased	VBD	O
when	WRB	O
fungi	NNS	O
were	VBD	O
incubated	VBN	O
in	IN	O
the	DT	O
presence	NN	O
of	IN	O
airway	JJ	O
mucin	NN	O
.	.	O
Thus	RB	O
,	,	O
A.	NNP	O
alternata	VBZ	O
likely	JJ	O
produces	VBZ	O
PAR-activating	JJ	O
enzyme	NN	O
(	(	O
s	JJ	O
)	)	O
during	IN	O
their	PRP$	O
germination	NN	O
and	CC	O
growth	NN	O
,	,	O
in	IN	O
particular	JJ	O
when	WRB	O
they	PRP	O
germinate	VBP	O
on	IN	O
mucosal	NN	O
surfaces	NNS	O
,	,	O
and	CC	O
eosinophils	VBZ	O
demonstrate	VB	O
a	DT	O
vigorous	JJ	O
inflammatory	JJ	O
response	NN	O
against	IN	O
these	DT	O
germinating	VBG	O
fungi	NNS	O
.	.	O
The	DT	O
model	NN	O
of	IN	O
a	DT	O
spore/eosinophil	NN	O
mixed	JJ	O
culture	NN	O
provides	VBZ	O
a	DT	O
tool	NN	O
to	TO	O
dissect	VB	O
the	DT	O
role	NN	O
of	IN	O
specific	JJ	O
Alternaria	NNP	O
molecule	NN	O
(	(	O
s	NN	O
)	)	O
in	IN	O
the	DT	O
eosinophil	NN	O
's	POS	O
recognition	NN	O
of	IN	O
and	CC	O
response	NN	O
to	TO	O
this	DT	O
fungus	NN	O
.	.	O
The	DT	O
polypeptide	NN	O
having	VBG	O
the	DT	O
amino	NN	O
acid	JJ	O
sequence	NN	O
set	VBN	O
forth	NN	O
in	IN	O
SEQ	NNP	O
ID	NNP	O
NO:2	NNP	O
was	VBD	O
recombinantly	RB	O
produced	VBN	O
in	IN	O
E.	NNP	O
coli	NNS	O
and	CC	O
tested	VBN	O
for	IN	O
the	DT	O
ability	NN	O
to	TO	O
stimulate	VB	O
eosinophil	JJ	O
degranulation	NN	O
.	.	O
This	DT	O
polypeptide	NN	O
stimulated	VBD	O
eosinophil	JJ	O
degranulation	NN	O
,	,	O
as	IN	O
measured	VBN	O
by	IN	O
EDN	NNP	O
release	NN	O
,	,	O
in	IN	O
a	DT	O
concentration-dependent	JJ	O
manner	NN	O
.	.	O
Example	JJ	O
6	CD	O
In	IN	O
Vivo	NNP	O
Mouse	NNP	O
Model	NNP	O
of	IN	O
Immune	NNP	O
Response	NNP	O
to	TO	O
Alternaria	NNP	O
In	IN	O
FIG	NNP	O
.	.	O
1	CD	O
,	,	O
PBMC	NNP	O
from	IN	O
CRS	NNP	O
patients	NNS	O
show	VBP	O
increased	VBN	O
cellular	JJ	O
and	CC	O
humoral	JJ	O
immune	NN	O
responses	NNS	O
to	TO	O
Alternaria	NNP	O
.	.	O
To	TO	O
dissect	VB	O
the	DT	O
role	NN	O
of	IN	O
immune	JJ	O
cells	NNS	O
in	IN	O
their	PRP$	O
responses	NNS	O
to	TO	O
fungi	VB	O
,	,	O
a	DT	O
mouse	NN	O
model	NN	O
was	VBD	O
developed	VBN	O
.	.	O
Because	IN	O
CRS	NNP	O
patients	NNS	O
showed	VBD	O
an	DT	O
increased	VBN	O
immune	NN	O
response	NN	O
to	TO	O
fungi	VB	O
,	,	O
BALB/c	NNP	O
mice	NN	O
were	VBD	O
sensitized	VBN	O
to	TO	O
Alternaria	NNP	O
by	IN	O
intraperitoneal	NN	O
(	(	O
i.p	NN	O
)	)	O
injection	NN	O
of	IN	O
Alternaria	NNP	O
extract	NN	O
(	(	O
Greer	NNP	O
Laboratories	NNPS	O
)	)	O
and	CC	O
subsequently	RB	O
challenged	VBD	O
mice	NNS	O
intranasally	RB	O
(	(	O
i.n	JJ	O
.	.	O
)	)	O
with	IN	O
the	DT	O
same	JJ	O
extract	NN	O
.	.	O
Mice	NNP	O
sensitized	VBD	O
and	CC	O
challenged	VBD	O
with	IN	O
Alternaria	NNP	O
exhibited	VBD	O
striking	VBG	O
airway	RB	O
eosinophilia	RB	O
.	.	O
Airway	NNP	O
eosinophilia	NN	O
was	VBD	O
also	RB	O
observed	VBN	O
in	IN	O
mice	NNS	O
sensitized	VBN	O
with	IN	O
PBS	NNP	O
(	(	O
no	DT	O
antigen	NN	O
)	)	O
and	CC	O
challenged	VBN	O
intranasally	RB	O
with	IN	O
Alternaria	NNP	O
.	.	O
Thus	RB	O
,	,	O
mice	NN	O
might	MD	O
have	VB	O
an	DT	O
innate	JJ	O
ability	NN	O
to	TO	O
produce	VB	O
an	DT	O
airway	JJ	O
eosinophilic	JJ	O
response	NN	O
to	TO	O
certain	JJ	O
fungi	NNS	O
,	,	O
which	WDT	O
may	MD	O
be	VB	O
similar	JJ	O
to	TO	O
the	DT	O
innate	NN	O
Th2	NNP	O
and	CC	O
eosinophilic	JJ	O
responses	NNS	O
to	TO	O
helminth	VB	O
parasites	NNS	O
in	IN	O
mice	NN	O
.	.	O
To	TO	O
test	VB	O
this	DT	O
hypothesis	NN	O
,	,	O
fungal	JJ	O
extracts	NNS	O
or	CC	O
OVA	NNP	O
(	(	O
as	IN	O
a	DT	O
control	NN	O
)	)	O
were	VBD	O
administered	VBN	O
intranasally	RB	O
to	TO	O
naive	JJ	O
mice	NN	O
without	IN	O
prior	JJ	O
sensitization	NN	O
on	IN	O
days	NNS	O
0	CD	O
,	,	O
3	CD	O
,	,	O
and	CC	O
6	CD	O
,	,	O
and	CC	O
airway	RB	O
inflammation	NN	O
was	VBD	O
analyzed	VBN	O
on	IN	O
day	NN	O
8	CD	O
.	.	O
Mice	NNP	O
exposed	VBD	O
to	TO	O
culture	NN	O
supernatant	NN	O
or	CC	O
cellular	JJ	O
extract	NN	O
of	IN	O
Alternaria	NNP	O
exhibited	VBD	O
significant	JJ	O
airway	NN	O
eosinophilia	NN	O
(	(	O
FIG	NNP	O
.	.	O
16	CD	O
)	)	O
.	.	O
Aspergillus	NNP	O
induced	VBD	O
mild	JJ	O
airway	RB	O
eosinophilia	NN	O
.	.	O
In	IN	O
contrast	NN	O
,	,	O
Candida	NNP	O
induced	VBD	O
neutrophilia	JJ	O
,	,	O
but	CC	O
no	DT	O
eosinophilia	NN	O
.	.	O
This	DT	O
airway	NN	O
eosinophilia	VBZ	O
in	IN	O
Alternaria-exposed	JJ	O
mice	NN	O
is	VBZ	O
probably	RB	O
not	RB	O
due	JJ	O
to	TO	O
accidental	JJ	O
prior	JJ	O
sensitization	NN	O
of	IN	O
the	DT	O
animals	NNS	O
to	TO	O
Alternaria	NNP	O
for	IN	O
the	DT	O
following	JJ	O
reasons	NNS	O
:	:	O
1	CD	O
)	)	O
mice	NN	O
from	IN	O
different	JJ	O
animal	NN	O
vendors	NNS	O
showed	VBD	O
similar	JJ	O
eosinophilic	JJ	O
responses	NNS	O
;	:	O
2	CD	O
)	)	O
no	DT	O
IgG	NNP	O
or	CC	O
IgE	NNP	O
antibodies	NNS	O
to	TO	O
Alternaria	NNP	O
were	VBD	O
detected	VBN	O
in	IN	O
naive	JJ	O
mouse	NN	O
serum	NN	O
;	:	O
and	CC	O
3	CD	O
)	)	O
spleen	NN	O
cells	NNS	O
from	IN	O
naive	JJ	O
mice	NNS	O
cultured	VBN	O
with	IN	O
Alternaria	NNP	O
antigen	NN	O
did	VBD	O
not	RB	O
produce	VB	O
IL-4	NNP	O
or	CC	O
IL-5	NNP	O
.	.	O
In	IN	O
addition	NN	O
,	,	O
the	DT	O
airway	RB	O
eosinophilic	JJ	O
response	NN	O
to	TO	O
Alternaria	NNP	O
was	VBD	O
reproducible	JJ	O
among	IN	O
different	JJ	O
strains	NNS	O
of	IN	O
mice	NNS	O
including	VBG	O
BALB/c	NNP	O
,	,	O
C57BL/6	NNP	O
,	,	O
C3H/HeJ	NNP	O
,	,	O
C3H/HeSnJ	NNP	O
,	,	O
and	CC	O
WBB6F1/J-KitW/KitW-v.	NNP	O
Generally	NNP	O
,	,	O
an	DT	O
intact	JJ	O
adaptive	JJ	O
immune	NN	O
system	NN	O
,	,	O
especially	RB	O
the	DT	O
Th2	NNP	O
cells	NNS	O
,	,	O
is	VBZ	O
needed	VBN	O
to	TO	O
develop	VB	O
robust	JJ	O
airway	NN	O
eosinophilia	NN	O
in	IN	O
mice	NN	O
sensitized	VBN	O
and	CC	O
challenged	VBN	O
with	IN	O
OVA	NNP	O
as	IN	O
described	VBN	O
elsewhere	RB	O
.	.	O
The	DT	O
contributions	NNS	O
of	IN	O
the	DT	O
adaptive	JJ	O
immune	NN	O
system	NN	O
in	IN	O
the	DT	O
development	NN	O
of	IN	O
airway	NN	O
eosinophilia	NNS	O
in	IN	O
naive	JJ	O
Alternaria-exposed	JJ	O
mice	NN	O
were	VBD	O
investigated	VBN	O
.	.	O
In	IN	O
FIG	NNP	O
.	.	O
17A	CD	O
,	,	O
there	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
in	IN	O
the	DT	O
early	JJ	O
eosinophilia	NN	O
(	(	O
i.e.	JJ	O
,	,	O
days	NNS	O
0.5	CD	O
and	CC	O
5	CD	O
)	)	O
between	IN	O
wild-type	JJ	O
animals	NNS	O
and	CC	O
Rag-1−/−	NNP	O
mice	NN	O
,	,	O
suggesting	VBG	O
that	IN	O
an	DT	O
innate	NN	O
immune	NN	O
response	NN	O
mediated	VBD	O
the	DT	O
early	JJ	O
eosinophilic	JJ	O
response	NN	O
to	TO	O
Alternaria	NNP	O
.	.	O
In	IN	O
contrast	NN	O
,	,	O
an	DT	O
adaptive	JJ	O
immune	NN	O
system	NN	O
,	,	O
presumably	RB	O
T	NNP	O
cells	NNS	O
,	,	O
was	VBD	O
required	VBN	O
for	IN	O
further	JJ	O
development	NN	O
of	IN	O
eosinophilia	NN	O
at	IN	O
a	DT	O
later	JJ	O
time	NN	O
point	NN	O
(	(	O
i.e.	JJ	O
,	,	O
day	NN	O
8	CD	O
)	)	O
.	.	O
When	WRB	O
Alternaria	NNP	O
was	VBD	O
administered	VBN	O
only	RB	O
once	RB	O
to	TO	O
the	DT	O
mouse	NN	O
airways	VBZ	O
,	,	O
IL-5	NNP	O
and	CC	O
IFN-γ	NNP	O
,	,	O
but	CC	O
not	RB	O
IL-4	NNP	O
,	,	O
were	VBD	O
detected	VBN	O
in	IN	O
BAL	NNP	O
fluids	NNS	O
by	IN	O
as	RB	O
early	JJ	O
as	IN	O
3	CD	O
hours	NNS	O
and	CC	O
peaked	VBD	O
at	IN	O
12	CD	O
hours	NNS	O
,	,	O
suggesting	VBG	O
that	IN	O
the	DT	O
early	JJ	O
cytokine	NN	O
production	NN	O
does	VBZ	O
not	RB	O
reflect	VB	O
a	DT	O
typical	JJ	O
Th2	NNP	O
pattern	NN	O
.	.	O
Furthermore	RB	O
,	,	O
the	DT	O
early	JJ	O
IL-5	JJ	O
and	CC	O
IFN-γ	JJ	O
responses	NNS	O
(	(	O
12	CD	O
hours	NNS	O
after	IN	O
first	JJ	O
exposure	NN	O
)	)	O
were	VBD	O
not	RB	O
reduced	VBN	O
in	IN	O
Rag-1−/−	NNP	O
mice	NN	O
(	(	O
FIG	NNP	O
.	.	O
17B	CD	O
)	)	O
.	.	O
Rather	RB	O
,	,	O
IL-5	NNP	O
production	NN	O
was	VBD	O
enhanced	VBN	O
in	IN	O
Rag-1−/−	NNP	O
mice	NN	O
,	,	O
suggesting	VBG	O
that	IN	O
innate	NN	O
immune	NN	O
cells	NNS	O
are	VBP	O
responsible	JJ	O
for	IN	O
this	DT	O
early	JJ	O
production	NN	O
of	IN	O
IL-5	NNP	O
and	CC	O
IFN-γ	NNP	O
and	CC	O
that	IN	O
adaptive	JJ	O
immune	JJ	O
cells	NNS	O
may	MD	O
show	VB	O
inhibitory	JJ	O
effects	NNS	O
on	IN	O
this	DT	O
innate	JJ	O
response	NN	O
.	.	O
Various	JJ	O
molecules	NNS	O
and	CC	O
their	PRP$	O
receptors	NNS	O
can	MD	O
be	VB	O
involved	VBN	O
in	IN	O
this	DT	O
Th2-like	JJ	O
airway	NN	O
inflammation	NN	O
in	IN	O
naive	JJ	O
mice	NN	O
exposed	VBD	O
to	TO	O
Alternaria	NNP	O
in	IN	O
vivo	NN	O
(	(	O
FIG	NNP	O
.	.	O
16	CD	O
)	)	O
.	.	O
In	IN	O
mice	NN	O
,	,	O
a	DT	O
small	JJ	O
amount	NN	O
of	IN	O
LPS	NNP	O
interacting	VBG	O
with	IN	O
TLR4	NNP	O
is	VBZ	O
a	DT	O
factor	NN	O
in	IN	O
promoting	VBG	O
Th2	NNP	O
sensitization	NN	O
to	TO	O
protein	VB	O
antigens	NNS	O
as	IN	O
described	NN	O
elsewhere	RB	O
.	.	O
In	IN	O
addition	NN	O
,	,	O
the	DT	O
cysteine	NN	O
proteinase	NN	O
gene	NN	O
from	IN	O
Leishmania	NNP	O
mexicana	NN	O
has	VBZ	O
been	VBN	O
implicated	VBN	O
in	IN	O
the	DT	O
upregulation	NN	O
of	IN	O
Th2	NNP	O
immunity	NN	O
and	CC	O
the	DT	O
downregulation	NN	O
of	IN	O
Th1	NNP	O
immunity	NN	O
to	TO	O
this	DT	O
pathogen	NN	O
in	IN	O
mice	NN	O
.	.	O
The	DT	O
Alternaria	NNP	O
preparation	NN	O
contained	VBD	O
a	DT	O
minimal	JJ	O
amount	NN	O
of	IN	O
LPS	NNP	O
(	(	O
0.4	CD	O
ng/mg	RB	O
dry	JJ	O
weight	NN	O
)	)	O
;	:	O
thus	RB	O
,	,	O
each	DT	O
mouse	NN	O
received	VBD	O
0.1	CD	O
ng	NNS	O
of	IN	O
LPS/challenge	NNP	O
.	.	O
Because	IN	O
this	DT	O
amount	NN	O
of	IN	O
LPS	NNP	O
is	VBZ	O
much	RB	O
smaller	JJR	O
than	IN	O
that	DT	O
used	VBD	O
previously	RB	O
to	TO	O
promote	VB	O
an	DT	O
airway	NN	O
Th2	NNP	O
response	NN	O
to	TO	O
OVA	NNP	O
(	(	O
i.e.	FW	O
,	,	O
100	CD	O
ng/challenge	NN	O
,	,	O
74	CD	O
)	)	O
,	,	O
it	PRP	O
is	VBZ	O
very	RB	O
unlikely	JJ	O
that	IN	O
LPS	NNP	O
contributes	VBZ	O
to	TO	O
this	DT	O
model	NN	O
.	.	O
Also	RB	O
,	,	O
prior	JJ	O
treatment	NN	O
of	IN	O
mouse	NN	O
airways	NNS	O
with	IN	O
1	CD	O
μg	NNS	O
LPS	NNP	O
significantly	RB	O
inhibited	VBD	O
this	DT	O
early	JJ	O
IL-5	JJ	O
production	NN	O
(	(	O
FIG	NNP	O
.	.	O
18A	CD	O
)	)	O
.	.	O
This	DT	O
early	JJ	O
IL-5	JJ	O
production	NN	O
was	VBD	O
significantly	RB	O
enhanced	VBN	O
in	IN	O
mice	JJ	O
deficient	NN	O
in	IN	O
TLR-4	NNP	O
(	(	O
C3H/HeJ	NNP	O
)	)	O
compared	VBN	O
to	TO	O
control	VB	O
mice	NN	O
(	(	O
C3H/HeOuJ	NNP	O
)	)	O
(	(	O
FIG	NNP	O
.	.	O
18B	CD	O
)	)	O
.	.	O
Early	JJ	O
IL-5	JJ	O
production	NN	O
was	VBD	O
also	RB	O
increased	VBN	O
in	IN	O
IL-10	NNP	O
deficient	NN	O
mice	NN	O
compared	VBN	O
to	TO	O
wild-type	JJ	O
controls	NNS	O
(	(	O
19.1±8.0	CD	O
vs	NN	O
7.6±2.8	CD	O
,	,	O
n=4	NN	O
)	)	O
,	,	O
suggesting	VBG	O
a	DT	O
role	NN	O
for	IN	O
IL-10	NNP	O
to	TO	O
down-regulate	VB	O
the	DT	O
early	JJ	O
IL-5	JJ	O
response	NN	O
.	.	O
Altogether	RB	O
,	,	O
naïve	JJ	O
mice	NN	O
likely	RB	O
show	JJ	O
innate	JJ	O
IL-5	NNP	O
and	CC	O
eosinophilic	JJ	O
responses	NNS	O
to	TO	O
airway	VB	O
exposure	NN	O
of	IN	O
Alternaria	NNP	O
,	,	O
and	CC	O
this	DT	O
innate	JJ	O
response	NN	O
may	MD	O
be	VB	O
down-regulated	JJ	O
by	IN	O
activation	NN	O
of	IN	O
TLR-4	NNP	O
or	CC	O
by	IN	O
production	NN	O
of	IN	O
IL-10	NNP	O
.	.	O
The	DT	O
in	IN	O
vitro	NN	O
experiments	NNS	O
suggested	VBD	O
a	DT	O
potential	JJ	O
role	NN	O
for	IN	O
Alternaria	NNP	O
aspartate	NN	O
protease	NN	O
(	(	O
s	NN	O
)	)	O
in	IN	O
the	DT	O
activation	NN	O
of	IN	O
eosinophils	NNS	O
(	(	O
FIG	NNP	O
.	.	O
9	CD	O
)	)	O
and	CC	O
airway	RB	O
epithelial	JJ	O
cells	NNS	O
(	(	O
FIG	NNP	O
.	.	O
11	CD	O
)	)	O
.	.	O
Thus	RB	O
,	,	O
it	PRP	O
is	VBZ	O
hypothesized	VBN	O
that	IN	O
the	DT	O
protease	NN	O
(	(	O
s	PRP	O
)	)	O
similar	JJ	O
to	TO	O
those	DT	O
involved	VBN	O
in	IN	O
eosinophil	JJ	O
degranulation	NN	O
and	CC	O
airway	RB	O
epithelial	JJ	O
cell	NN	O
production	NN	O
of	IN	O
IL-8	NNP	O
in	IN	O
vitro	NN	O
may	MD	O
be	VB	O
involved	VBN	O
in	IN	O
the	DT	O
development	NN	O
of	IN	O
airway	NN	O
eosinophilia	NN	O
in	IN	O
vivo	NN	O
in	IN	O
mice	NN	O
.	.	O
To	TO	O
address	VB	O
this	DT	O
question	NN	O
in	IN	O
vivo	NN	O
,	,	O
Alternaria	NNP	O
extract	NN	O
was	VBD	O
treated	VBN	O
with	IN	O
pepstatin	JJ	O
A-agarose	JJ	O
to	TO	O
remove	VB	O
aspartate	JJ	O
protease	NN	O
(	(	O
s	JJ	O
)	)	O
or	CC	O
control	VB	O
agarose	JJ	O
(	(	O
FIG	NNP	O
.	.	O
9	CD	O
)	)	O
and	CC	O
was	VBD	O
administered	VBN	O
to	TO	O
naïve	VB	O
mice	NN	O
.	.	O
Pepstatin	VB	O
A	DT	O
treatment	NN	O
significantly	RB	O
inhibited	VBD	O
both	DT	O
early	JJ	O
production	NN	O
of	IN	O
IL-5	NNP	O
at	IN	O
12	CD	O
hours	NNS	O
and	CC	O
airway	RB	O
eosinophilia	NNS	O
on	IN	O
day	NN	O
8	CD	O
(	(	O
FIG	NNP	O
.	.	O
19	CD	O
)	)	O
.	.	O
FIG	NNP	O
.	.	O
20	CD	O
shows	NNS	O
that	IN	O
the	DT	O
same	JJ	O
peak	JJ	O
fraction	NN	O
from	IN	O
the	DT	O
DEAE	NNP	O
fractionation	NN	O
(	(	O
i.e.	FW	O
,	,	O
Fraction	NNP	O
#	#	O
18	CD	O
of	IN	O
FIG	NNP	O
.	.	O
12	CD	O
)	)	O
,	,	O
which	WDT	O
contained	VBD	O
strong	JJ	O
aspartate	JJ	O
protease	NN	O
activity	NN	O
and	CC	O
potently	RB	O
induced	VBN	O
eosinophil	JJ	O
degranulation	NN	O
,	,	O
also	RB	O
induced	VBD	O
marked	JJ	O
airway	RB	O
eosinophilia	VBP	O
when	WRB	O
administered	VBN	O
into	IN	O
naïve	JJ	O
mice	NN	O
.	.	O
Example	JJ	O
7	CD	O
Effects	NNS	O
of	IN	O
Glycolytic	NNP	O
Enzyme	NNP	O
Homologs	NNP	O
on	IN	O
Immune	NNP	O
Cell	NNP	O
Activation	NNP	O
In	IN	O
Vitro	NNP	O
and	CC	O
In	IN	O
Vivo	NNP	O
The	DT	O
following	NN	O
was	VBD	O
performed	VBN	O
to	TO	O
characterize	VB	O
the	DT	O
responses	NNS	O
of	IN	O
eosinophils	NNS	O
(	(	O
in	IN	O
vitro	NN	O
)	)	O
and	CC	O
mouse	$	O
airways	NNS	O
(	(	O
in	IN	O
vivo	NN	O
)	)	O
to	TO	O
the	DT	O
homologous	JJ	O
enzymes	NNS	O
from	IN	O
other	JJ	O
fungal	JJ	O
species	NNS	O
,	,	O
some	DT	O
of	IN	O
which	WDT	O
are	VBP	O
commercially	RB	O
available	JJ	O
.	.	O
In	IN	O
Table	NNP	O
1	CD	O
,	,	O
A.	NNP	O
alternate	VBP	O
xylanase	NNP	O
(	(	O
a	DT	O
glycolytic	JJ	O
enzyme	NN	O
)	)	O
(	(	O
AAF05698.1	NNP	O
)	)	O
was	VBD	O
identified	VBN	O
by	IN	O
pepstatin	JJ	O
A-affinity	NNP	O
chromatography	NN	O
of	IN	O
an	DT	O
Alternaria	NNP	O
extract	NN	O
.	.	O
Thus	RB	O
,	,	O
the	DT	O
commercially	RB	O
available	JJ	O
xylanase	NN	O
isolated	VBD	O
from	IN	O
Trichoderma	NNP	O
viride	NN	O
was	VBD	O
used	VBN	O
(	(	O
Sigma	NNP	O
catalog	NN	O
#	#	O
X3876	NNP	O
)	)	O
,	,	O
and	CC	O
its	PRP$	O
biological	JJ	O
activity	NN	O
examined	VBD	O
.	.	O
Incubation	NN	O
of	IN	O
isolated	JJ	O
human	JJ	O
eosinophils	NNS	O
with	IN	O
Trichoderma	NNP	O
xylanase	NNP	O
induced	VBD	O
EDN	NNP	O
release	NN	O
(	(	O
FIG	NNP	O
.	.	O
21A	CD	O
)	)	O
.	.	O
Instillation	NN	O
of	IN	O
Trichoderma	NNP	O
xylanase	NNP	O
into	IN	O
the	DT	O
airways	NNS	O
of	IN	O
naïve	JJ	O
mice	NN	O
induced	VBD	O
increases	NNS	O
in	IN	O
airway	NN	O
levels	NNS	O
of	IN	O
IL-5	NNP	O
in	IN	O
vivo	NN	O
(	(	O
FIG	NNP	O
.	.	O
21B	CD	O
)	)	O
;	:	O
IL-5	JJ	O
production	NN	O
was	VBD	O
not	RB	O
inhibited	VBN	O
in	IN	O
Rag-1−/−	NNP	O
mice	NN	O
.	.	O
Thus	RB	O
,	,	O
the	DT	O
fungus-derived	JJ	O
immunostimulatory	NN	O
activities	NNS	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
Alternaria	NNP	O
,	,	O
but	CC	O
are	VBP	O
likely	JJ	O
shared	VBN	O
with	IN	O
certain	JJ	O
other	JJ	O
fungal	JJ	O
species	NNS	O
.	.	O
Furthermore	RB	O
,	,	O
the	DT	O
eosinophil	JJ	O
activation	NN	O
assay	NN	O
in	IN	O
vitro	NN	O
and	CC	O
the	DT	O
mouse	NN	O
airway	NN	O
response	NN	O
in	IN	O
vivo	NN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
the	DT	O
airway	NN	O
epithelial	JJ	O
cell	NN	O
culture	NN	O
provide	VBP	O
models	NNS	O
to	TO	O
examine	VB	O
the	DT	O
effects	NNS	O
of	IN	O
specific	JJ	O
immunostimulatory	NN	O
molecules	NNS	O
produced	VBN	O
by	IN	O
fungi	NNS	O
and	CC	O
to	TO	O
dissect	VB	O
the	DT	O
molecular	JJ	O
mechanisms	NNS	O
involved	VBN	O
in	IN	O
this	DT	O
fungus-immune	JJ	O
cell	NN	O
interaction	NN	O
.	.	O
Example	RB	O
8	CD	O
Characterizing	VBG	O
the	DT	O
Airway	NNP	O
Immune	NNP	O
and	CC	O
Inflammatory	NNP	O
Responses	NNP	O
to	TO	O
Environmental	NNP	O
Fungi	NNP	O
in	IN	O
Patients	NNP	O
with	IN	O
CRS	NNP	O
PBMC	NNP	O
are	VBP	O
isolated	VBN	O
from	IN	O
CRS	NNP	O
patients	NNS	O
with	IN	O
or	CC	O
without	IN	O
nasal	JJ	O
polyps	NNS	O
,	,	O
AR	NNP	O
patients	NNS	O
and	CC	O
normal	JJ	O
individuals	NNS	O
,	,	O
and	CC	O
their	PRP$	O
proliferative	JJ	O
and	CC	O
cytokine	JJ	O
responses	NNS	O
to	TO	O
fungal	VB	O
antigens	NNS	O
are	VBP	O
compared	VBN	O
.	.	O
CD4+	NNP	O
cell	NN	O
proliferation	NN	O
is	VBZ	O
measured	VBN	O
by	IN	O
dilution	NN	O
of	IN	O
the	DT	O
carboxyfluorescein	NN	O
diacetate	NN	O
succinimidyl	NN	O
ester	NN	O
(	(	O
CFSE	NNP	O
)	)	O
.	.	O
Twenty-five	JJ	O
cytokines	NNS	O
and	CC	O
chemokines	NNS	O
in	IN	O
the	DT	O
supernatants	NNS	O
are	VBP	O
quantitated	VBN	O
simultaneously	RB	O
by	IN	O
a	DT	O
Luminex	NNP	O
system	NN	O
.	.	O
Stimulated	VBN	O
PBMC	NNP	O
are	VBP	O
stained	VBN	O
with	IN	O
antibodies	NNS	O
for	IN	O
cell	NN	O
surface	NN	O
markers	NNS	O
and	CC	O
intracellular	JJ	O
cytokines	NNS	O
,	,	O
and	CC	O
are	VBP	O
analyzed	VBN	O
by	IN	O
FACS	NNP	O
to	TO	O
identify	VB	O
cells	NNS	O
producing	VBG	O
IL-5	NNP	O
,	,	O
IL-13	NNP	O
,	,	O
and	CC	O
IFN-γ	NNP	O
.	.	O
Special	JJ	O
attention	NN	O
is	VBZ	O
focused	VBN	O
on	IN	O
whether	IN	O
CD4+	NNP	O
T	NNP	O
cells	NNS	O
and	CC	O
CD56+	NNP	O
NK	NNP	O
cells	NNS	O
produce	VBP	O
these	DT	O
cytokines	NNS	O
.	.	O
Subjects	NNS	O
.	.	O
Patients	NNS	O
with	IN	O
CRS	NNP	O
are	VBP	O
studied	VBN	O
,	,	O
using	VBG	O
patients	NNS	O
with	IN	O
AR	NNP	O
and	CC	O
normal	JJ	O
individuals	NNS	O
as	IN	O
controls	NNS	O
.	.	O
Patients	NNS	O
who	WP	O
received	VBD	O
systemic	JJ	O
glucocorticoids	NNS	O
during	IN	O
the	DT	O
past	JJ	O
4	CD	O
weeks	NNS	O
,	,	O
who	WP	O
are	VBP	O
smokers	NNS	O
,	,	O
or	CC	O
who	WP	O
were	VBD	O
diagnosed	VBN	O
with	IN	O
an	DT	O
immunodeficiency	NN	O
or	CC	O
cystic	JJ	O
fibrosis	NN	O
are	VBP	O
excluded	VBN	O
.	.	O
The	DT	O
diagnosis	NN	O
of	IN	O
CRS	NNP	O
is	VBZ	O
made	VBN	O
based	VBN	O
on	IN	O
the	DT	O
fulfillment	NN	O
of	IN	O
all	DT	O
three	CD	O
criteria	NNS	O
:	:	O
i	NN	O
)	)	O
2	CD	O
or	CC	O
more	JJR	O
of	IN	O
the	DT	O
following	JJ	O
symptoms	NNS	O
for	IN	O
more	JJR	O
than	IN	O
12	CD	O
weeks—anterior	JJ	O
or	CC	O
posterior	JJ	O
mucopurulent	NN	O
drainage	NN	O
,	,	O
nasal	JJ	O
obstruction	NN	O
,	,	O
facial	JJ	O
pain-pressure-fullness	NN	O
,	,	O
and	CC	O
decreased	VBD	O
sense	NN	O
of	IN	O
smell	NN	O
;	:	O
ii	NN	O
)	)	O
anterior	VBZ	O
rhinoscopy	NN	O
or	CC	O
nasal	JJ	O
endoscopy	NN	O
to	TO	O
document	VB	O
signs	NNS	O
of	IN	O
inflammation	NN	O
;	:	O
and	CC	O
iii	VB	O
)	)	O
sinus	NN	O
CT	NNP	O
scan	JJ	O
demonstrating	NN	O
isolated	VBD	O
or	CC	O
diffuse	VB	O
mucosal	JJ	O
thickening	NN	O
.	.	O
CRS	NN	O
with	IN	O
nasal	JJ	O
polyps	NNS	O
(	(	O
CRSwNP	NNP	O
)	)	O
is	VBZ	O
defined	VBN	O
as	IN	O
those	DT	O
CRS	NNP	O
patients	NNS	O
who	WP	O
now	RB	O
have	VBP	O
or	CC	O
who	WP	O
had	VBD	O
nasal	JJ	O
polyps	NNS	O
in	IN	O
the	DT	O
middle	JJ	O
meatus	NN	O
,	,	O
as	IN	O
determined	VBN	O
by	IN	O
anterior	JJ	O
rhinoscopy	NN	O
or	CC	O
nasal	JJ	O
endoscopy	NN	O
.	.	O
CRS	NN	O
without	IN	O
nasal	JJ	O
polyps	NNS	O
(	(	O
CRSsNP	NNP	O
)	)	O
is	VBZ	O
defined	VBN	O
as	IN	O
CRS	NNP	O
patients	NNS	O
who	WP	O
fulfill	VBP	O
all	DT	O
three	CD	O
criteria	NNS	O
for	IN	O
CRS	NNP	O
as	IN	O
described	VBN	O
above	IN	O
,	,	O
but	CC	O
who	WP	O
do	VBP	O
not	RB	O
have	VB	O
demonstrable	JJ	O
nasal	JJ	O
polyps	NNS	O
in	IN	O
the	DT	O
middle	JJ	O
meatus	NN	O
both	DT	O
in	IN	O
the	DT	O
past	JJ	O
and	CC	O
at	IN	O
present	JJ	O
.	.	O
Seasonal	NNP	O
allergic	JJ	O
rhinitis	NN	O
(	(	O
AR	NNP	O
)	)	O
to	TO	O
ragweed	VB	O
.	.	O
The	DT	O
clinical	JJ	O
diagnosis	NN	O
of	IN	O
AR	NNP	O
is	VBZ	O
established	VBN	O
by	IN	O
history	NN	O
,	,	O
where	WRB	O
patients	NNS	O
describe	VB	O
the	DT	O
typical	JJ	O
seasonal	JJ	O
signs	NNS	O
of	IN	O
nose	JJ	O
itching	NN	O
,	,	O
sneezing	VBG	O
and	CC	O
clear	JJ	O
rhinorrhea	NN	O
,	,	O
and	CC	O
is	VBZ	O
confirmed	VBN	O
with	IN	O
a	DT	O
positive	JJ	O
skin	NN	O
test	NN	O
and/or	NN	O
elevated	VBD	O
specific	JJ	O
serum	NN	O
IgE	NNP	O
level	NN	O
for	IN	O
short	JJ	O
ragweed	NN	O
antigen	NN	O
.	.	O
Patients	NNS	O
with	IN	O
AR	NNP	O
are	VBP	O
to	TO	O
have	VB	O
no	DT	O
history	NN	O
or	CC	O
symptoms	NNS	O
of	IN	O
CRS	NNP	O
or	CC	O
asthma	NN	O
and	CC	O
are	VBP	O
to	TO	O
have	VB	O
normal	JJ	O
lung	NN	O
function	NN	O
.	.	O
Normal	NNP	O
Controls	NNP	O
.	.	O
The	DT	O
normal	JJ	O
controls	NNS	O
are	VBP	O
healthy	JJ	O
individuals	NNS	O
with	IN	O
no	DT	O
history	NN	O
of	IN	O
allergy	NN	O
or	CC	O
asthma	NN	O
and	CC	O
negative	JJ	O
skin	NN	O
prick	JJ	O
test	NN	O
results	NNS	O
to	TO	O
fungi	VB	O
and	CC	O
common	JJ	O
aeroallergens	NNS	O
.	.	O
Demographic	JJ	O
Characterization	NNP	O
of	IN	O
Patients	NNPS	O
and	CC	O
Normal	NNP	O
Individuals	NNP	O
.	.	O
Questionnaire	NN	O
:	:	O
Each	DT	O
patient	NN	O
is	VBZ	O
asked	VBN	O
to	TO	O
complete	VB	O
the	DT	O
questionnaire	NN	O
regarding	VBG	O
the	DT	O
history	NN	O
of	IN	O
his	PRP$	O
or	CC	O
her	PRP$	O
sinus	NN	O
symptoms	NNS	O
,	,	O
aspirin	JJ	O
sensitivity	NN	O
,	,	O
sinus	NN	O
operations	NNS	O
,	,	O
and	CC	O
recently	RB	O
used	VBD	O
and	CC	O
current	JJ	O
medications	NNS	O
.	.	O
Patients	NNS	O
are	VBP	O
also	RB	O
asked	VBN	O
regarding	VBG	O
their	PRP$	O
history	NN	O
of	IN	O
asthma	NN	O
and	CC	O
AR	NNP	O
,	,	O
smoking	VBG	O
habits	NNS	O
,	,	O
and	CC	O
use	NN	O
of	IN	O
allergen	NN	O
immunotherapy	NN	O
.	.	O
Skin	JJ	O
tests	NNS	O
:	:	O
Skin	NNP	O
prick	NN	O
tests	NNS	O
are	VBP	O
performed	VBN	O
with	IN	O
a	DT	O
battery	NN	O
of	IN	O
18	CD	O
commercially	RB	O
available	JJ	O
fungal	JJ	O
extracts	NNS	O
and	CC	O
8	CD	O
common	JJ	O
aeroallergen	NN	O
extracts	NNS	O
,	,	O
including	VBG	O
Dermatophagoides	NNP	O
pteronyssinus	NN	O
,	,	O
D.	NNP	O
farinae	NN	O
,	,	O
cockroach	NN	O
,	,	O
short	JJ	O
ragweed	NN	O
pollen	NN	O
,	,	O
mixed	JJ	O
grass	NN	O
pollen	NN	O
,	,	O
mixed	JJ	O
tree	NN	O
pollen	NN	O
,	,	O
cat	NN	O
epithelium	NN	O
,	,	O
and	CC	O
dog	NN	O
dander	NN	O
.	.	O
Total	JJ	O
and	CC	O
specific	JJ	O
IgE	NNP	O
:	:	O
Total	JJ	O
serum	NN	O
IgE	NNP	O
is	VBZ	O
measured	VBN	O
by	IN	O
two-site	JJ	O
ELISA	NNP	O
.	.	O
Allergen-specific	JJ	O
IgE	NNP	O
antibody	NN	O
levels	NNS	O
are	VBP	O
determined	VBN	O
by	IN	O
RAST	NNP	O
using	VBG	O
8	CD	O
fungal	JJ	O
allergens	NNS	O
and	CC	O
8	CD	O
common	JJ	O
aeroallergens	NNS	O
.	.	O
Assessment	NN	O
of	IN	O
CRS	NNP	O
:	:	O
To	TO	O
assess	VB	O
the	DT	O
extent	NN	O
of	IN	O
the	DT	O
CRS	NNP	O
,	,	O
symptoms	NNS	O
and	CC	O
quality	NN	O
of	IN	O
life	NN	O
(	(	O
QOL	NNP	O
)	)	O
are	VBP	O
scored	VBN	O
according	VBG	O
to	TO	O
the	DT	O
Symptom	NNP	O
Score	NNP	O
(	(	O
0-10	JJ	O
visual	JJ	O
analogue	NN	O
scale	NN	O
of	IN	O
6	CD	O
sinusitis-related	JJ	O
symptoms	NNS	O
and	CC	O
Gliklich	NNP	O
and	CC	O
Metson	NNP	O
QOL	NNP	O
Score	NNP	O
.	.	O
Sinus	NNP	O
CT	NNP	O
scans	NNS	O
are	VBP	O
scored	VBN	O
according	VBG	O
to	TO	O
CT	NNP	O
scoring	VBG	O
systems	NNS	O
described	VBN	O
elsewhere	RB	O
(	(	O
e.g.	UH	O
,	,	O
the	DT	O
Lund-Mackay	NNP	O
staging	NN	O
system	NN	O
and	CC	O
the	DT	O
digital	JJ	O
analysis	NN	O
of	IN	O
scanned	JJ	O
images	NNS	O
)	)	O
.	.	O
Sample	JJ	O
Size	NNP	O
Given	NNP	O
the	DT	O
conservative	JJ	O
assumption	NN	O
that	IN	O
IL-5	NNP	O
is	VBZ	O
produced	VBN	O
by	IN	O
PBMC	NNP	O
from	IN	O
≧83	NNP	O
%	NN	O
of	IN	O
the	DT	O
patients	NNS	O
with	IN	O
CRS	NNP	O
and	CC	O
is	VBZ	O
produced	VBN	O
in	IN	O
36	CD	O
%	NN	O
of	IN	O
the	DT	O
normal	JJ	O
controls	NNS	O
,	,	O
we	PRP	O
are	VBP	O
to	TO	O
have	VB	O
80	CD	O
%	NN	O
power	NN	O
with	IN	O
a	DT	O
probability	NN	O
of	IN	O
a	DT	O
type	NN	O
1	CD	O
error	NN	O
rate	NN	O
of	IN	O
0.05	CD	O
with	IN	O
20	CD	O
patients	NNS	O
in	IN	O
each	DT	O
group	NN	O
.	.	O
Therefore	RB	O
,	,	O
20	CD	O
CRSwNP	NNP	O
,	,	O
20	CD	O
CRSsNP	NNP	O
,	,	O
20	CD	O
AR	NNP	O
,	,	O
and	CC	O
20	CD	O
normal	JJ	O
controls	NNS	O
are	VBP	O
recruited	VBN	O
.	.	O
Cell	NNP	O
Proliferation	NNP	O
and	CC	O
Cytokine	NNP	O
Production	NNP	O
by	IN	O
PBMC	NNP	O
PBMC	NNP	O
are	VBP	O
cultured	VBN	O
for	IN	O
24	CD	O
hours	NNS	O
or	CC	O
96	CD	O
hours	NNS	O
(	(	O
for	IN	O
cytokine	NN	O
assay	NN	O
)	)	O
or	CC	O
for	IN	O
168	CD	O
hours	NNS	O
(	(	O
for	IN	O
proliferation	NN	O
assay	NN	O
)	)	O
with	IN	O
or	CC	O
without	IN	O
25	CD	O
μg/mL	JJ	O
extracts	NNS	O
of	IN	O
Alternaria	NNP	O
,	,	O
Aspergillus	NNP	O
,	,	O
Cladosporium	NNP	O
,	,	O
and	CC	O
short	JJ	O
ragweed	NN	O
(	(	O
Greer	NNP	O
Laboratories	NNPS	O
)	)	O
,	,	O
2	CD	O
μg/mL	JJ	O
tetanus	NN	O
toxoid	NN	O
,	,	O
or	CC	O
5	CD	O
μg/mL	JJ	O
Con-A	NNP	O
.	.	O
The	DT	O
optimal	JJ	O
concentrations	NNS	O
of	IN	O
antigens	NNS	O
and	CC	O
duration	NN	O
of	IN	O
culture	NN	O
have	VBP	O
been	VBN	O
determined	VBN	O
elsewhere	RB	O
.	.	O
The	DT	O
concentrations	NNS	O
of	IN	O
a	DT	O
panel	NN	O
of	IN	O
25	CD	O
cytokines	NNS	O
and	CC	O
chemokines	NNS	O
(	(	O
IL-1β	NNP	O
,	,	O
IL-Ra	NNP	O
,	,	O
IL-2	NNP	O
,	,	O
IL-2R	NNP	O
,	,	O
IL-4	NNP	O
,	,	O
IL-5	NNP	O
,	,	O
IL-6	NNP	O
,	,	O
IL-7	NNP	O
,	,	O
IL-8	NNP	O
,	,	O
IL-10	NNP	O
,	,	O
IL-12p40/p70	NNP	O
,	,	O
IL-13	NNP	O
,	,	O
IL-15	NNP	O
,	,	O
IL-17	NNP	O
,	,	O
TNF-α	NNP	O
,	,	O
IFN-α	NNP	O
,	,	O
IFN-γ	NNP	O
,	,	O
GM-CSF	NNP	O
,	,	O
MIP-1α	NNP	O
,	,	O
MIP-β	NNP	O
,	,	O
IP-10	NNP	O
,	,	O
MIG	NNP	O
,	,	O
eotaxin	NN	O
,	,	O
RANTES	NNP	O
,	,	O
MCP-1	NNP	O
)	)	O
are	VBP	O
measured	VBN	O
by	IN	O
a	DT	O
Luminex	NNP	O
100	CD	O
IS	NNP	O
system	NN	O
(	(	O
Upstate	NNP	O
)	)	O
and	CC	O
25-plex	JJ	O
antibody	NN	O
bead	JJ	O
kit	NN	O
(	(	O
BioSource	NNP	O
International	NNP	O
)	)	O
.	.	O
The	DT	O
differences	NNS	O
in	IN	O
the	DT	O
amounts	NNS	O
of	IN	O
individual	JJ	O
cytokine/chemokines	NNS	O
among	IN	O
the	DT	O
groups	NNS	O
are	VBP	O
analyzed	VBN	O
by	IN	O
Mann-Whitney	NNP	O
U	NNP	O
test	NN	O
.	.	O
The	DT	O
pattern	NN	O
and	CC	O
cluster	NN	O
of	IN	O
cytokine	NN	O
production	NN	O
in	IN	O
each	DT	O
subject	NN	O
group	NN	O
are	VBP	O
analyzed	VBN	O
by	IN	O
Spotfire	NNP	O
DecisionSite	NNP	O
software	NN	O
(	(	O
Somerville	NNP	O
)	)	O
.	.	O
For	IN	O
the	DT	O
CD4+	NNP	O
T	NNP	O
cell	NN	O
proliferation	NN	O
assay	NN	O
,	,	O
PBMC	NNP	O
are	VBP	O
labeled	VBN	O
with	IN	O
5	CD	O
mM	NNS	O
CFSE	NNP	O
for	IN	O
10	CD	O
min	NN	O
before	IN	O
addition	NN	O
of	IN	O
antigens	NNS	O
.	.	O
After	IN	O
culture	NN	O
,	,	O
PBMC	NNP	O
are	VBP	O
stained	VBN	O
with	IN	O
PE-conjugated	JJ	O
anti-CD4	JJ	O
and	CC	O
analyzed	VBN	O
by	IN	O
FACS	NNP	O
;	:	O
CFSE	NNP	O
dye	NN	O
is	VBZ	O
diluted	VBN	O
in	IN	O
the	DT	O
proliferating	VBG	O
population	NN	O
of	IN	O
the	DT	O
CD4+	NNP	O
T	NNP	O
cells	NNS	O
,	,	O
and	CC	O
the	DT	O
numbers	NNS	O
of	IN	O
cells	NNS	O
that	WDT	O
have	VBP	O
proliferated	VBN	O
per	IN	O
1,000	CD	O
CD4+	NNP	O
T	NNP	O
cells	NNS	O
are	VBP	O
determined	VBN	O
.	.	O
A	DT	O
pilot	NN	O
study	NN	O
showed	VBD	O
that	IN	O
when	WRB	O
PBMCs	NNP	O
from	IN	O
a	DT	O
CRS	NNP	O
patient	NN	O
were	VBD	O
stimulated	VBN	O
with	IN	O
Alternaria	NNP	O
extract	NN	O
,	,	O
a	DT	O
population	NN	O
of	IN	O
CFSElow	NNP	O
CD4+	NNP	O
T	NNP	O
cells	NNS	O
emerged	VBN	O
by	IN	O
day	NN	O
4	CD	O
,	,	O
and	CC	O
represented	VBD	O
66.9	CD	O
%	NN	O
of	IN	O
total	JJ	O
CD4+	NNP	O
T	NNP	O
cells	NNS	O
on	IN	O
day	NN	O
7	CD	O
(	(	O
FIG	NNP	O
.	.	O
22	CD	O
)	)	O
;	:	O
no	DT	O
changes	NNS	O
were	VBD	O
observed	VBN	O
in	IN	O
PBMCs	NNP	O
cultured	VBD	O
in	IN	O
medium	NN	O
alone	RB	O
.	.	O
A	DT	O
side-by-side	JJ	O
comparison	NN	O
of	IN	O
a	DT	O
normal	JJ	O
individual	NN	O
and	CC	O
a	DT	O
CRS	NNP	O
patient	NN	O
in	IN	O
a	DT	O
separate	JJ	O
experiment	NN	O
(	(	O
compared	VBN	O
on	IN	O
day	NN	O
7	CD	O
)	)	O
showed	VBD	O
that	IN	O
a	DT	O
higher	JJR	O
proportion	NN	O
of	IN	O
CD4+	NNP	O
cells	NNS	O
were	VBD	O
CFSElow	NNP	O
in	IN	O
the	DT	O
CRS	NNP	O
patient	NN	O
than	IN	O
those	DT	O
in	IN	O
the	DT	O
normal	JJ	O
individual	NN	O
(	(	O
43.2	CD	O
%	NN	O
vs.	FW	O
4.8	CD	O
%	NN	O
)	)	O
(	(	O
FIG	NNP	O
.	.	O
23	CD	O
)	)	O
.	.	O
In	IN	O
contrast	NN	O
,	,	O
many	JJ	O
CD4+	NNP	O
cells	NNS	O
were	VBD	O
CFSElow	NNP	O
in	IN	O
both	CC	O
the	DT	O
CRS	NNP	O
patient	NN	O
and	CC	O
normal	JJ	O
individual	NN	O
when	WRB	O
they	PRP	O
were	VBD	O
stimulated	VBN	O
with	IN	O
tetanus	NN	O
toxoid	NN	O
(	(	O
43.2	CD	O
%	NN	O
vs.	FW	O
47.9	CD	O
%	NN	O
)	)	O
.	.	O
FACS	NNP	O
Analyses	NNP	O
of	IN	O
Cytokine	NNP	O
Producing	NNP	O
Cells	NNP	O
The	DT	O
PBMCs	NNP	O
producing	VBG	O
IL-5	NNP	O
,	,	O
IL-13	NNP	O
and	CC	O
IFN-γ	NNP	O
are	VBP	O
analyzed	VBN	O
by	IN	O
FACS	NNP	O
.	.	O
IL-5	NN	O
is	VBZ	O
likely	JJ	O
produced	VBN	O
by	IN	O
CD4+	NNP	O
T	NNP	O
cells	NNS	O
,	,	O
CD8+	NNP	O
T	NNP	O
cells	NNS	O
,	,	O
and	CC	O
CD56+NK	NNP	O
cells	NNS	O
.	.	O
Thus	RB	O
,	,	O
FITC-conjugated	JJ	O
antibodies	NNS	O
are	VBP	O
used	VBN	O
for	IN	O
these	DT	O
cell	NN	O
surface	NN	O
markers	NNS	O
and	CC	O
PE-conjugated	JJ	O
antibodies	NNS	O
to	TO	O
IL-4	NNP	O
,	,	O
IL-5	NNP	O
,	,	O
IL-13	NNP	O
,	,	O
and	CC	O
IFN-γ	NNP	O
to	TO	O
identify	VB	O
cytokine-producing	JJ	O
cells	NNS	O
.	.	O
After	IN	O
stimulation	NN	O
with	IN	O
antigens	NNS	O
,	,	O
PBMC	NNP	O
are	VBP	O
re-stimulated	JJ	O
with	IN	O
ionomycin	JJ	O
plus	CC	O
PMA	NNP	O
in	IN	O
the	DT	O
presence	NN	O
of	IN	O
brefeldin	NN	O
A	NNP	O
.	.	O
Cell	NNP	O
surface	NN	O
antigens	NNS	O
are	VBP	O
stained	VBN	O
with	IN	O
FITC-conjugated	JJ	O
anti-CD3	NN	O
,	,	O
CD4	NNP	O
,	,	O
CD8	NNP	O
or	CC	O
CD56	NNP	O
(	(	O
Becton	NNP	O
Dickinson	NNP	O
)	)	O
.	.	O
After	IN	O
washing	VBG	O
,	,	O
cells	NNS	O
are	VBP	O
fixed	VBN	O
and	CC	O
permeabilized	VBN	O
simultaneously	RB	O
by	IN	O
Cytofix/Cytoperm	NNP	O
solution	NN	O
(	(	O
Pharmingen	NNP	O
)	)	O
,	,	O
and	CC	O
stained	VBD	O
with	IN	O
PE-conjugated	JJ	O
anti-cytokine	JJ	O
or	CC	O
control	NN	O
mouse	NN	O
Ig	NNP	O
.	.	O
In	IN	O
Vitro	NNP	O
Organ	NNP	O
Culture	NNP	O
of	IN	O
Sinus	NNP	O
Tissue	NNP	O
Specimens	NNP	O
from	IN	O
CRS	NNP	O
Patients	NNPS	O
Produce	NNP	O
Distinctive	NNP	O
Pro-Inflammatory	NNP	O
Cytokines	NNP	O
Large	NNP	O
quantities	NNS	O
of	IN	O
sinus	NN	O
tissue	NN	O
specimens	NNS	O
are	VBP	O
obtained	VBN	O
from	IN	O
CRS	NNP	O
patients	NNS	O
during	IN	O
endoscopic	JJ	O
sinus	NN	O
surgery	NN	O
.	.	O
Specimens	NNS	O
from	IN	O
the	DT	O
ethmoid	JJ	O
sinuses	NNS	O
of	IN	O
normal	JJ	O
individuals	NNS	O
(	(	O
non-allergic	JJ	O
,	,	O
no	DT	O
asthma	NN	O
,	,	O
no	DT	O
CRS	NNP	O
)	)	O
undergoing	VBG	O
septoplasty	JJ	O
procedures	NNS	O
are	VBP	O
used	VBN	O
as	IN	O
a	DT	O
negative	JJ	O
control	NN	O
.	.	O
Other	JJ	O
disease	NN	O
control	NN	O
specimens	NNS	O
are	VBP	O
obtained	VBN	O
from	IN	O
patients	NNS	O
with	IN	O
AR	NNP	O
,	,	O
who	WP	O
undergo	VBP	O
septoplasty	NN	O
.	.	O
To	TO	O
examine	VB	O
the	DT	O
immunological	JJ	O
responses	NNS	O
by	IN	O
sinus	NN	O
mucosa	NN	O
to	TO	O
fungi	VB	O
,	,	O
an	DT	O
organ	JJ	O
culture	NN	O
system	NN	O
is	VBZ	O
used	VBN	O
,	,	O
rather	RB	O
than	IN	O
isolated	VBN	O
mononuclear	JJ	O
cells	NNS	O
.	.	O
Organ	JJ	O
culture	NN	O
can	MD	O
allow	VB	O
for	IN	O
the	DT	O
study	NN	O
the	DT	O
mucosal	NN	O
immune	JJ	O
responses	NNS	O
and	CC	O
tolerance	NN	O
that	WDT	O
are	VBP	O
likely	JJ	O
be	VB	O
mediated	VBN	O
by	IN	O
a	DT	O
complex	JJ	O
network	NN	O
of	IN	O
epithelial	JJ	O
cells	NNS	O
,	,	O
antigen	NN	O
presenting	VBG	O
cells	NNS	O
,	,	O
lymphocytes	NNS	O
and	CC	O
potentially	RB	O
other	JJ	O
mucosal	JJ	O
resident	NN	O
cells	NNS	O
,	,	O
and	CC	O
each	DT	O
cellular	JJ	O
component	NN	O
may	MD	O
play	VB	O
an	DT	O
role	NN	O
.	.	O
Tissues	NNS	O
are	VBP	O
minced	VBN	O
into	IN	O
5-mm	JJ	O
pieces	NNS	O
,	,	O
and	CC	O
then	RB	O
cultured	VBD	O
with	IN	O
fungal	JJ	O
extracts	NNS	O
(	(	O
e.g.	NN	O
,	,	O
Alternaria	NNP	O
,	,	O
Cladosporium	NNP	O
,	,	O
Aspergillus	NNP	O
)	)	O
,	,	O
Con-A	NNP	O
or	CC	O
tetanus	NN	O
toxoid	NN	O
for	IN	O
24	CD	O
hours	NNS	O
or	CC	O
96	CD	O
hours	NNS	O
.	.	O
First	RB	O
,	,	O
the	DT	O
concentrations	NNS	O
of	IN	O
25	CD	O
cytokines	NNS	O
and	CC	O
chemokines	NNS	O
,	,	O
including	VBG	O
IL-10	NNP	O
,	,	O
in	IN	O
the	DT	O
supernatants	NNS	O
are	VBP	O
analyzed	VBN	O
by	IN	O
a	DT	O
Luminex	NNP	O
system	NN	O
.	.	O
The	DT	O
concentration	NN	O
of	IN	O
TGF-β	NNP	O
is	VBZ	O
measured	VBN	O
by	IN	O
ELISA	NNP	O
.	.	O
Second	JJ	O
,	,	O
once	RB	O
several	JJ	O
cytokines	NNS	O
(	(	O
e.g	NN	O
.	.	O
IL-5	NNP	O
)	)	O
are	VBP	O
verified	VBN	O
to	TO	O
be	VB	O
produced	VBN	O
at	IN	O
elevated	JJ	O
levels	NNS	O
during	IN	O
the	DT	O
CRS	NNP	O
organ	JJ	O
culture	NN	O
,	,	O
the	DT	O
cell	NN	O
types	NNS	O
that	WDT	O
produce	VBP	O
these	DT	O
cytokines	NNS	O
are	VBP	O
identified	VBN	O
.	.	O
After	IN	O
antigenic	JJ	O
stimulation	NN	O
for	IN	O
96	CD	O
hours	NNS	O
,	,	O
the	DT	O
tissue	NN	O
specimens	NNS	O
are	VBP	O
treated	VBN	O
with	IN	O
a	DT	O
cocktail	NN	O
of	IN	O
highly	RB	O
pure	JJ	O
collagenases	NNS	O
(	(	O
Blendzyme	NNP	O
3	CD	O
,	,	O
Roche	NNP	O
)	)	O
.	.	O
In	IN	O
preliminary	JJ	O
studies	NNS	O
,	,	O
the	DT	O
yield	NN	O
was	VBD	O
12	CD	O
to	TO	O
70×106	CD	O
cells/specimen	NNS	O
,	,	O
and	CC	O
the	DT	O
viability	NN	O
was	VBD	O
65˜95	CD	O
%	NN	O
.	.	O
The	DT	O
single	JJ	O
cell	NN	O
suspension	NN	O
are	VBP	O
recovered	VBN	O
after	IN	O
passing	VBG	O
through	IN	O
a	DT	O
nylon	JJ	O
mesh	NN	O
with	IN	O
100	CD	O
μm	NNS	O
pore	RB	O
size	NN	O
.	.	O
The	DT	O
cell	NN	O
types	NNS	O
(	(	O
CD4+	NNP	O
,	,	O
CD8+	NNP	O
,	,	O
CD56+	NNP	O
)	)	O
producing	VBG	O
cytokines	NNS	O
(	(	O
IL-5	NNP	O
,	,	O
IL-13	NNP	O
,	,	O
IFN-γ	NNP	O
)	)	O
are	VBP	O
analyzed	VBN	O
by	IN	O
intracellular	JJ	O
cytokine	NN	O
staining	NN	O
and	CC	O
FACS	NNP	O
analysis	NN	O
.	.	O
Subjects	NNS	O
.	.	O
Patients	NNS	O
with	IN	O
CRS	NNP	O
,	,	O
who	WP	O
are	VBP	O
undergoing	VBG	O
endoscopic	NN	O
sinus	NN	O
surgery	NN	O
,	,	O
are	VBP	O
studied	VBN	O
,	,	O
using	VBG	O
normal	JJ	O
individuals	NNS	O
as	IN	O
controls	NNS	O
.	.	O
The	DT	O
criteria	NNS	O
for	IN	O
CRS	NNP	O
patients	NNS	O
and	CC	O
normal	JJ	O
individuals	NNS	O
are	VBP	O
the	DT	O
same	JJ	O
as	IN	O
described	VBN	O
above	IN	O
.	.	O
The	DT	O
patients	NNS	O
with	IN	O
CRSwNP	NNP	O
are	VBP	O
enrolled	VBN	O
because	IN	O
the	DT	O
patients	NNS	O
with	IN	O
CRSwNP	NNP	O
tend	VBP	O
to	TO	O
have	VB	O
more	RBR	O
expensive	JJ	O
disease	NN	O
than	IN	O
those	DT	O
with	IN	O
CRSsNP	NNP	O
.	.	O
For	IN	O
this	DT	O
study	NN	O
,	,	O
patients	NNS	O
who	WP	O
are	VBP	O
not	RB	O
using	VBG	O
nasal	NN	O
or	CC	O
inhaled	JJ	O
steroids	NNS	O
for	IN	O
4	CD	O
weeks	NNS	O
before	IN	O
the	DT	O
surgery	NN	O
are	VBP	O
specifically	RB	O
selected	VBN	O
.	.	O
The	DT	O
goal	NN	O
is	VBZ	O
to	TO	O
detect	VB	O
at	IN	O
least	JJS	O
1.5	CD	O
SD	NNP	O
differences	NNS	O
in	IN	O
means	NNS	O
between	IN	O
two	CD	O
groups	NNS	O
as	IN	O
significant	JJ	O
with	IN	O
80	CD	O
%	NN	O
power	NN	O
with	IN	O
a	DT	O
probability	NN	O
of	IN	O
a	DT	O
type	NN	O
I	PRP	O
error	VBP	O
rate	NN	O
of	IN	O
0.05	CD	O
.	.	O
Therefore	RB	O
,	,	O
tissues	NNS	O
from	IN	O
7	CD	O
CRS	NNP	O
patients	NNS	O
and	CC	O
7	CD	O
normal	JJ	O
controls	NNS	O
for	IN	O
each	DT	O
of	IN	O
the	DT	O
3	CD	O
experiments	NNS	O
are	VBP	O
obtained	VBN	O
.	.	O
Because	IN	O
the	DT	O
sample	NN	O
size	NN	O
is	VBZ	O
not	RB	O
based	VBN	O
on	IN	O
preliminary	JJ	O
data	NNS	O
,	,	O
a	DT	O
second	JJ	O
power	NN	O
calculation	NN	O
is	VBZ	O
performed	VBN	O
once	RB	O
7	CD	O
subjects	NNS	O
in	IN	O
each	DT	O
group	NN	O
have	VBP	O
completed	VBN	O
the	DT	O
study	NN	O
.	.	O
If	IN	O
there	EX	O
is	VBZ	O
a	DT	O
risk	NN	O
for	IN	O
type	NN	O
II	NNP	O
error	NN	O
,	,	O
the	DT	O
sample	NN	O
size	NN	O
is	VBZ	O
increased	VBN	O
.	.	O
Analyses	NNS	O
of	IN	O
the	DT	O
functions	NNS	O
of	IN	O
CD4+CD25+	NNP	O
regulatory	JJ	O
T	NNP	O
cells	NNS	O
.	.	O
CD4+	NNP	O
T	NNP	O
cells	NNS	O
are	VBP	O
isolated	VBN	O
from	IN	O
single	JJ	O
cell	NN	O
suspensions	NNS	O
of	IN	O
sinus	NN	O
tissue	NN	O
fragments	NNS	O
by	IN	O
negative	JJ	O
immunomagnetic	JJ	O
selection	NN	O
,	,	O
followed	VBN	O
by	IN	O
positive	JJ	O
selection	NN	O
for	IN	O
CD25+	NNP	O
cells	NNS	O
by	IN	O
magnetic	JJ	O
cell	NN	O
sorting	NN	O
(	(	O
StemCell	NNP	O
Technologies	NNPS	O
)	)	O
.	.	O
Isolated	VBN	O
CD4+	NNP	O
CD25−	NNP	O
cells	NNS	O
are	VBP	O
incubated	VBN	O
with	IN	O
serial	JJ	O
dilutions	NNS	O
of	IN	O
isolated	JJ	O
CD4+CD25+	NNP	O
cells	NNS	O
in	IN	O
the	DT	O
presence	NN	O
of	IN	O
autologous	JJ	O
irradiated	JJ	O
mononuclear	NN	O
cells	NNS	O
for	IN	O
96	CD	O
hours	NNS	O
and	CC	O
in	IN	O
the	DT	O
presence	NN	O
or	CC	O
absence	NN	O
of	IN	O
fungal	JJ	O
extract	NN	O
(	(	O
e.g	NN	O
.	.	O
Alternaria	NNP	O
)	)	O
.	.	O
The	DT	O
production	NN	O
of	IN	O
cytokines	NNS	O
(	(	O
IL-5	NNP	O
,	,	O
IL-13	NNP	O
,	,	O
IFN-γ	NNP	O
)	)	O
in	IN	O
the	DT	O
supernatant	NN	O
is	VBZ	O
measured	VBN	O
by	IN	O
ELISA	NNP	O
,	,	O
and	CC	O
the	DT	O
proliferation	NN	O
of	IN	O
CFSE-labeled	NNP	O
CD4+CD25−	NNP	O
cells	NNS	O
is	VBZ	O
examined	VBN	O
.	.	O
In	IN	O
some	DT	O
experiments	NNS	O
,	,	O
antibodies	NNS	O
to	TO	O
IL-10	NNP	O
and	CC	O
IL-10Rα-chain	NNP	O
and	CC	O
a	DT	O
soluble	JJ	O
TGF-βRII-Fc	JJ	O
chimeric	NN	O
protein	NN	O
(	(	O
all	DT	O
from	IN	O
R	NNP	O
&	CC	O
D	NNP	O
systems	NNS	O
)	)	O
are	VBP	O
included	VBN	O
in	IN	O
the	DT	O
culture	NN	O
to	TO	O
examine	VB	O
the	DT	O
role	NN	O
of	IN	O
IL-10	NNP	O
and	CC	O
TGF-β	NNP	O
to	TO	O
dampen	VB	O
the	DT	O
cytokine	NN	O
and	CC	O
proliferative	JJ	O
responses	NNS	O
.	.	O
In	IN	O
Vivo	NNP	O
Intranasal	NNP	O
Challenge	NNP	O
with	IN	O
Alternaria	NNP	O
in	IN	O
CRS	NNP	O
Patients	NNP	O
Subjects	NNP	O
.	.	O
CRS	NNP	O
patients	NNS	O
without	IN	O
demonstrable	JJ	O
IgE	NNP	O
antibodies	NNS	O
to	TO	O
Alternaria	NNP	O
are	VBP	O
studied	VBN	O
using	VBG	O
CRS	NNP	O
patients	NNS	O
with	IN	O
IgE	NNP	O
antibodies	NNS	O
to	TO	O
Alternaria	NNP	O
and	CC	O
normal	JJ	O
individuals	NNS	O
as	IN	O
controls	NNS	O
.	.	O
The	DT	O
criteria	NNS	O
for	IN	O
CRS	NNP	O
patients	NNS	O
and	CC	O
normal	JJ	O
individuals	NNS	O
are	VBP	O
the	DT	O
same	JJ	O
as	IN	O
described	VBN	O
above	IN	O
,	,	O
and	CC	O
patients	NNS	O
who	WP	O
are	VBP	O
not	RB	O
on	IN	O
nasal	NN	O
or	CC	O
inhaled	JJ	O
steroids	NNS	O
for	IN	O
4	CD	O
weeks	NNS	O
before	IN	O
the	DT	O
study	NN	O
are	VBP	O
selected	VBN	O
.	.	O
The	DT	O
presence	NN	O
or	CC	O
absence	NN	O
of	IN	O
IgE	NNP	O
antibodies	NNS	O
to	TO	O
Alternaria	NNP	O
is	VBZ	O
examined	VBN	O
by	IN	O
both	DT	O
skin	JJ	O
tests	NNS	O
and	CC	O
IgE	NNP	O
RAST	NNP	O
.	.	O
About	RB	O
30	CD	O
%	NN	O
of	IN	O
patients	NNS	O
with	IN	O
CRS	NNP	O
have	VBP	O
demonstrable	JJ	O
IgE	NNP	O
antibodies	NNS	O
to	TO	O
Alternaria	NNP	O
.	.	O
Asthma	NNP	O
is	VBZ	O
not	RB	O
required	VBN	O
for	IN	O
inclusion	NN	O
;	:	O
if	IN	O
CRS	NNP	O
patients	NNS	O
do	VBP	O
have	VB	O
a	DT	O
history	NN	O
of	IN	O
asthma	NN	O
,	,	O
they	PRP	O
may	MD	O
be	VB	O
included	VBN	O
in	IN	O
the	DT	O
study	NN	O
if	IN	O
their	PRP$	O
asthma	NN	O
is	VBZ	O
mild	JJ	O
as	IN	O
defined	VBN	O
by	IN	O
all	DT	O
of	IN	O
the	DT	O
following	JJ	O
parameters	NNS	O
;	:	O
(	(	O
1	CD	O
)	)	O
a	DT	O
baseline	JJ	O
FEV1	NNP	O
of	IN	O
more	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
80	CD	O
%	NN	O
of	IN	O
predicted	VBN	O
,	,	O
(	(	O
2	CD	O
)	)	O
no	DT	O
need	NN	O
for	IN	O
any	DT	O
maintenance	NN	O
therapy	NN	O
for	IN	O
asthma	NN	O
with	IN	O
inhaled	JJ	O
steroids	NNS	O
,	,	O
long-acting	JJ	O
bronchodilators	NNS	O
,	,	O
or	CC	O
systemic	JJ	O
steroids	NNS	O
,	,	O
(	(	O
3	CD	O
)	)	O
no	DT	O
need	NN	O
for	IN	O
treatment	NN	O
with	IN	O
theophylline	NN	O
or	CC	O
leukotriene	JJ	O
inhibitors	NNS	O
on	IN	O
daily	JJ	O
basis	NN	O
,	,	O
and	CC	O
(	(	O
4	CD	O
)	)	O
no	DT	O
history	NN	O
of	IN	O
emergency	NN	O
room	NN	O
visits	NNS	O
or	CC	O
hospitalization	NN	O
because	IN	O
of	IN	O
asthma	NN	O
in	IN	O
the	DT	O
last	JJ	O
ten	JJ	O
years	NNS	O
.	.	O
Based	VBN	O
on	IN	O
preliminary	JJ	O
data	NNS	O
,	,	O
for	IN	O
a	DT	O
dichotomous	JJ	O
endpoint	NN	O
(	(	O
e.g.	JJ	O
,	,	O
detectable	JJ	O
level	NN	O
of	IN	O
IL-5	NNP	O
)	)	O
,	,	O
a	DT	O
sample-size	NN	O
of	IN	O
n=10	JJ	O
per	IN	O
group	NN	O
provides	VBZ	O
statistical	JJ	O
power	NN	O
of	IN	O
84	CD	O
%	NN	O
to	TO	O
detect	VB	O
a	DT	O
difference	NN	O
between	IN	O
groups	NNS	O
.	.	O
Statistical	JJ	O
power	NN	O
is	VBZ	O
increased	VBN	O
when	WRB	O
data	NNS	O
are	VBP	O
analyzed	VBN	O
as	IN	O
continuous	JJ	O
variables	NNS	O
.	.	O
10	CD	O
subjects	NNS	O
are	VBP	O
recruited	VBN	O
for	IN	O
each	DT	O
of	IN	O
the	DT	O
3	CD	O
groups	NNS	O
.	.	O
Intranasal	NNP	O
challenge	NN	O
and	CC	O
sample	NN	O
collection	NN	O
.	.	O
Intranasal	NNP	O
challenge	NN	O
with	IN	O
Alternaria	NNP	O
is	VBZ	O
performed	VBN	O
as	IN	O
described	NN	O
elsewhere	RB	O
.	.	O
Briefly	NNP	O
,	,	O
before	IN	O
nasal	JJ	O
challenge	NN	O
,	,	O
CRS	NNP	O
patients	NNS	O
with	IN	O
IgE	NNP	O
antibodies	NNS	O
to	TO	O
Alternaria	NNP	O
undergo	JJ	O
endpoint	NN	O
titration	NN	O
to	TO	O
establish	VB	O
the	DT	O
optimal	JJ	O
dose	NN	O
for	IN	O
starting	VBG	O
their	PRP$	O
intranasal	NN	O
challenge	NN	O
.	.	O
Endpoint	NNP	O
titration	NN	O
is	VBZ	O
performed	VBN	O
by	IN	O
a	DT	O
skin	NN	O
prick	NN	O
test	NN	O
with	IN	O
escalating	VBG	O
or	CC	O
decreasing	VBG	O
dosages	NNS	O
of	IN	O
Alternaria	NNP	O
extract	NN	O
(	(	O
ALK	NNP	O
Abello	NNP	O
,	,	O
product	NN	O
#	#	O
ALTE21P41L	NNP	O
)	)	O
starting	VBG	O
at	IN	O
18	CD	O
PNU/mL	NNP	O
.	.	O
If	IN	O
there	EX	O
is	VBZ	O
no	DT	O
reaction	NN	O
(	(	O
wheal	JJ	O
and	CC	O
flare	NN	O
)	)	O
at	IN	O
18	CD	O
PNU/mL	NNP	O
,	,	O
the	DT	O
next	JJ	O
higher	JJR	O
concentration	NN	O
is	VBZ	O
tested	VBN	O
until	IN	O
a	DT	O
wheal	NN	O
and	CC	O
flare	NN	O
response	NN	O
occurs	VBZ	O
.	.	O
If	IN	O
there	EX	O
is	VBZ	O
a	DT	O
reaction	NN	O
at	IN	O
18	CD	O
PNU/mL	NNP	O
,	,	O
the	DT	O
next	JJ	O
lowest	NN	O
concentration	NN	O
is	VBZ	O
tested	VBN	O
until	IN	O
no	DT	O
wheal	NN	O
and	CC	O
flare	NN	O
develops	NNS	O
.	.	O
The	DT	O
starting	NN	O
dosage	NN	O
for	IN	O
the	DT	O
nasal	JJ	O
challenge	NN	O
for	IN	O
CRS	NNP	O
patients	NNS	O
with	IN	O
anti-Alternaria	JJ	O
IgE	NNP	O
antibody	NN	O
is	VBZ	O
the	DT	O
highest	JJS	O
concentration	NN	O
that	WDT	O
causes	VBZ	O
no	DT	O
wheal	NN	O
and	CC	O
flare	JJ	O
response	NN	O
.	.	O
CRS	JJ	O
patients	NNS	O
who	WP	O
do	VBP	O
not	RB	O
have	VB	O
IgE	NNP	O
antibody	NN	O
to	TO	O
Alternaria	NNP	O
(	(	O
i.e.	NN	O
,	,	O
both	DT	O
skin	JJ	O
test	NN	O
negative	JJ	O
and	CC	O
RAST	NNP	O
negative	JJ	O
)	)	O
or	CC	O
normal	JJ	O
individuals	NNS	O
are	VBP	O
started	VBN	O
at	IN	O
18	CD	O
PNU/mL	NNP	O
.	.	O
For	IN	O
nasal	JJ	O
challenge	NN	O
,	,	O
the	DT	O
Alternaria	NNP	O
extract	NN	O
(	(	O
ALK	NNP	O
Abello	NNP	O
,	,	O
product	NN	O
#	#	O
ALTE21P41L	NNP	O
)	)	O
is	VBZ	O
administered	VBN	O
by	IN	O
a	DT	O
metered	JJ	O
nasal	NN	O
spray	NN	O
pump	NN	O
(	(	O
Callipot	NNP	O
)	)	O
that	IN	O
delivers	VBZ	O
0.1	CD	O
mL	NN	O
of	IN	O
extract	JJ	O
per	IN	O
nostril	NN	O
.	.	O
If	IN	O
no	DT	O
reaction	NN	O
occurs	VBZ	O
,	,	O
it	PRP	O
is	VBZ	O
proceed	VBN	O
with	IN	O
a	DT	O
3-fold	JJ	O
higher	JJR	O
concentration	NN	O
(	(	O
e.g	NN	O
.	.	O
54	CD	O
PNU/mL	NNP	O
)	)	O
up	RB	O
to	TO	O
40,000	CD	O
PNU/mL	NNP	O
.	.	O
The	DT	O
interval	NN	O
between	IN	O
each	DT	O
challenge	NN	O
is	VBZ	O
15	CD	O
minutes	NNS	O
.	.	O
The	DT	O
cumulative	JJ	O
dose	NN	O
of	IN	O
Alternaria	NNP	O
received	VBN	O
by	IN	O
each	DT	O
subject	NN	O
is	VBZ	O
<	JJ	O
12,000	CD	O
PNU	NNP	O
.	.	O
The	DT	O
nasal	JJ	O
lavage	NN	O
specimens	NNS	O
are	VBP	O
collected	VBN	O
before	IN	O
and	CC	O
24	CD	O
hours	NNS	O
after	IN	O
the	DT	O
challenge	NN	O
.	.	O
Three	CD	O
milliliters	NNS	O
of	IN	O
saline	NN	O
are	VBP	O
introduced	VBN	O
into	IN	O
each	DT	O
nostril	NN	O
,	,	O
and	CC	O
secretions	NNS	O
are	VBP	O
collected	VBN	O
into	IN	O
a	DT	O
container	NN	O
.	.	O
The	DT	O
specimens	NNS	O
are	VBP	O
processed	VBN	O
immediately	RB	O
for	IN	O
cell	NN	O
count	NN	O
and	CC	O
differentials	NNS	O
,	,	O
and	CC	O
supernatants	NNS	O
are	VBP	O
stored	VBN	O
for	IN	O
cytokine	NN	O
and	CC	O
eosinophil	NN	O
granule	NN	O
protein	NN	O
assays	NNS	O
.	.	O
The	DT	O
peak	JJ	O
expiratory	JJ	O
flow	NN	O
rate	NN	O
(	(	O
PEFR	NNP	O
)	)	O
is	VBZ	O
measured	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
after	IN	O
each	DT	O
dose	NN	O
.	.	O
A	DT	O
pulmonary	JJ	O
function	NN	O
test	NN	O
(	(	O
flow	JJ	O
volume	NN	O
loop	NN	O
)	)	O
is	VBZ	O
performed	VBN	O
with	IN	O
measurement	NN	O
of	IN	O
forced	JJ	O
expiratory	NN	O
volume	NN	O
1	CD	O
(	(	O
FEV1	NNP	O
)	)	O
before	IN	O
,	,	O
immediately	RB	O
after	IN	O
,	,	O
and	CC	O
24	CD	O
hours	NNS	O
after	IN	O
the	DT	O
escalating	VBG	O
intranasal	NN	O
challenge	NN	O
protocol	NN	O
.	.	O
There	EX	O
is	VBZ	O
a	DT	O
stopping	JJ	O
rule	NN	O
in	IN	O
place	NN	O
.	.	O
At	IN	O
baseline	NN	O
and	CC	O
after	IN	O
each	DT	O
challenge	NN	O
,	,	O
all	DT	O
subjects	NNS	O
are	VBP	O
asked	VBN	O
for	IN	O
their	PRP$	O
symptoms	NNS	O
.	.	O
These	DT	O
symptoms	NNS	O
(	(	O
nasal	JJ	O
blockage	NN	O
,	,	O
nasal	JJ	O
discharge	NN	O
,	,	O
number	NN	O
of	IN	O
sneezes	NNS	O
,	,	O
nasal	JJ	O
itching	NN	O
,	,	O
difficulty	NN	O
breathing	NN	O
,	,	O
cough	NN	O
or	CC	O
wheezing	NN	O
)	)	O
are	VBP	O
recorded	VBN	O
on	IN	O
a	DT	O
four-point	JJ	O
scale	NN	O
(	(	O
0	CD	O
to	TO	O
3	CD	O
)	)	O
.	.	O
The	DT	O
total	JJ	O
symptom	NN	O
score	NN	O
is	VBZ	O
calculated	VBN	O
as	IN	O
the	DT	O
sum	NN	O
of	IN	O
the	DT	O
individual	JJ	O
symptom	NN	O
scores	NNS	O
.	.	O
The	DT	O
nasal	JJ	O
challenge	NN	O
is	VBZ	O
stopped	VBN	O
at	IN	O
the	DT	O
dosage	NN	O
of	IN	O
Alternaria	NNP	O
extract	NN	O
that	WDT	O
produces	VBZ	O
either	DT	O
:	:	O
i	NN	O
)	)	O
1	CD	O
mL	NN	O
of	IN	O
nasal	JJ	O
secretions	NNS	O
or	CC	O
more	JJR	O
than	IN	O
5	CD	O
sneezes	NNS	O
within	IN	O
15	CD	O
minutes	NNS	O
,	,	O
ii	NN	O
)	)	O
a	DT	O
symptom	JJ	O
score	NN	O
of	IN	O
3	CD	O
for	IN	O
two	CD	O
or	CC	O
more	JJR	O
of	IN	O
the	DT	O
symptoms	NNS	O
mentioned	VBN	O
above	IN	O
,	,	O
or	CC	O
iii	NN	O
)	)	O
difficulty	NN	O
breathing	VBG	O
with	IN	O
a	DT	O
decrease	NN	O
of	IN	O
the	DT	O
PEFR	NNP	O
or	CC	O
FEV1	NNP	O
by	IN	O
15	CD	O
%	NN	O
or	CC	O
more	JJR	O
.	.	O
Samples	NNS	O
and	CC	O
data	NNS	O
obtained	VBN	O
.	.	O
Nasal	NNP	O
lavage	NN	O
fluids	NNS	O
are	VBP	O
collected	VBN	O
from	IN	O
study	NN	O
subjects	NNS	O
before	IN	O
and	CC	O
24	CD	O
hours	NNS	O
after	IN	O
intranasal	JJ	O
challenge	NN	O
,	,	O
and	CC	O
the	DT	O
total	JJ	O
leukocyte	NN	O
counts	NNS	O
and	CC	O
differentials	NNS	O
are	VBP	O
determined	VBN	O
.	.	O
The	DT	O
concentrations	NNS	O
of	IN	O
cytokines/chemokines	NNS	O
,	,	O
including	VBG	O
IL-4	NNP	O
,	,	O
IL-5	NNP	O
,	,	O
IL-13	NNP	O
,	,	O
IFN-γ	NNP	O
,	,	O
TNF-α	NNP	O
,	,	O
IL-10	NNP	O
,	,	O
and	CC	O
eotaxin	NN	O
,	,	O
in	IN	O
nasal	JJ	O
lavage	NN	O
fluids	NNS	O
are	VBP	O
quantitated	VBN	O
by	IN	O
specific	JJ	O
ELISA	NNP	O
(	(	O
Endogen	NNP	O
)	)	O
.	.	O
The	DT	O
sensitivity	NN	O
of	IN	O
these	DT	O
ELISA	NNP	O
is	VBZ	O
generally	RB	O
<	JJ	O
0.7	CD	O
pg/mL	NN	O
.	.	O
Eosinophil	NNP	O
granule	NN	O
MBP	NNP	O
and	CC	O
EDN	NNP	O
are	VBP	O
analyzed	VBN	O
by	IN	O
RIA	NNP	O
to	TO	O
monitor	VB	O
eosinophilic	JJ	O
inflammation	NN	O
.	.	O
Example	RB	O
9	CD	O
Identifying	VBG	O
Alternaria	NNP	O
Products	NNPS	O
that	IN	O
Trigger	NNP	O
Profound	NNP	O
Th2-Like	NNP	O
Inflammation	NNP	O
In	IN	O
Vitro	NNP	O
in	IN	O
Human	NNP	O
Airway	NNP	O
Cells	NNP	O
and	CC	O
In	IN	O
Vivo	NNP	O
in	IN	O
Mouse	NNP	O
Airways	NNPS	O
The	DT	O
following	VBG	O
describes	JJ	O
methods	NNS	O
and	CC	O
materials	NNS	O
for	IN	O
producing	VBG	O
recombinant	JJ	O
candidate	NN	O
A.	NN	O
alternate	VBP	O
immunomodulatory	NN	O
proteins	NNS	O
and	CC	O
characterizing	VBG	O
their	PRP$	O
immune	JJ	O
responses	NNS	O
in	IN	O
vitro	NN	O
and	CC	O
in	IN	O
vivo	NN	O
.	.	O
Purified	NNP	O
recombinant	JJ	O
forms	NNS	O
of	IN	O
the	DT	O
Alternaria	NNP	O
protein	NN	O
candidates	NNS	O
are	VBP	O
produced	VBN	O
.	.	O
These	DT	O
proteins	NNS	O
are	VBP	O
used	VBN	O
to	TO	O
perform	VB	O
various	JJ	O
in	IN	O
vitro	NN	O
and	CC	O
in	IN	O
vivo	JJ	O
immunological	JJ	O
assays	NNS	O
and	CC	O
to	TO	O
elucidate	VB	O
the	DT	O
role	NN	O
of	IN	O
these	DT	O
proteins	NNS	O
individually	RB	O
and	CC	O
in	IN	O
concert	NN	O
in	IN	O
CRS	NNP	O
pathogenesis	NN	O
.	.	O
Candidate	NNP	O
proteins	NNS	O
identified	VBN	O
is	VBZ	O
Table	JJ	O
1	CD	O
are	VBP	O
expressed	VBN	O
recombinantly	RB	O
.	.	O
Constructs	NNS	O
are	VBP	O
made	VBN	O
to	TO	O
consist	VB	O
of	IN	O
the	DT	O
following	NN	O
:	:	O
1	CD	O
)	)	O
the	DT	O
trpC	NN	O
and	CC	O
ToxA	NNP	O
promoter	NN	O
,	,	O
2	CD	O
)	)	O
a	DT	O
PCR	NNP	O
amplified	JJ	O
cDNA	NN	O
or	CC	O
genomic	JJ	O
region	NN	O
from	IN	O
A.	NN	O
alternata	NNS	O
corresponding	VBG	O
to	TO	O
the	DT	O
full-length	JJ	O
candidate	NN	O
genes	NNS	O
of	IN	O
the	DT	O
enzymes	NNS	O
,	,	O
and	CC	O
3	CD	O
)	)	O
a	DT	O
PCR	NNP	O
generated	VBN	O
histidine	NN	O
tag	NN	O
(	(	O
e.g.	JJ	O
,	,	O
6×-His	JJ	O
)	)	O
engineered	VBD	O
just	RB	O
prior	RB	O
to	TO	O
the	DT	O
stop	NN	O
codon	NN	O
(	(	O
C-terminus	NNP	O
)	)	O
to	TO	O
aid	NN	O
in	IN	O
purification	NN	O
.	.	O
These	DT	O
constructs	NNS	O
are	VBP	O
then	RB	O
introduced	VBN	O
into	IN	O
A.	NN	O
alternata	NN	O
protoplasts	NNS	O
using	VBG	O
standard	JJ	O
polyethylene	NN	O
glycol	NN	O
(	(	O
PEG	NNP	O
)	)	O
-mediated	VBD	O
fungal	JJ	O
transformation	NN	O
approaches	NNS	O
.	.	O
Individual	JJ	O
mutants	NNS	O
are	VBP	O
grown	VBN	O
in	IN	O
potato	NN	O
dextrose	JJ	O
broth	NN	O
with	IN	O
hygromycin	NN	O
,	,	O
and	CC	O
expression	NN	O
levels	NNS	O
of	IN	O
the	DT	O
introduced	VBN	O
genes	NNS	O
are	VBP	O
verified	VBN	O
using	VBG	O
RT-PCR	NNP	O
or	CC	O
northern	JJ	O
blotting	NN	O
,	,	O
and	CC	O
SDS-PAGE	NNP	O
.	.	O
Individual	JJ	O
mutants	NNS	O
exhibiting	VBG	O
high-level	JJ	O
expression	NN	O
of	IN	O
the	DT	O
protein	NN	O
of	IN	O
interest	NN	O
are	VBP	O
grown	VBN	O
in	IN	O
larger	JJR	O
amounts	NNS	O
,	,	O
culture	NN	O
filtrates	NNS	O
are	VBP	O
purified	VBN	O
,	,	O
and	CC	O
Immobilized	NNP	O
Metal	NNP	O
Affinity	NNP	O
Chromatography	NNP	O
(	(	O
IMAC	NNP	O
)	)	O
for	IN	O
the	DT	O
histidine-tagged	JJ	O
protein	NN	O
purification	NN	O
involves	VBZ	O
using	VBG	O
a	DT	O
HPLC	NNP	O
system	NN	O
and	CC	O
Ni	NNP	O
Sepharose	NNP	O
chromatography	NN	O
.	.	O
Alternatively	RB	O
,	,	O
routine	JJ	O
recombinant	NN	O
protein	NN	O
expression	NN	O
systems	NNS	O
with	IN	O
organisms	NNS	O
like	IN	O
E.	NNP	O
coli	NNS	O
and	CC	O
Pichia	NNP	O
pastoris	NN	O
are	VBP	O
used	VBN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
E.	NNP	O
coli	NN	O
was	VBD	O
used	VBN	O
to	TO	O
produce	VB	O
one	CD	O
of	IN	O
eight	CD	O
candidates	NNS	O
,	,	O
A.	NNP	O
alternata	VBZ	O
xylanase	NNP	O
(	(	O
AAF05698.1	NNP	O
)	)	O
(	(	O
FIG	NNP	O
.	.	O
26	CD	O
)	)	O
.	.	O
In	IN	O
Vitro	NNP	O
and	CC	O
In	IN	O
Vivo	NNP	O
Assays	NNP	O
for	IN	O
Activity	NNP	O
of	IN	O
Recombinant	NNP	O
Alternaria	NNP	O
Proteins	NNP	O
.	.	O
Eosinophil	NNP	O
[	NNP	O
Ca2+	NNP	O
]	NNP	O
i	NN	O
response	NN	O
and	CC	O
degranulation	NN	O
.	.	O
For	IN	O
degranulation	NN	O
,	,	O
isolated	VBN	O
eosinophils	NNS	O
are	VBP	O
incubated	VBN	O
with	IN	O
different	JJ	O
concentrations	NNS	O
of	IN	O
recombinant	JJ	O
proteins	NNS	O
(	(	O
10	CD	O
ng/mL−1	RB	O
mg/mL	NN	O
)	)	O
for	IN	O
3	CD	O
hours	NNS	O
,	,	O
and	CC	O
EDN	NNP	O
released	VBD	O
into	IN	O
supernatants	NNS	O
is	VBZ	O
measured	VBN	O
by	IN	O
RIA	NNP	O
to	TO	O
indicate	VB	O
degranulation	NN	O
.	.	O
Changes	NNS	O
in	IN	O
[	NNP	O
Ca2+	NNP	O
]	NNP	O
i	NN	O
are	VBP	O
measured	VBN	O
using	VBG	O
FACS	NNP	O
analysis	NN	O
and	CC	O
eosinophils	NNS	O
loaded	VBN	O
with	IN	O
a	DT	O
calcium	NN	O
indicator	NN	O
,	,	O
indo-1	JJ	O
.	.	O
The	DT	O
involvement	NN	O
of	IN	O
PAR-2	NNP	O
and	CC	O
proteolytic/glycolytic	JJ	O
enzymes	NNS	O
is	VBZ	O
verified	VBN	O
by	IN	O
a	DT	O
PAR-2	NNP	O
peptide	NN	O
antagonist	NN	O
,	,	O
LSIGKV	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:35	NNP	O
)	)	O
,	,	O
and	CC	O
enzyme	JJ	O
inhibitors	NNS	O
,	,	O
such	JJ	O
as	IN	O
pepstatin	JJ	O
A-agarose	JJ	O
,	,	O
ATBI	NNP	O
,	,	O
ritonavir	NN	O
,	,	O
and	CC	O
allosamidine	NN	O
.	.	O
The	DT	O
active	JJ	O
cleavage	NN	O
of	IN	O
PAR-2	NNP	O
is	VBZ	O
verified	VBN	O
by	IN	O
fluorescent	NN	O
quenched	VBN	O
peptide	RB	O
substrate	JJ	O
[	NNS	O
Abz-SKGRSLIGK	NNP	O
(	(	O
Dnp	NNP	O
)	)	O
D	NNP	O
]	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:37	NNP	O
)	)	O
and	CC	O
by	IN	O
analysis	NN	O
of	IN	O
stimulated	VBN	O
eosinophils	NNS	O
by	IN	O
FACS	NNP	O
and	CC	O
immunoblot	NN	O
using	VBG	O
anti-PAR-2	JJ	O
antibody	NN	O
(	(	O
which	WDT	O
recognizes	VBZ	O
the	DT	O
N-terminus	NNP	O
of	IN	O
PAR-2	NNP	O
)	)	O
.	.	O
Although	IN	O
unlikely	JJ	O
,	,	O
the	DT	O
involvement	NN	O
of	IN	O
TLR2	NNP	O
or	CC	O
TLR4/CD14	NNP	O
is	VBZ	O
examined	VBN	O
using	VBG	O
blocking	VBG	O
antibodies	NNS	O
to	TO	O
these	DT	O
molecules	NNS	O
(	(	O
eBioscience	NN	O
)	)	O
.	.	O
Epithelial	JJ	O
cell	NN	O
production	NN	O
of	IN	O
cytokines	NNS	O
.	.	O
The	DT	O
airway	JJ	O
epithelial	JJ	O
cell	NN	O
line	NN	O
,	,	O
BEAS-2B	NNP	O
,	,	O
is	VBZ	O
stimulated	VBN	O
with	IN	O
different	JJ	O
concentrations	NNS	O
of	IN	O
recombinant	JJ	O
proteins	NNS	O
for	IN	O
24	CD	O
hours	NNS	O
,	,	O
similarly	RB	O
to	TO	O
Alternaria	NNP	O
crude	NN	O
extract	NN	O
experiments	NNS	O
in	IN	O
FIGS	NNP	O
.	.	O
10	CD	O
and	CC	O
11	CD	O
.	.	O
Cytokines	NNS	O
,	,	O
including	VBG	O
IL-8	JJ	O
and	CC	O
IL-6	NNP	O
,	,	O
released	VBN	O
into	IN	O
supernatant	NN	O
are	VBP	O
measured	VBN	O
by	IN	O
ELISA	NNP	O
.	.	O
The	DT	O
epithelial	JJ	O
cells	NNS	O
'	POS	O
PAR-2	NN	O
is	VBZ	O
analyzed	VBN	O
similarly	RB	O
to	TO	O
the	DT	O
analysis	NN	O
for	IN	O
eosinophils	NNS	O
.	.	O
Cytokine	NNP	O
responses	NNS	O
and	CC	O
airway	RB	O
eosinophilia	NNS	O
in	IN	O
mouse	NN	O
airways	NNS	O
in	IN	O
vivo	NN	O
.	.	O
Naïve	NNP	O
mice	NN	O
are	VBP	O
exposed	VBN	O
intranasally	RB	O
to	TO	O
recombinant	VB	O
proteins	NNS	O
(	(	O
1	CD	O
μg-100	JJ	O
μg/challenge	NN	O
)	)	O
on	IN	O
days	NNS	O
0	CD	O
,	,	O
3	CD	O
,	,	O
and	CC	O
6	CD	O
(	(	O
see	VB	O
FIGS	NNP	O
.	.	O
16	CD	O
and	CC	O
20	CD	O
)	)	O
.	.	O
At	IN	O
12	CD	O
hours	NNS	O
after	IN	O
the	DT	O
first	JJ	O
challenge	NN	O
,	,	O
on	IN	O
day	NN	O
5	CD	O
,	,	O
or	CC	O
day	NN	O
8	CD	O
,	,	O
the	DT	O
trachea	NN	O
is	VBZ	O
cannulated	VBN	O
,	,	O
and	CC	O
the	DT	O
lung	NN	O
is	VBZ	O
lavaged	VBN	O
with	IN	O
0.5	CD	O
mL	NNS	O
of	IN	O
HBSS	NNP	O
.	.	O
Total	JJ	O
numbers	NNS	O
of	IN	O
cells	NNS	O
and	CC	O
differentials	NNS	O
in	IN	O
BAL	NNP	O
fluids	NNS	O
are	VBP	O
determined	VBN	O
.	.	O
Supernatants	NNS	O
are	VBP	O
collected	VBN	O
,	,	O
and	CC	O
the	DT	O
concentrations	NNS	O
of	IN	O
cytokines	NNS	O
(	(	O
IL-5	NNP	O
,	,	O
IL-4	NNP	O
,	,	O
IL-13	NNP	O
,	,	O
IFN-γ	NNP	O
)	)	O
are	VBP	O
measured	VBN	O
by	IN	O
ELISA	NNP	O
.	.	O
Tissue	NN	O
samples	NNS	O
of	IN	O
the	DT	O
lungs	NNS	O
are	VBP	O
examined	VBN	O
histologically	RB	O
.	.	O
Blood	NN	O
is	VBZ	O
collected	VBN	O
by	IN	O
cardiac	JJ	O
puncture	NN	O
on	IN	O
day	NN	O
8	CD	O
to	TO	O
quantitate	VB	O
IgE	NNP	O
and	CC	O
IgG	NNP	O
antibodies	NNS	O
to	TO	O
recombinant	VB	O
proteins	NNS	O
.	.	O
Cellular	JJ	O
and	CC	O
humoral	JJ	O
immune	NN	O
responses	NNS	O
by	IN	O
CRS	NNP	O
patients	NNS	O
.	.	O
PBMC	NNP	O
are	VBP	O
isolated	VBN	O
from	IN	O
normal	JJ	O
individuals	NNS	O
and	CC	O
CRS	NNP	O
patients	NNS	O
by	IN	O
using	VBG	O
the	DT	O
same	JJ	O
criteria	NNS	O
as	IN	O
described	VBN	O
above	IN	O
.	.	O
PBMC	NNS	O
are	VBP	O
incubated	VBN	O
with	IN	O
serial	JJ	O
dilutions	NNS	O
of	IN	O
recombinant	JJ	O
proteins	NNS	O
for	IN	O
24	CD	O
hours	NNS	O
(	(	O
for	IN	O
IL-4	NNP	O
)	)	O
,	,	O
for	IN	O
96	CD	O
hours	NNS	O
(	(	O
for	IN	O
IL-5	NNP	O
,	,	O
IL-13	NNP	O
,	,	O
and	CC	O
IFN-γ	NNP	O
)	)	O
,	,	O
or	CC	O
for	IN	O
168	CD	O
hours	NNS	O
for	IN	O
CFSE-based	JJ	O
CD4+	NNP	O
T	NNP	O
cell	NN	O
proliferation	NN	O
assay	VBP	O
as	IN	O
described	VBN	O
above	IN	O
.	.	O
Serum	NNP	O
concentrations	NNS	O
of	IN	O
IgE	NNP	O
,	,	O
IgG	NNP	O
,	,	O
and	CC	O
IgG4	NNP	O
antibody	NN	O
to	TO	O
recombinant	VB	O
proteins	NNS	O
are	VBP	O
measured	VBN	O
by	IN	O
immunoassay	NN	O
and	CC	O
western	JJ	O
blot	NN	O
.	.	O
Development	NNP	O
of	IN	O
A.	NNP	O
alternata	NNS	O
Knockout	NNP	O
(	(	O
KO	NNP	O
)	)	O
Mutants	NNS	O
for	IN	O
Specific	NNP	O
Immunostimulatory	NNP	O
Proteins	NNP	O
and	CC	O
Analyses	NNP	O
of	IN	O
Immune	NNP	O
Responses	NNP	O
In	IN	O
Vitro	NNP	O
and	CC	O
In	IN	O
Vivo	NNP	O
with	IN	O
Whole	NNP	O
Fungi	NNP	O
and	CC	O
Fungal	NNP	O
Products	NNP	O
.	.	O
KO	NNP	O
mutants	NNS	O
are	VBP	O
generated	VBN	O
for	IN	O
each	DT	O
candidate	NN	O
immunostimulatory	NN	O
protein	NN	O
.	.	O
First	RB	O
,	,	O
the	DT	O
secreted	JJ	O
products	NNS	O
from	IN	O
KO	NNP	O
A.	NN	O
alternata	NNS	O
are	VBP	O
used	VBN	O
to	TO	O
deduce	VB	O
whether	IN	O
the	DT	O
absence	NN	O
of	IN	O
a	DT	O
specific	JJ	O
protein	NN	O
significantly	RB	O
affects	VBZ	O
the	DT	O
activation	NN	O
of	IN	O
immune	JJ	O
cells	NNS	O
in	IN	O
vitro	NN	O
and	CC	O
in	IN	O
vivo	NN	O
.	.	O
Second	NNP	O
,	,	O
similar	JJ	O
experiments	NNS	O
with	IN	O
whole	JJ	O
fungus	NN	O
(	(	O
i.e.	FW	O
,	,	O
fungal	JJ	O
spores	NNS	O
and	CC	O
fungal	JJ	O
hyphae	NN	O
)	)	O
are	VBP	O
compare	VBG	O
the	DT	O
immune	JJ	O
responses	NNS	O
triggered	VBN	O
by	IN	O
KO	NNP	O
to	TO	O
the	DT	O
wild	JJ	O
type	NN	O
.	.	O
Fungal	NNP	O
mutant	JJ	O
generation	NN	O
.	.	O
The	DT	O
LME	NNP	O
approach	NN	O
is	VBZ	O
used	VBN	O
as	IN	O
described	VBN	O
above	IN	O
to	TO	O
disrupt	VB	O
the	DT	O
target	NN	O
genes	NNS	O
.	.	O
The	DT	O
LME	NNP	O
constructs	NNS	O
consistently	RB	O
produce	VBP	O
stable	JJ	O
transformants	NNS	O
for	IN	O
diverse	JJ	O
categories	NNS	O
of	IN	O
genes	NNS	O
.	.	O
Typically	RB	O
,	,	O
when	WRB	O
using	VBG	O
the	DT	O
LME	NNP	O
constructs	NNS	O
,	,	O
100	CD	O
%	NN	O
of	IN	O
the	DT	O
transformants	NNS	O
are	VBP	O
targeted	VBN	O
gene	NN	O
disruption	NN	O
mutants	NNS	O
compared	VBN	O
to	TO	O
inconsistent	VB	O
transformation	NN	O
and	CC	O
usually	RB	O
less	JJR	O
than	IN	O
10	CD	O
%	NN	O
targeted	VBN	O
gene	NN	O
disruption	NN	O
with	IN	O
circular	JJ	O
plasmid	NN	O
disruption	NN	O
constructs	NNS	O
.	.	O
All	DT	O
mutants	NNS	O
are	VBP	O
subjected	VBN	O
to	TO	O
molecular	JJ	O
characterization	NN	O
to	TO	O
confirm	VB	O
that	DT	O
gene	NN	O
(	(	O
s	PRP	O
)	)	O
are	VBP	O
disrupted	VBN	O
.	.	O
In	IN	O
vitro	NN	O
and	CC	O
in	IN	O
vivo	JJ	O
assays	NNS	O
.	.	O
Wild-type	JJ	O
and	CC	O
KO	NNP	O
Alternaria	NNP	O
are	VBP	O
cultured	VBN	O
in	IN	O
liquid	JJ	O
medium	NN	O
.	.	O
Proteins	NNS	O
released	VBN	O
from	IN	O
these	DT	O
fungi	NNS	O
into	IN	O
supernatants	NNS	O
are	VBP	O
analyzed	VBN	O
for	IN	O
their	PRP$	O
immunostimulatory	NN	O
activities	NNS	O
in	IN	O
vitro	NN	O
with	IN	O
eosinophils	NNS	O
and	CC	O
BEAS-2B	NNP	O
cells	NNS	O
and	CC	O
in	IN	O
vivo	NN	O
mouse	NN	O
airways	VBZ	O
as	IN	O
described	VBN	O
above	IN	O
.	.	O
Spores	NNS	O
are	VBP	O
collected	VBN	O
from	IN	O
wild-type	JJ	O
and	CC	O
KO	NNP	O
Alternaria	NNP	O
.	.	O
These	DT	O
spores	NNS	O
are	VBP	O
cultured	VBN	O
in	IN	O
vitro	NN	O
in	IN	O
HBSS	NNP	O
medium	NN	O
with	IN	O
airway	JJ	O
mucin	NN	O
and	CC	O
allowed	VBN	O
to	TO	O
germinate	VB	O
.	.	O
Eosinophils	NNS	O
are	VBP	O
added	VBN	O
,	,	O
and	CC	O
their	PRP$	O
responses	NNS	O
to	TO	O
wild-type	JJ	O
and	CC	O
KO	NNP	O
Alternaria	NNP	O
are	VBP	O
examined	VBN	O
as	IN	O
in	IN	O
FIG	NNP	O
.	.	O
13	CD	O
.	.	O
Example	RB	O
10	CD	O
Inhibiting	VBG	O
Alternaria-Induced	NNP	O
Eosinophilic	NNP	O
Degranulation	NNP	O
To	TO	O
monitor	VB	O
eosinophil	JJ	O
function	NN	O
in	IN	O
response	NN	O
to	TO	O
extracts	NNS	O
from	IN	O
Alternaria	NNP	O
,	,	O
degranulation	NN	O
of	IN	O
human	JJ	O
eosinophils	NNS	O
was	VBD	O
measured	VBN	O
by	IN	O
quantitating	VBG	O
released	VBN	O
eosinophil-derived	JJ	O
neurotoxin	NN	O
(	(	O
EDN	NNP	O
)	)	O
and/or	NN	O
MBP	NNP	O
.	.	O
In	IN	O
brief	NN	O
,	,	O
freshly	RB	O
isolated	VBN	O
eosinophils	NNS	O
were	VBD	O
suspended	VBN	O
in	IN	O
HBSS	NNP	O
with	IN	O
25	CD	O
mM	NNS	O
HEPES	NNP	O
and	CC	O
0.01	CD	O
%	NN	O
gelatin	NN	O
at	IN	O
5×105	CD	O
cells/mL	NN	O
.	.	O
Eosinophils	NNS	O
and	CC	O
stimuli	NNS	O
were	VBD	O
incubated	VBN	O
in	IN	O
96-well	CD	O
tissue	NN	O
culture	NN	O
plates	VBZ	O
for	IN	O
3	CD	O
hours	NNS	O
at	IN	O
37°	CD	O
C.	NNP	O
and	CC	O
5	CD	O
%	NN	O
CO2	NNP	O
.	.	O
Cell-free	JJ	O
supernatants	NNS	O
were	VBD	O
stored	VBN	O
at	IN	O
−20°	NNP	O
C.	NNP	O
A	NNP	O
specific	JJ	O
RIA	NNP	O
quantitated	VBD	O
eosinophil	JJ	O
degranulation	NN	O
by	IN	O
measuring	VBG	O
the	DT	O
concentration	NN	O
of	IN	O
EDN	NNP	O
in	IN	O
the	DT	O
supernatants	NNS	O
.	.	O
The	DT	O
following	JJ	O
inhibited	JJ	O
Alternaria-induced	NNP	O
eosinophilic	JJ	O
degranulation	NN	O
:	:	O
CV6209	NNP	O
(	(	O
PAF	NNP	O
receptor	VBP	O
antagonist	NN	O
)	)	O
,	,	O
heparin	UH	O
,	,	O
EDTA	NNP	O
,	,	O
EGTA	NNP	O
,	,	O
pepstatin	NN	O
agarose	RB	O
,	,	O
PAR2-inhibitory	NNP	O
peptide	NN	O
,	,	O
Jasplakinlide	NNP	O
(	(	O
actin	JJ	O
inhibitor	NN	O
)	)	O
,	,	O
and	CC	O
Lanthunum	NNP	O
(	(	O
Ca	NNP	O
channel	NNP	O
inhibitor	NN	O
)	)	O
.	.	O
The	DT	O
following	VBG	O
did	VBD	O
not	RB	O
inhibit	VB	O
eosinophilic	JJ	O
degranulation	NN	O
:	:	O
Chymostatin	NNP	O
,	,	O
Chloroquine	NNP	O
,	,	O
Phosphoramidon	NNP	O
,	,	O
APSF	NNP	O
,	,	O
Calpastatin	NNP	O
,	,	O
Antipain	NNP	O
,	,	O
Bestatin	NNP	O
,	,	O
Leupeptin	NNP	O
,	,	O
Pefabloc	NNP	O
SC	NNP	O
,	,	O
Aprotinin	NNP	O
,	,	O
Cytochalasin	NNP	O
B	NNP	O
,	,	O
Colchitin	NNP	O
,	,	O
E64	NNP	O
,	,	O
Calpain	NNP	O
inhibitor	NN	O
,	,	O
SB203580	NNP	O
(	(	O
p38	JJ	O
MAPK	NNP	O
inhibitor	NN	O
)	)	O
,	,	O
Genistein	NNP	O
,	,	O
Wortmannin	NNP	O
,	,	O
Ro-31-8220	NNP	O
,	,	O
Rottelrin	NNP	O
,	,	O
GF109203X	NNP	O
,	,	O
PD98059	NNP	O
(	(	O
ERK	NNP	O
inhibitor	NN	O
)	)	O
,	,	O
Cyclosporin	NNP	O
A	NNP	O
,	,	O
FK	NNP	O
506	CD	O
,	,	O
W-7	NNP	O
,	,	O
and	CC	O
TLCK	NNP	O
.	.	O
Other	JJ	O
Embodiments	NNS	O
It	PRP	O
is	VBZ	O
to	TO	O
be	VB	O
understood	JJ	O
that	IN	O
while	IN	O
the	DT	O
invention	NN	O
has	VBZ	O
been	VBN	O
described	VBN	O
in	IN	O
conjunction	NN	O
with	IN	O
the	DT	O
detailed	JJ	O
description	NN	O
thereof	NN	O
,	,	O
the	DT	O
foregoing	NN	O
description	NN	O
is	VBZ	O
intended	VBN	O
to	TO	O
illustrate	VB	O
and	CC	O
not	RB	O
limit	VB	O
the	DT	O
scope	NN	O
of	IN	O
the	DT	O
invention	NN	O
,	,	O
which	WDT	O
is	VBZ	O
defined	VBN	O
by	IN	O
the	DT	O
scope	NN	O
of	IN	O
the	DT	O
appended	JJ	O
claims	NNS	O
.	.	O
Other	JJ	O
aspects	NNS	O
,	,	O
advantages	NNS	O
,	,	O
and	CC	O
modifications	NNS	O
are	VBP	O
within	IN	O
the	DT	O
scope	NN	O
of	IN	O
the	DT	O
following	JJ	O
claims	NNS	O
.	.	O
Claims	NNS	O
(	(	O
1	CD	O
)	)	O
Priority	NN	O
Applications	NNP	O
(	(	O
5	CD	O
)	)	O
Applications	NNPS	O
Claiming	NNP	O
Priority	NNP	O
(	(	O
1	CD	O
)	)	O
Publications	NNPS	O
(	(	O
2	CD	O
)	)	O
Family	RB	O
ID=38224928	NNP	O
Family	NNP	O
Applications	NNP	O
(	(	O
4	CD	O
)	)	O
Family	NNP	O
Applications	NNP	O
Before	NNP	O
(	(	O
3	CD	O
)	)	O
Country	NN	O
Status	NNP	O
(	(	O
1	CD	O
)	)	O
Families	NNPS	O
Citing	VBG	O
this	DT	O
family	NN	O
(	(	O
2	CD	O
)	)	O
Citations	NNPS	O
(	(	O
1	CD	O
)	)	O
Patent	NN	O
Citations	NNP	O
(	(	O
2	CD	O
)	)	O
Non-Patent	JJ	O
Citations	NNP	O
(	(	O
148	CD	O
)	)	O
Also	RB	O
Published	VBN	O
As	IN	O
Similar	JJ	O
Documents	NNP	O
Legal	NNP	O
Events	NNP	O
Owner	NNP	O
name	NN	O
:	:	O
NATIONAL	NNP	O
INSTITUTES	NNP	O
OF	NNP	O
HEALTH	NNP	O
(	(	O
NIH	NNP	O
)	)	O
,	,	O
U.S.	NNP	O
DEPT	NNP	O
.	.	O
OF	IN	O
Free	NNP	O
format	NN	O
text	NN	O
:	:	O
CONFIRMATORY	NNP	O
LICENSE	NNP	O
;	:	O
ASSIGNOR	NNP	O
:	:	O
MAYO	NNP	O
FOUNDATION	NNP	O
FOR	NNP	O
MEDICAL	NNP	O
EDUCATION	NNP	O
AND	NNP	O
RESEARCH	NNP	O
;	:	O
REEL/FRAME:026147/0837	NNP	O
Effective	NNP	O
date	NN	O
:	:	O
20110414	CD	O
Owner	NNP	O
name	NN	O
:	:	O
LAWRENCE	NNP	O
,	,	O
CHRISTOPHER	NNP	O
,	,	O
VIRGINIA	NNP	O
Free	NNP	O
format	NN	O
text	NN	O
:	:	O
ASSIGNMENT	NNP	O
OF	IN	O
ASSIGNORS	NNP	O
INTEREST	NNP	O
;	:	O
ASSIGNOR	NNP	O
:	:	O
MAYO	NNP	O
FOUNDATION	NNP	O
FOR	NNP	O
MEDICAL	NNP	O
EDUCATION	NNP	O
AND	NNP	O
RESEARCH	NNP	O
;	:	O
REEL/FRAME:026215/0584	NNP	O
Effective	NNP	O
date	NN	O
:	:	O
20070329	CD	O
Owner	NNP	O
name	NN	O
:	:	O
VIRGINIA	NNP	O
POLYTECHNIC	NNP	O
INSTITUTE	NNP	O
AND	NNP	O
STATE	NNP	O
UNIVERSIT	NNP	O
Free	NNP	O
format	NN	O
text	NN	O
:	:	O
ASSIGNMENT	NNP	O
OF	IN	O
ASSIGNORS	NNP	O
INTEREST	NNP	O
;	:	O
ASSIGNOR	NNP	O
:	:	O
LAWRENCE	NNP	O
,	,	O
CHRISTOPHER	NNP	O
;	:	O
REEL/FRAME:026215/0589	NNP	O
Effective	NNP	O
date	NN	O
:	:	O
20070222	CD	O
Owner	NNP	O
name	NN	O
:	:	O
MAYO	NNP	O
FOUNDATION	NNP	O
FOR	NNP	O
MEDICAL	NNP	O
EDUCATION	NNP	O
AND	NNP	O
RESEARCH	NNP	O
Free	NNP	O
format	VBD	O
text	NN	O
:	:	O
ASSIGNMENT	NNP	O
OF	IN	O
ASSIGNORS	NNP	O
INTEREST	NNP	O
;	:	O
ASSIGNORS	NNP	O
:	:	O
KITA	NNP	O
,	,	O
HIROHITO	NNP	O
;	:	O
PONIKAU	NNP	O
,	,	O
JENS	NNP	O
;	:	O
LAWRENCE	NNP	O
,	,	O
CHRISTOPHER	NNP	O
;	:	O
SIGNING	NNP	O
DATES	NNP	O
FROM	NNP	O
20070110	CD	O
TO	NNP	O
20070122	CD	O
;	:	O
REEL/FRAME:026215/0651	NNP	O
Owner	NNP	O
name	NN	O
:	:	O
VIRGINIA	NNP	O
TECH	NNP	O
INTELLECTUAL	NNP	O
PROPERTIES	NNP	O
,	,	O
INC.	NNP	O
,	,	O
VIRGI	NNP	O
Free	NNP	O
format	NN	O
text	NN	O
:	:	O
ASSIGNMENT	NNP	O
OF	IN	O
ASSIGNORS	NNP	O
INTEREST	NNP	O
;	:	O
ASSIGNOR	NNP	O
:	:	O
VIRGINIA	NNP	O
POLYTECHNIC	NNP	O
INSTITUTE	NNP	O
AND	NNP	O
STATE	NNP	O
UNIVERSITY	NNP	O
;	:	O
REEL/FRAME:026215/0596	NNP	O
Effective	NNP	O
date	NN	O
:	:	O
20070302	CD	O
Year	NN	O
of	IN	O
fee	JJ	O
payment	NN	O
:	:	O
4	CD	O
